

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 401/04, 405/04, 409/14, A61K 31/505, C07D 403/04, 401/14, A61K 31/44		A2	(11) International Publication Number: WO 98/24782 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22390 (22) International Filing Date: 4 December 1997 (04.12.97) (30) Priority Data: 60/032,128 5 December 1996 (05.12.96) US 60/050,950 13 June 1997 (13.06.97) US Not furnished 21 November 1997 (21.11.97) US (71) Applicant (for all designated States except US): AMGEN INC. [US/US]; Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA. 91320-1789 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SPOHR, Ulrike, D. [CA/US]; 2925 Glenwood Drive #305, Boulder, CO 80301 (US). MALONE, Michael, J. [US/US]; 6054H Gunbarrel Avenue, Boulder, CO 80301 (US). MANTLO, Nathan, B. [US/US]; 2538 Ginny Way, Lafayette, CO 80026 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE (57) Abstract Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE

BACKGROUND OF THE INVENTION

5 This is a nonprovisional application derived from
U.S. provisional application serial no. 60/032,128 filed
December 5, 1996, U.S. provisional application serial
no. 60/050,950 filed June 13, 1997 and U.S.
nonprovisional patent application serial no. not yet
10 assigned filed November 21, 1997 each of which are
incorporated herein by reference in their entirety. The
present invention comprises a new class of compounds
useful in treating diseases, such as TNF- α , IL-1 β , IL-6
and/or IL-8 mediated diseases and other maladies, such
15 as pain and diabetes. In particular, the compounds of
the invention are useful for the prophylaxis and
treatment of diseases or conditions involving
inflammation. This invention also relates to
intermediates and processes useful in the preparation of
20 such compounds.

Interleukin-1 (IL-1) and Tumor Necrosis Factor α
(TNF- α) are pro-inflammatory cytokines secreted by a
variety of cells, including monocytes and macrophages,
in response to many inflammatory stimuli (e.g.,
25 lipopolysaccharide - LPS) or external cellular stress
(e.g., osmotic shock and peroxide).

Elevated levels of TNF- α and/or IL-1 over basal
levels have been implicated in mediating or exacerbating
a number of disease states including rheumatoid
30 arthritis; Pagets disease; osteoporosis; multiple
myeloma; uveitis; acute and chronic myelogenous
leukemia; pancreatic β cell destruction; osteoarthritis;
rheumatoid spondylitis; gouty arthritis; inflammatory
bowel disease; adult respiratory distress syndrome
35 (ARDS); psoriasis; Crohn's disease; allergic rhinitis;
ulcerative colitis; anaphylaxis; contact dermatitis;
asthma; muscle degeneration; cachexia; Reiter's

syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF- α .

It has been reported that TNF- α plays a role in head trauma, stroke, and ischemia. For instance, in animal models of head trauma (rat), TNF- α levels increased in the contused hemisphere (Shohami et al., *J. Cereb. Blood Flow Metab.* 14, 615 (1994)). In a rat model of ischemia wherein the middle cerebral artery was occluded, the levels of TNF- α mRNA of TNF- α increased (Feurstein et al., *Neurosci. Lett.* 164, 125 (1993)). Administration of TNF- α into the rat cortex has been reported to result in significant neutrophil accumulation in capillaries and adherence in small blood vessels. TNF- α promotes the infiltration of other cytokines (IL-1 β , IL-6) and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein, *Stroke* 25, 1481 (1994)). TNF- α has also been implicated to play a role in type II diabetes (Endocrinol. 130, 43-52, 1994; and Endocrinol. 136, 1474-1481, 1995).

TNF- α appears to play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF- α secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al., *J. Immunol.* 142, 431 (1989)). Lahdevirta et al., (*Am. J. Med.* 85, 289 (1988)) discussed the role of TNF- α in the HIV associated states of cachexia and muscle degradation.

TNF- α is upstream in the cytokine cascade of inflammation. As a result, elevated levels of TNF- α may lead to elevated levels of other inflammatory and proinflammatory cytokines, such as IL-1, IL-6, and IL-8.

5 Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress
10 syndrome (ARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis;
15 sepsis; septic shock; and toxic shock syndrome. Viruses sensitive to TNF- α inhibition, e.g., HIV-1, HIV-2, HIV-3, are also affected by IL-1.

TNF- α and IL-1 appear to play a role in pancreatic β cell destruction and diabetes. Pancreatic β cells
20 produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic β cells often accompanies type I diabetes. Pancreatic β cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by a
25 functional resistance to insulin. Further, type II diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production. Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin.
30 Glucagon receptors have been found in the liver, kidney and adipose tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it
35 is thought that insulin responsiveness in the liver will

improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.

In rheumatoid arthritis models in animals, multiple intra-articular injections of IL-1 have led to an acute and destructive form of arthritis (Chandrasekhar et al., *Clinical Immunol Immunopathol.* 55, 382 (1990)). In studies using cultured rheumatoid synovial cells, IL-1 is a more potent inducer of stromelysin than is TNF- α (Firestein, *Am. J. Pathol.* 140, 1309 (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration has been observed. The emigration is attributed to the induction of chemokines (e.g., IL-8), and the up-regulation of adhesion molecules (Dinarello, *Eur. Cytokine Netw.* 5, 517-531 (1994)).

IL-1 also appears to play a role in promoting certain viral life cycles. For example, cytokine-induced increase of HIV expression in a chronically infected macrophage line has been associated with a concomitant and selective increase in IL-1 production (Folks et al., *J. Immunol.* 136, 40 (1986)). Beutler et al. (*J. Immunol.* 135, 3969 (1985)) discussed the role of IL-1 in cachexia. Baracos et al. (*New Eng. J. Med.* 308, 553 (1983)) discussed the role of IL-1 in muscle degeneration.


In rheumatoid arthritis, both IL-1 and TNF- α induce synoviocytes and chondrocytes to produce collagenase and neutral proteases, which leads to tissue destruction within the arthritic joints. In a model of arthritis (collagen-induced arthritis (CIA) in rats and mice), intra-articular administration of TNF- α either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahn et al., *Lymphokine Cytokine Res.* 11, 253 (1992); and Cooper, *Clin. Exp. Immunol.* 898, 244 (1992)).

IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil

infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8, including, but not limited to, the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis. In addition to the chemotaxis effect on neutrophils, IL-8 also has the ability to activate neutrophils. Thus, reduction in IL-8 levels may lead to diminished neutrophil infiltration.

Several approaches have been taken to block the effect of TNF- α . One approach involves using soluble receptors for TNF- α (e.g., TNFR-55 or TNFR-75), which have demonstrated efficacy in animal models of TNF- α -mediated disease states. A second approach to neutralizing TNF- α using a monoclonal antibody specific to TNF- α , cA2, has demonstrated improvement in swollen joint count in a Phase II human trial of rheumatoid arthritis (Feldmann et al., *Immunological Reviews*, pp. 195-223 (1995)). These approaches block the effects of TNF- α and IL-1 by either protein sequestration or receptor antagonism.

Bennett et al. (*J. Med. Chem.* 21, 623 (1978)) synthesized a number of pyrimidines of the form:



i

where, *inter alia*, R_a¹ is 2-, 3-, or 4-pyridyl, R_a² is H, methyl, or phenyl, and R_a³ is H, amino. They reported that none of these compounds tested against rat adjuvant-induced edema displayed a level of activity sufficient to warrant further investigation and that additional testing confirmed that the compounds represented a series of false positives in the carrageenan-induced edema model.

Ife et al. (Bioorg. Med. Chem. Lett. 5, 543 (1995)) reported that another pyrimidine (R_1^1 = 2-methylphenyl, R_2^1 = 2-pyridyl, and R_3^1 = n-propyl, wherein R_1^1 , R_2^1 , and R_3^1 are as in structure 1, supra) had several times lower
5 H^+/K^+ -ATPase inhibitory activity than related 4-(2-pyridyl)-5-phenylthiazole compounds.


WO 97/33883 describes substituted pyrimidine compounds useful in treating cytokine mediated diseases.

10

BRIEF DESCRIPTION OF THE INVENTION

The present invention comprises a new class of compounds useful in the prophylaxis and treatment of diseases, such as $TNF-\alpha$, IL-1 β , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and
15 diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds, methods for the prophylaxis
20 and treatment of $TNF-\alpha$, IL-1 β , IL-6 and/or IL-8 mediated diseases, such as inflammatory, pain and diabetes diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.

25 The compounds of the invention are represented by the following general structure:




wherein R^1 , R^2 , R^{11} and R^{12} are defined below.

30 The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any way. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided compounds of the formula:



(I)

or a pharmaceutically acceptable salt thereof, wherein

- R₁ and R₂ are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; preferably, 0-2; more preferably, 0-1; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ and R₂ is 0-4; preferably, 0-3; more preferably, 0-2; most preferably, 0-1;
- preferably, R₂ is a radical of hydrogen, C₁-C₄ alkyl, halo, hydroxy, C₁-C₄ alkoxy, C₁-C₂ haloalkoxy of 1-3 halo radicals, thiol, C₁-C₄ alkylthio, aminosulfonyl, C₁-C₄ alkylaminosulfonyl, di-(C₁-C₄ alkyl)aminosulfonyl, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino or C₁-C₂ haloalkyl of 1-3 halo radicals;
- more preferably, R₂ is a radical of hydrogen, C₁-C₄ alkyl, halo, hydroxy, C₁-C₄ alkoxy, trifluoromethoxy, thiol, C₁-C₄ alkylthio, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino or trifluoromethyl;

more preferably, R₂ is a radical of hydrogen, methyl, ethyl, fluoro, chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, acetylamino or trifluoromethyl; and most preferably, R₂ is a radical of hydrogen or hydroxy;

wherein each Z is independently a

- (1) bond;
- (2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, halo, alkyl or haloalkyl;
- (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;

preferably, each Z is independently a

- (1) bond;
- (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino,

- (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- more preferably, each Z is independently a
- (1) bond;
- (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or

- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

more preferably, each Z is independently a

- (1) bond;
- (2) C₁-C₈ alkyl or C₂-C₈ alkenyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
- (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl radicals; or
- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;

more preferably, each Z is independently a

- (1) bond;
- (2) C₁-C₄ alkyl or C₂-C₅ alkenyl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂

- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 10 (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or C₁-C₄ alkyl radicals; or
- (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 20 more preferably, each Z is independently a
- (1) bond;
- (2) C₁-C₄ alkyl or C₂-C₅ alkenyl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals; or
- 30 (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 35 radicals;

more preferably, each Z is independently a

- (1) bond; or
- (2) C₁-C₄ alkyl radical optionally substituted by 1-2
- 5 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl
- 10 radicals; and

most preferably, each Z is independently a

- (1) bond; or
- (2) C₁-C₄ alkyl radical optionally substituted by 1-2
- 15 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;

each Y is independently a

- (1) hydrogen radical;
- 20 (2) halo or nitro radical;
- (3) -C(O)-R₂₀ or -C(NR₅)-NR₅R₂₁ radical;
- (4) -OR₂₁, -O-C(O)-R₂₁, -O-C(O)-NR₅R₂₁ or -O-C(O)-NR₂₂-S(O)₂-R₂₀ radical;
- (5) -SR₂₁, -S(O)-R₂₀, -S(O)₂-R₂₀, -S(O)₂-NR₅R₂₁, -S(O)₂-
- 25 NR₂₂-C(O)-R₂₁, -S(O)₂-NR₂₂-C(O)-OR₂₀ or -S(O)₂-NR₂₂-C(O)-NR₅R₂₁ radical; or
- (6) -NR₅R₂₁, -NR₂₂-C(O)-R₂₁, -NR₂₂-C(O)-OR₂₀, -NR₂₂-C(O)-NR₅R₂₁, -NR₂₂-C(NR₅)-NR₅R₂₁, -NR₂₂-S(O)₂-R₂₀ or -NR₂₂-S(O)₂-NR₅R₂₁ radical;

30

preferably, each Y is independently a

- (1) hydrogen radical;
- (2) halo radical;
- (3) -C(O)-R₂₀ or -C(NR₅)-NR₅R₂₁ radical;
- 35 (4) -OR₂₁, -O-C(O)-R₂₁ or -O-C(O)-NR₅R₂₁ radical;

13

- (5) $-\text{SR}_{21}$, $-\text{S(O)}-\text{R}_{20}$, $-\text{S(O)}_2-\text{R}_{20}$ or $-\text{S(O)}_2-\text{NR}_5\text{R}_{21}$ radical;
or
(6) $-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{C(O)}-\text{R}_{21}$, $-\text{NR}_{22}-\text{C(O)}-\text{OR}_{20}$, $-\text{NR}_{22}-\text{C(O)}-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{C(NR}_5)-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{S(O)}_2-\text{R}_{20}$ or $-\text{NR}_{22}-\text{S(O)}_2-\text{NR}_5\text{R}_{21}$ radical;

- more preferably, each Y is independently a
(1) hydrogen radical;
(2) $-\text{C(O)}-\text{R}_{20}$ radical;
10 (3) $-\text{OR}_{21}$, $-\text{SR}_{21}$, $-\text{S(O)}-\text{R}_{20}$, $-\text{S(O)}_2-\text{R}_{20}$ or $-\text{S(O)}_2-\text{NR}_5\text{R}_{21}$ radical; or
(4) $-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{C(O)}-\text{R}_{21}$, $-\text{NR}_{22}-\text{C(O)}-\text{OR}_{20}$, $-\text{NR}_{22}-\text{C(O)}-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{S(O)}_2-\text{R}_{20}$ or $-\text{NR}_{22}-\text{S(O)}_2-\text{NR}_5\text{R}_{21}$ radical;

- 15 more preferably, each Y is independently a
(1) hydrogen radical;
(2) $-\text{C(O)}-\text{R}_{20}$ radical;
(3) $-\text{OR}_{21}$, $-\text{SR}_{21}$, $-\text{S(O)}-\text{R}_{20}$, $-\text{S(O)}_2-\text{R}_{20}$ or $-\text{S(O)}_2-\text{NR}_5\text{R}_{21}$ radical; or
20 (4) $-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{C(O)}-\text{R}_{21}$ or $-\text{NR}_{22}-\text{S(O)}_2-\text{R}_{20}$ radical;

- more preferably, each Y is independently a
(1) $-\text{C(O)}-\text{R}_{20}$ radical;
(2) $-\text{OR}_{21}$, $-\text{SR}_{21}$, $-\text{S(O)}-\text{R}_{20}$, $-\text{S(O)}_2-\text{R}_{20}$ or $-\text{S(O)}_2-\text{NR}_5\text{R}_{21}$ radical; or
25 (3) $-\text{NR}_5\text{R}_{21}$, $-\text{NR}_{22}-\text{C(O)}-\text{R}_{21}$ or $-\text{NR}_{22}-\text{S(O)}_2-\text{R}_{20}$ radical.

- most preferably, each Y is independently a $-\text{OR}_{21}$, $-\text{SR}_{21}$ or $-\text{NR}_5\text{R}_{21}$ radical;

30

wherein each R_5 is independently

- (1) hydrogen radicals;
(2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino,
35 dialkylamino, hydroxy, alkoxy, alkylthio, $-\text{SO}_3\text{H}$ or halo;
or

(3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl;

preferably, each R₅ is independently

- (1) hydrogen radicals;
- (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO₃H or halo; or
- (3) aryl, heteroaryl, aryl-C₁-C₄-alkyl, heteroaryl-C₁-C₄-alkyl, heterocyclyl, heterocyclyl-C₁-C₄-alkyl, C₃-C₈ cycloalkyl or C₃-C₈-cycloalkyl-C₁-C₄-alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

20

more preferably, each R₅ is independently

- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO₃H or halo; or
- (3) aryl, heteroaryl, aryl-C₁-C₄-alkyl, heteroaryl-C₁-C₄-alkyl, heterocyclyl, heterocyclyl-C₁-C₄-alkyl, C₃-C₈ cycloalkyl or C₃-C₈-cycloalkyl-C₁-C₄-alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

35

more preferably, each R₅ is independently

- (1) hydrogen radicals;
(2) C₁-C₄ alkyl or C₂-C₅ alkenyl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -
5 SO₃H or halo; or
(3) phenyl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, heterocyclyl-C₁-C₂-alkyl or C₃-C₆-cycloalkyl-C₁-C₂-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-
10 C₄ alkylthio, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;

more preferably, each R₅ is independently

- (1) hydrogen radical;
15 (2) C₁-C₄ alkyl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂-alkyl)amino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo; or
(3) phenyl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, heterocyclyl-C₁-C₂-alkyl or C₃-C₆-cycloalkyl-C₁-C₂-alkyl
20 radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂-alkyl)amino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, methoxy, methylthio, C₁-C₄ alkyl or trifluoromethyl radicals;

25 more preferably, each R₅ is independently

- (1) hydrogen radical;
(2) C₁-C₄ alkyl radical optionally substituted by 1-3
halo radicals; or
(3) phenyl-C₁-C₂-alkyl or heteroaryl-C₁-C₂-alkyl,
30 radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;

more preferably, each R₅ is independently hydrogen or

- 35 C₁-C₄ alkyl radical; and most preferably, each R₅ is a hydrogen radical;

wherein each R₂₀ is independently

- (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, N-(alkoxy-carbonyl)-N-(alkyl)amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, alkanoyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkyl or haloalkyl;
- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, alkoxy-carbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
- preferably, each R₂₀ is independently
- (1) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅
alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄
alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo, C₁-C₄ alkyl or
5 C₁-C₄ haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3
radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy,
10 C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄
haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted
by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
15 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄
alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio,
cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3
halo radicals;
- 20 more preferably, each R₂₀ is independently
(1) C₁-C₈ alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl radicals
optionally substituted by 1-3 radicals of amino, C₁-C₄
alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino,
(C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-
25 N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄
alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄
alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo
or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-
alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl or
30 heteroaryl radicals optionally substituted by 1-3
radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅
alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄

alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or

(3) aryl or heteroaryl radicals optionally substituted
10 by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-
15 3 halo radicals;

more preferably, each R₂₀ is independently

(1) C₁-C₈ alkyl or C₂-C₅ alkenyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino,
20 di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄

alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₆ cycloalkyl,
25 heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo,
30 C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄

- alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
- more preferably, each R₂₀ is independently
- (1) C₁-C₈ alkyl or C₂-C₅ alkenyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
- (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or trifluoromethyl radicals;

more preferably, each R₂₀ is independently

(1) C₁-C₈ alkyl radicals optionally substituted by 1-3

radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄

alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄

alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy,

C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄

alkylsulfonyl, halo or C₃-C₆ cycloalkyl, heterocyclyl,

10 aryl or heteroaryl radicals optionally substituted by 1-

2' radicals of amino, di-(C₁-C₄ alkyl)amino, C₁-C₅

alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄

alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄

alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl

15 radicals;

(2) heterocyclyl radical optionally substituted by 1-2

radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-

C₄ alkyl; or

(3) aryl or heteroaryl radicals optionally substituted

20 by 1-2 radicals of (C₁-C₄ alkoxy)carbonyl, amino, C₁-C₄

alkylamino, di-(C₁-C₄ alkyl)amino, hydroxy, C₁-C₄ alkoxy,

C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or

trifluoromethyl radicals;

25 more preferably, each R₂₀ is independently

(1) C₁-C₆ alkyl radicals optionally substituted by 1-3

radicals of amino, methylamino, dimethylamino, t-

butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-

(methyl)amino, aminocarbonylamino, hydroxy, butoxy,

30 methoxy, butylthio, methylthio, methylsulfinyl,

methylsulfonyl, halo or C₅-C₆ cycloalkyl, heterocyclyl,

phenyl or heteroaryl radicals optionally substituted by

1-2 radicals of amino, dimethylamino, acetamino,

hydroxy, methoxy, methylthio, halo, methyl or

35 trifluoromethyl radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy or C₁-C₄ alkyl; or

(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

more preferably, each R₂₀ is independently

(1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C₅-C₆ cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

(2) heterocyclyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

most preferably, each R₂₀ is independently

(1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

(2) heterocyclyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

each R₂₁ is independently hydrogen radical or R₂₀;

each R₂₂ is independently

(1) hydrogen radical;

- 5 (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, 10 alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, 15 alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR₂₂-C(O)-NH₂, then R₂₂ is other than an optionally substituted aryl radical;

- 20 preferably, each R₂₂ is independently

(1) hydrogen radical;

(2) C₁-C₄ alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, 25 di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or

- 30 (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ 35 alkylsulfonyl, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; provided when Z is a

bond and Y is $\text{-NR}_{22}\text{-C(O)-NH}_2$, then R_{22} is other than an optionally substituted aryl radical;

more preferably, each R_{22} is independently

- 5 (1) hydrogen radical; or
(2) $\text{C}_1\text{-C}_4$ alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di- $(\text{C}_1\text{-C}_2\text{ alkyl})$ amino, $\text{C}_1\text{-C}_5$ alkanoylamino, $(\text{C}_1\text{-C}_4\text{ alkoxy})$ carbonylamino, hydroxy, $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_4$ alkylthio, cyano, halo, $\text{C}_1\text{-C}_4$ alkyl or $\text{C}_1\text{-C}_2$ haloalkyl of 1-3 halo radicals;
- 10

more preferably, each R_{22} is independently hydrogen or $\text{C}_1\text{-C}_4$ alkyl radical; and most preferably, each R_{22} is independently hydrogen or methyl radical;

15

R_{11} and R_{12} are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of

- (1) R_{30} ;
- 20 (2) halo or cyano radicals;
- (3) -C(O)-R_{30} , -C(O)-OR_{29} , $\text{-C(O)-NR}_{31}\text{R}_{32}$ or $\text{-C(NR}_{31}\text{)-NR}_{31}\text{R}_{32}$ radicals;
- (4) -OR_{29} , -O-C(O)-R_{29} , $\text{-O-C(O)-NR}_{31}\text{R}_{32}$ or $\text{-O-C(O)-NR}_{33}\text{-S(O)}_2\text{-R}_{30}$ radicals;
- 25 (5) -SR_{29} , -S(O)-R_{30} , $\text{-S(O)}_2\text{-R}_{30}$, $\text{-S(O)}_2\text{-NR}_{31}\text{R}_{32}$, $\text{-S(O)}_2\text{-NR}_{33}\text{-C(O)-R}_{30}$, $\text{-S(O)}_2\text{-NR}_{33}\text{-C(O)-OR}_{30}$ or $\text{-S(O)}_2\text{-NR}_{33}\text{-C(O)-NR}_{31}\text{R}_{32}$ radicals; or
- (6) $\text{-NR}_{31}\text{R}_{32}$, $\text{-NR}_{33}\text{-C(O)-R}_{29}$, $\text{-NR}_{33}\text{-C(O)-OR}_{30}$, $\text{-NR}_{33}\text{-C(O)-NR}_{31}\text{R}_{32}$, $\text{-NR}_{33}\text{-C(NR}_{31}\text{)-NR}_{31}\text{R}_{32}$, $\text{-NR}_{33}\text{-S(O)}_2\text{-R}_{30}$ or $\text{-NR}_{33}\text{-S(O)}_2\text{-NR}_{31}\text{R}_{32}$ radicals;
- 30 provided that (1) R_{11} is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R_{11} and R_{12} is 0-1;
- 35

preferably, R₁₁ and R₁₂ are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of

- 5 (1) R₃₀;
(2) halo or cyano radicals;
(3) -C(O)-R₃₀, -C(O)-OR₂₉, -C(O)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals;
(4) -OR₂₉, -O-C(O)-R₂₉, -O-C(O)-NR₃₁R₃₂ or -O-C(O)-NR₃₃-S(O)₂-R₃₀ radicals;
10 (5) -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -S(O)₂-NR₃₃-C(O)-R₃₀, -S(O)₂-NR₃₃-C(O)-OR₃₀ or -S(O)₂-NR₃₃-C(O)-NR₃₁R₃₂ radicals; or
(6) -NR₃₁R₃₂, -NR₃₃-C(O)-R₂₉, -NR₃₃-C(O)-OR₃₀, -NR₃₃-C(O)-NR₃₁R₃₂, -NR₃₃-C(NR₃₁)-NR₃₁R₃₂, -NR₃₃-S(O)₂-R₃₀ or -NR₃₃-S(O)₂-NR₃₁R₃₂ radicals;
15 provided that (1) R₁₁ is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the
20 total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

more preferably, R₁₁ and R₁₂ are each independently an
25 aryl or heteroaryl radical optionally substituted by 1-2 radicals of

- (1) R₃₀;
(2) halo or cyano radicals;
(3) -C(O)-R₃₀, -C(O)-OR₂₉, -C(O)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals; or
30 (4) -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂, -NR₃₃-C(O)-R₂₉ or -NR₃₃-C(O)-OR₃₀ radicals;

more preferably, R₁₁ is an aryl radical and R₁₂ is a
35 heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of

- (1) R₃₀;
(2) halo or cyano radicals;
(3) -C(O)-R₃₀, -C(O)-OR₂₉, -C(O)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals; or.
5 (4) -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals;

more preferably, R₁₁ is an aryl radical and R₁₂ is a heteroaryl radical, wherein the aryl and heteroaryl
10 radicals are optionally substituted by 1-2 radicals of
(1) R₃₀;

- (2) halo or cyano radicals; or
(3) -C(O)-NR₃₁R₃₂, -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals;

15

more preferably, R₁₁ is an aryl radical optionally substituted by 1-2 radicals of (1) R₃₀; (2) halo or cyano radicals; or (3) -C(O)-NR₃₁R₃₂, -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-
20 C(O)-R₂₉ radicals; more preferably, R₁₁ is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; more
25 preferably, R₁₁ is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl
30 radicals; and most preferably, R₁₁ is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals;

35

more preferably, R_{12} is a heteroaryl radical optionally substituted by 1-2 radicals of (1) R_{30} ; (2) halo or cyano radicals; or (3) $-C(O)-NR_{31}R_{32}$, $-OR_{29}$, $-SR_{29}$, $-NR_{31}R_{32}$ or $-NR_{33}-C(O)-R_{29}$ radicals; more preferably, R_{12} is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; more preferably, R_{12} is a 4-pyridyl, 4-quinolinyl, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and most preferably, R_{12} is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals;

wherein each R_{30} is independently

- (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of $-NR_{31}R_{31}$, $-CO_2R_{23}$, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl;
- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino,

hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;

preferably, each R_{30} is independently

- 5 (1) C_1 - C_4 alkyl, C_2 - C_4 alkenyl or C_2 - C_4 alkynyl radicals optionally substituted by 1-3 radicals of $-NR_{31}R_{31}$, $-CO_2R_{23}$, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, cyano, halo or aryl- C_1 - C_4 -alkoxy, aryl- C_1 - C_4 -alkylthio, aryl- C_1 - C_4 -
- 10 alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4
- 15 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, cyano, halo, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4
- 20 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4
- 25 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, halo, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;
- 30 more preferably, each R_{30} is independently
(1) C_1 - C_4 alkyl radical optionally substituted by 1-3 radicals of
(a) $-NR_{31}R_{31}$;
- 35 (b) C_1 - C_4 alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3

- radicals of amino, alkylamino, di-(C₁-C₄-alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl;
- 5 or
- (c) hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, or phenyl-C₁-C₄-alkoxy, phenyl-C₁-C₄-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
- 10 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- (2) C₁-C₄ haloalkyl of 1-3 halo radical; or
- 15 (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl
- 20 radicals;
- more preferably, each R₃₀ is independently
- (1) C₁-C₄ alkyl radical optionally substituted by
- (a) amino, C₁-C₄ alkylamino or di-(C₁-C₄-alkyl)amino
- 25 radicals; or
- (b) hydroxy, C₁-C₄ alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 30 alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- (2) C₁-C₂ haloalkyl of 1-3 halo radical; or
- (3) aryl or heteroaryl radicals optionally substituted
- 35 by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

5

more preferably, each R₃₀ is independently

(1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

10

(2) trifluoromethyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino,

15

acetamido, hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

more preferably, each R₃₀ is independently

(1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

20

(2) trifluoromethyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

25

30 most preferably, R₃₀ is independently

(1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

35

(2) trifluoromethyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

5

each R₂₉ is independently hydrogen radical or R₃₀; and most preferably, R₂₉ is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

10

each R₃₁ is independently

(1) hydrogen radicals;

(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or

15

(3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;

20

25

preferably, each R₃₁ is independently

(1) hydrogen radicals;

(2) C₁-C₄ alkyl radical optionally substituted by an C₃-C₈ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or

30

(3) aryl, heteroaryl, heterocyclyl or C₃-C₈ cycloalkyl radical optionally substituted by 1-3 radicals of amino,

35

C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3
5 halo radicals;

more preferably, each R₃₁ is independently

- (1) hydrogen radicals; or
- (2) C₁-C₄ alkyl radical optionally substituted by an
10 phenyl or heteroaryl radical optionally substituted by
1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄
alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄
alkylthio, cyano, C₁-C₄ alkyl or trifluoromethyl
15 radicals;

more preferably, each R₃₁ is independently hydrogen or
C₁-C₄ alkyl radicals; and most preferably, each R₃₁ is
independently hydrogen, methyl or ethyl radicals;

20

each R₃₂ is independently

- (1) hydrogen radicals;
- (2) alkyl radical optionally substituted by an
cycloalkyl, aryl, heterocyclyl or heteroaryl radical
25 optionally substituted by 1-3 radicals of amino,
alkylamino, dialkylamino, alkanoylamino,
alkoxycarbonylamino, alkylsulfonylamino, hydroxy,
alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
- (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical
30 optionally substituted by 1-3 radicals of amino,
alkylamino, dialkylamino, alkanoylamino,
alkoxycarbonylamino, alkylsulfonylamino, hydroxy,
alkoxy, alkylthio, cyano, alkyl or haloalkyl;

35 preferably, each R₃₂ is independently

- (1) hydrogen radicals;

- (2) C₁-C₄ alkyl radical optionally substituted by an C₃-C₈ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (3) aryl, heteroaryl, heterocyclyl or C₃-C₈ cycloalkyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

15

more preferably, each R₃₂ is independently

- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl radical optionally substituted by an C₃-C₆ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (3) aryl, heteroaryl, heterocyclyl or C₃-C₆ cycloalkyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

more preferably, each R₃₂ is independently

- (1) hydrogen radicals;

- (2) C₁-C₄ alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; or
- (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals;

more preferably, each R₃₂ is independently

- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl radical or C₁-C₂ alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or
- (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;

most preferably, R₃₂ is independently

- (1) hydrogen or C₁-C₄ alkyl radical; or
- (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals;
- and

30

wherein each R₃₃ is independently

- (1) hydrogen radical; or
- (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,
- 35

alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;

preferably, each R_{33} is independently

- 5 (1) hydrogen radical; or
(2) C_1 - C_4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;

- more preferably, each R_{33} is independently hydrogen or
15 C_1 - C_4 alkyl radical; and most preferably, each R_{33} is independently hydrogen or methyl radical.

The following provisos relate to compounds of the invention, only, and not to the pharmaceutical
20 compositions or methods of use, which encompass the full breadth of compounds recited above (unless expressly stated otherwise):


1. when R^1 and R^{12} are the same and are a 5- or 6-member ring having from 1-3 heteroatoms
25 independently selected from N, S, and O, to which ring a benzene ring is optionally fused, R^{11} is phenyl or naphthyl optionally substituted with halo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthiol, hydroxy, amino, C_1 - C_6 alkylamino, or dialkylamino, or R^{11} is a 5- or 6-membered ring having from 1-3 heteroatoms independently selected from N, S, and O, to which ring a benzene ring is optionally fused and optionally substituted with C_1 - C_6 alkyl, then R^2 is other than OH or NH_2 ;
30
2. when R^2 is H, R^{11} is phenyl and R^{12} is phenyl or 4-pyridyl, then R^1 is other than H, methyl, or amino;
35

3. when R^2 is H, R^{11} is 2-methylphenyl and R^{12} is 2-pyridyl, then R^1 is other than n-propyl; and
4. when R^{11} and R^{12} are each an optionally substituted phenyl radical, then R^1 is other than an
- 5 optionally substituted 2-pyridyl radical.

The compounds of this invention may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially

10 racemic mixtures and separate enantiomers and diastereomers.

Compounds of interest include the following:



wherein R^2 is H and R^{11} , R^{12} , and R^1 are one of the

15 combinations given in the following table:

R^{11}	R^{12}	R^1
Phenyl	4-pyridyl	1-piperazinyl
4-fluorophenyl	4-pyridyl	1-piperazinyl
3-fluorophenyl	4-pyridyl	1-piperazinyl
2-fluorophenyl	4-pyridyl	1-piperazinyl
4-chlorophenyl	4-pyridyl	1-piperazinyl
3-chlorophenyl	4-pyridyl	1-piperazinyl
2-chlorophenyl	4-pyridyl	1-piperazinyl
4-tolyl	4-pyridyl	1-piperazinyl
3-tolyl	4-pyridyl	1-piperazinyl
2-tolyl	4-pyridyl	1-piperazinyl
4-trifluoro-methylphenyl	4-pyridyl	1-piperazinyl
3-trifluoro-methylphenyl	4-pyridyl	1-piperazinyl
2,6-dichlorophenyl	4-pyridyl	1-piperazinyl
2,6-dimethyl phenyl	4-pyridyl	1-piperazinyl
3,4-dichlorophenyl	4-pyridyl	1-piperazinyl
3,4-dimethyl phenyl	4-pyridyl	1-piperazinyl
2,4-dichlorophenyl	4-pyridyl	1-piperazinyl

2,4-dimethyl phenyl	4-pyridyl	1-piperazinyl
Phenyl	2-amino-4- pyridyl	1-piperazinyl
4-fluorophenyl	2-amino-4- pyridyl	1-piperazinyl
3-fluorophenyl	2-amino-4- pyridyl	1-piperazinyl
2-fluorophenyl	2-amino-4- pyridyl	1-piperazinyl
4-chlorophenyl	2-amino-4- pyridyl	1-piperazinyl
3-chlorophenyl	2-amino-4- pyridyl	1-piperazinyl
2-chlorophenyl	2-amino-4- pyridyl	1-piperazinyl
4-tolyl	2-amino-4- pyridyl	1-piperazinyl
3-tolyl	2-amino-4- pyridyl	1-piperazinyl
2-tolyl	2-amino-4- pyridyl	1-piperazinyl
4-trifluoro- methylphenyl	2-amino-4- pyridyl	1-piperazinyl
3-trifluoro- methylphenyl	2-amino-4- pyridyl	1-piperazinyl
2,6- dichlorophenyl	2-amino-4- pyridyl	1-piperazinyl
2,6-dimethyl phenyl	2-amino-4- pyridyl	1-piperazinyl
3,4- dichlorophenyl	2-amino-4- pyridyl	1-piperazinyl
3,4-dimethyl phenyl	2-amino-4- pyridyl	1-piperazinyl
2,4- dichlorophenyl	2-amino-4- pyridyl	1-piperazinyl
2,4-dimethyl phenyl	2-amino-4- pyridyl	1-piperazinyl
Phenyl	2-acetamido- 4-pyridyl	1-piperazinyl
4-fluorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
3-fluorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
2-fluorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
4-chlorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
3-chlorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
2-chlorophenyl	2-acetamido- 4-pyridyl	1-piperazinyl
4-tolyl	2-acetamido- 4-pyridyl	1-piperazinyl

3-tolyl	2-acetamido-4-pyridyl	1-piperazinyl
2-tolyl	2-acetamido-4-pyridyl	1-piperazinyl
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	1-piperazinyl
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	1-piperazinyl
2,6-dichlorophenyl	2-acetamido-4-pyridyl	1-piperazinyl
2,6-dimethylphenyl	2-acetamido-4-pyridyl	1-piperazinyl
3,4-dichlorophenyl	2-acetamido-4-pyridyl	1-piperazinyl
3,4-dimethylphenyl	2-acetamido-4-pyridyl	1-piperazinyl
2,4-dichlorophenyl	2-acetamido-4-pyridyl	1-piperazinyl
2,4-dimethylphenyl	2-acetamido-4-pyridyl	1-piperazinyl
Phenyl	2-amino-4-pyrimidinyl	1-piperazinyl
4-fluorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
3-fluorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
2-fluorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
4-chlorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
3-chlorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
2-chlorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
4-tolyl	2-amino-4-pyrimidinyl	1-piperazinyl
3-tolyl	2-amino-4-pyrimidinyl	1-piperazinyl
2-tolyl	2-amino-4-pyrimidinyl	1-piperazinyl
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	1-piperazinyl
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	1-piperazinyl
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	1-piperazinyl
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	1-piperazinyl
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	1-piperazinyl

2,4-dimethylphenyl	2-amino-4-pyrimidinyl	1-piperazinyl
Phenyl	4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-tolyl	4-pyridyl	2,6-dichlorobenzyl
3-tolyl	4-pyridyl	2,6-dichlorobenzyl
2-tolyl	4-pyridyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	4-pyridyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	4-pyridyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2,6-dimethylphenyl	4-pyridyl	2,6-dichlorobenzyl
3,4-dichlorophenyl	4-pyridyl	2,6-dichlorobenzyl
3,4-dimethylphenyl	4-pyridyl	2,6-dichlorobenzyl
2,4-dichlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2,4-dimethylphenyl	4-pyridyl	2,6-dichlorobenzyl
Phenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-tolyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-tolyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2-tolyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl

2,6-dimethyl phenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
3,4- dichlorophenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
3,4-dimethyl phenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2,4- dichlorophenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
2,4-dimethyl phenyl	2-amino-4- pyridyl	2,6-dichlorobenzyl
Phenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-tolyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-tolyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2-tolyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
4-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3-trifluoro- methylphenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2,6- dichlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2,6-dimethyl phenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3,4- dichlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
3,4-dimethyl phenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2,4- dichlorophenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
2,4-dimethyl phenyl	2-acetamido- 4-pyridyl	2,6-dichlorobenzyl
Phenyl	2-amino-4- pyrimidinyl	2,6-dichlorobenzyl
4-fluorophenyl	2-amino-4- pyrimidinyl	2,6-dichlorobenzyl
3-fluorophenyl	2-amino-4- pyrimidinyl	2,6-dichlorobenzyl
2-fluorophenyl	2-amino-4- pyrimidinyl	2,6-dichlorobenzyl

4-chlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-chlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2-chlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
4-tolyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-tolyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2-tolyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
Phenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
4-fluorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
3-fluorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
2-fluorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
4-chlorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
3-chlorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
2-chlorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
4-tolyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
3-tolyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
2-tolyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
4-trifluoromethylphenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
3-trifluoromethylphenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino
2,6-dichlorophenyl	4-pyridyl	2-(2-chlorophenyl)ethylamino

2,6-dimethyl phenyl	4-pyridyl	2-(2-chlorophenyl) ethylamino
3,4- dichlorophenyl	4-pyridyl	2-(2-chlorophenyl) ethylamino
3,4-dimethyl phenyl	4-pyridyl	2-(2-chlorophenyl) ethylamino
2,4- dichlorophenyl	4-pyridyl	2-(2-chlorophenyl) ethylamino
2,4-dimethyl phenyl	4-pyridyl	2-(2-chlorophenyl) ethylamino
4-fluorophenyl	4-pyridyl	3-(3-fluorophenyl) propylamino
4-fluorophenyl	2-amino-4- pyrimidinyl	3-(3-fluorophenyl) propylamino
benzyl	4-pyridyl	3-phenylpropylamino
benzyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2-thienyl	4-pyridyl	3-phenylpropylamino
2-thienyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
cyclohexyl	4-pyridyl	3-phenylpropylamino
cyclohexyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
tert-butyl	4-pyridyl	3-phenylpropylamino
tert-butyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
4-fluorophenyl	4- piperidinyl	3-phenylpropylamino
4-fluorophenyl	4- piperidinyl	2-(4-fluorophenyl) ethylamino
4-fluorophenyl	4-pyranyl	3-phenylpropylamino
4-fluorophenyl	4-pyranyl	2-(4-fluorophenyl) ethylamino
Phenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
4-fluorophenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
3-fluorophenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
2-fluorophenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
4-chlorophenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
3-chlorophenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
2-chlorophenyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
4-tolyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
3-tolyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino
2-tolyl	2-amino-4- pyridyl	2-(2-chlorophenyl) ethylamino

4-trifluoro-methylphenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
3-trifluoro-methylphenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,6-dimethyl phenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
3,4-dichlorophenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
3,4-dimethyl phenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,4-dichlorophenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,4-dimethyl phenyl	2-amino-4-pyridyl	2-(2-chlorophenyl) ethylamino
Phenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
4-fluorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
3-fluorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2-fluorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
4-chlorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
3-chlorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2-chlorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
4-tolyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
3-tolyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2-tolyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
4-trifluoro-methylphenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
3-trifluoro-methylphenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,6-dimethyl phenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
3,4-dimethyl phenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,4-dichlorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
2,4-dimethyl phenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl) ethylamino
Phenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino

4-fluorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
3-fluorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2-fluorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
4-chlorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
3-chlorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2-chlorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
4-tolyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
3-tolyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2-tolyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl) ethylamino
Phenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
4-fluorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3-fluorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2-fluorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
4-chlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3-chlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2-chlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
4-tolyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3-tolyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2-tolyl	4-pyridyl	2-(4-fluorophenyl) ethylamino

4-trifluoro-methylphenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
3-trifluoro-methylphenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,6-dichlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,6-dimethyl phenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
3,4-dichlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
3,4-dimethyl phenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,4-dichlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,4-dimethyl phenyl	4-pyridyl	2-(4-fluorophenyl)ethyl amino
Phenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
4-fluorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
3-fluorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2-fluorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
4-chlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
3-chlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2-chlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
4-tolyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
3-tolyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2-tolyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
4-trifluoro-methylphenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
3-trifluoro-methylphenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,6-dichlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,6-dimethyl phenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
3,4-dichlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
3,4-dimethyl phenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,4-dichlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
2,4-dimethyl phenyl	2-amino-4-pyridyl	2-(4-fluorophenyl)ethyl amino
Phenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl)ethyl amino

4-fluorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
3-fluorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2-fluorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
4-chlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
3-chlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2-chlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
4-tolyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
3-tolyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2-tolyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
3,4-dimethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2,4-dichlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
2,4-dimethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethyl amino
Phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
4-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
3-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
2-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
4-chlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
3-chlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
2-chlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
4-tolyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
3-tolyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino
2-tolyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethyl amino

4-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
3-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
2,6-dimethyl phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
3,4-dimethyl phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
2,4-dimethyl phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl)ethyl amino
Phenyl	4-pyridyl	3-phenylpropylamino
4-fluorophenyl	4-pyridyl	3-phenylpropylamino
3-fluorophenyl	4-pyridyl	3-phenylpropylamino
2-fluorophenyl	4-pyridyl	3-phenylpropylamino
4-chlorophenyl	4-pyridyl	3-phenylpropylamino
3-chlorophenyl	4-pyridyl	3-phenylpropylamino
2-chlorophenyl	4-pyridyl	3-phenylpropylamino
4-tolyl	4-pyridyl	3-phenylpropylamino
3-tolyl	4-pyridyl	3-phenylpropylamino
2-tolyl	4-pyridyl	3-phenylpropylamino
4-trifluoro-methylphenyl	4-pyridyl	3-phenylpropylamino
3-trifluoro-methylphenyl	4-pyridyl	3-phenylpropylamino
2,6-dichlorophenyl	4-pyridyl	3-phenylpropylamino
2,6-dimethyl phenyl	4-pyridyl	3-phenylpropylamino
3,4-dichlorophenyl	4-pyridyl	3-phenylpropylamino
3,4-dimethyl phenyl	4-pyridyl	3-phenylpropylamino
2,4-dichlorophenyl	4-pyridyl	3-phenylpropylamino
2,4-dimethyl phenyl	4-pyridyl	3-phenylpropylamino
Phenyl	2-amino-4-pyridyl	3-phenylpropylamino
4-fluorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
3-fluorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
2-fluorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
4-chlorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
3-chlorophenyl	2-amino-4-pyridyl	3-phenylpropylamino

2-chlorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
4-tolyl	2-amino-4-pyridyl	3-phenylpropylamino
3-tolyl	2-amino-4-pyridyl	3-phenylpropylamino
2-tolyl	2-amino-4-pyridyl	3-phenylpropylamino
4-trifluoromethylphenyl	2-amino-4-pyridyl	3-phenylpropylamino
3-trifluoromethylphenyl	2-amino-4-pyridyl	3-phenylpropylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
2,6-dimethylphenyl	2-amino-4-pyridyl	3-phenylpropylamino
3,4-dichlorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
3,4-dimethylphenyl	2-amino-4-pyridyl	3-phenylpropylamino
2,4-dichlorophenyl	2-amino-4-pyridyl	3-phenylpropylamino
2,4-dimethylphenyl	2-amino-4-pyridyl	3-phenylpropylamino
Phenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
4-fluorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
3-fluorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
2-fluorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
4-chlorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
3-chlorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
2-chlorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
4-tolyl	2-acetamido-4-pyridyl	3-phenylpropylamino
3-tolyl	2-acetamido-4-pyridyl	3-phenylpropylamino
2-tolyl	2-acetamido-4-pyridyl	3-phenylpropylamino
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	3-phenylpropylamino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	3-phenylpropylamino

3,4-dimethyl phenyl	2-acetamido- 4-pyridyl	3-phenylpropylamino
2,4- dichlorophenyl	2-acetamido- 4-pyridyl	3-phenylpropylamino
2,4-dimethyl phenyl	2-acetamido- 4-pyridyl	3-phenylpropylamino
Phenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
4-fluorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
3-fluorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2-fluorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
4-chlorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
3-chlorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2-chlorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
4-tolyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
3-tolyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2-tolyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
4-trifluoro- methylphenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
3-trifluoro- methylphenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2,6- dichlorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2,6-dimethyl phenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
3,4- dichlorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
3,4-dimethyl phenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2,4- dichlorophenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
2,4-dimethyl phenyl	2-amino-4- pyrimidinyl	3-phenylpropylamino
Phenyl	4-pyridyl	3-imidazolylpropylamino
4-fluorophenyl	4-pyridyl	3-imidazolylpropylamino
3-fluorophenyl	4-pyridyl	3-imidazolylpropylamino
2-fluorophenyl	4-pyridyl	3-imidazolylpropylamino
4-chlorophenyl	4-pyridyl	3-imidazolylpropylamino
3-chlorophenyl	4-pyridyl	3-imidazolylpropylamino
2-chlorophenyl	4-pyridyl	3-imidazolylpropylamino
4-tolyl	4-pyridyl	3-imidazolylpropylamino
3-tolyl	4-pyridyl	3-imidazolylpropylamino
2-tolyl	4-pyridyl	3-imidazolylpropylamino
4-trifluoro- methylphenyl	4-pyridyl	3-imidazolylpropylamino

3-trifluoro-methylphenyl	4-pyridyl	3-imidazolylpropylamino
2,6-dichlorophenyl	4-pyridyl	3-imidazolylpropylamino
2,6-dimethylphenyl	4-pyridyl	3-imidazolylpropylamino
3,4-dichlorophenyl	4-pyridyl	3-imidazolylpropylamino
3,4-dimethylphenyl	4-pyridyl	3-imidazolylpropylamino
2,4-dichlorophenyl	4-pyridyl	3-imidazolylpropylamino
2,4-dimethylphenyl	4-pyridyl	3-imidazolylpropylamino
Phenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
4-fluorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
3-fluorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2-fluorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
4-chlorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
3-chlorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2-chlorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
4-tolyl	2-amino-4-pyridyl	3-imidazolylpropylamino
3-tolyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2-tolyl	2-amino-4-pyridyl	3-imidazolylpropylamino
4-trifluoro-methylphenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
3-trifluoro-methylphenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2,6-dimethylphenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
3,4-dichlorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
3,4-dimethylphenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2,4-dichlorophenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
2,4-dimethylphenyl	2-amino-4-pyridyl	3-imidazolylpropylamino
Phenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
4-fluorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino


3-fluorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2-fluorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
4-chlorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
3-chlorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2-chlorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
4-tolyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
3-tolyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2-tolyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
3,4-dimethylphenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2,4-dichlorophenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
2,4-dimethylphenyl	2-acetamido-4-pyridyl	3-imidazolylpropylamino
Phenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
3-fluorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2-fluorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
4-chlorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
3-chlorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2-chlorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
4-tolyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
3-tolyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2-tolyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino

3-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	3-imidazolylpropylamino
4-fluorophenyl	4-pyridyl	4-fluorobenzylamino
4-fluorophenyl	2-acetamido-4-pyridyl	4-fluorobenzylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	4-fluorobenzylamino
4-fluorophenyl	4-pyridyl	2-(2-chlorophenyl-1-methyl)ethyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	2-(2-chlorophenyl-1-methyl)ethyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	2-(2-chlorophenyl-1-methyl)ethyl) amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-1-methyl-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-(4-fluorophenyl)-1-methyl-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(4-fluorophenyl)-1-methyl-propyl) amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(1,1-dimethyl-3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(1,1-dimethyl-3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	4-pyridyl	(3-(2-fluorophenyl)-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-(2-fluorophenyl)-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(2-fluorophenyl)-propyl) amino
4-fluorophenyl	4-pyridyl	(3-methyl-3-phenylpropyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-methyl-3-phenylpropyl) amino

4-fluorophenyl	2-amino-4-pyrimidinyl	(3-methyl-3-phenylpropyl) amino
4-fluorophenyl	4-pyridyl	(2-methyl-3-phenylpropyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-methyl-3-phenylpropyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-methyl-3-phenylpropyl) amino
3-fluorophenyl	4-pyridyl	(S)-tetrahydroisoquinol-3-ylmethylenamino
2-fluorophenyl	2-amino-4-pyridyl	(S)-3-benzylpiperazinyl
3-chlorophenyl	2-acetamido-4-pyridyl	(S)-2-N-isopropylamino-3-phenylpropylamino
2-chlorophenyl	2-amino-4-pyrimidinyl	(S)-2-N-glycylamino-3-phenylpropylamino
4-tolyl	4-pyridyl	(S)-2-amino-3-phenylpropylamino
3-tolyl	2-amino-4-pyridyl	(R)-2-amino-3-phenylpropylamino
2-tolyl	2-acetamido-4-pyridyl	3-amino-3-phenylpropylamino
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	(S)-2-amino-3-(2-fluorophenyl)propylamino
3-trifluoromethylphenyl	4-pyridyl	(S)-2-amino-3-(2-methylphenyl)propylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	3-amino-3-(2-fluorophenyl)propylamino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	3-amino-3-(2-methylphenyl)propylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-amino-2-methyl-3-phenylpropylamino
3,4-dimethylphenyl	4-pyridyl	3-amino-2-methyl-3-phenylpropylamino
3-fluorophenyl	2-amino-4-pyridyl	(S)-2-amino-3-phenylpropylamino
2-fluorophenyl	2-acetamido-4-pyridyl	(S)-2-amino-3-(2-fluorophenyl)propylamino
3-chlorophenyl	2-amino-4-pyrimidinyl	(S)-2-amino-3-(2-methylphenyl)propylamino
2-chlorophenyl	4-pyridyl	(S)-2-N-isopropylamino-3-phenylpropylamino
4-tolyl	2-amino-4-pyridyl	(S)-2-N-glycylamino-3-phenylpropylamino
3-tolyl	2-acetamido-4-pyridyl	2-amino-2-methyl-3-phenylpropylamino
2-tolyl	2-amino-4-pyrimidinyl	(R)-2-amino-3-phenylpropylamino
4-trifluoromethylphenyl	4-pyridyl	3-amino-3-phenylpropylamino
3-trifluoromethylphenyl	2-amino-4-pyridyl	3-amino-3-(2-fluorophenyl)propylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	3-amino-3-(2-methylphenyl)propylamino

2,6-dimethyl phenyl	2-amino-4- pyrimidinyl	3-amino-2-methyl-3- phenylpropylamino
3,4- dichlorophenyl	4-pyridyl	(S)-tetrahydroisoquinol- 3-ylmethylenamino
3,4-dimethyl phenyl	4-pyridyl	(S)-3-benzylpiperazinyl

and



wherein R² is -OH and R¹¹, R¹², and R¹ are one of the combinations given in the following table:

R ¹¹	R ¹²	R ¹
Phenyl	4-pyridyl	4-pyridyl
4-fluorophenyl	4-pyridyl	4-pyridyl
3-fluorophenyl	4-pyridyl	4-pyridyl
2-fluorophenyl	4-pyridyl	4-pyridyl
4-chlorophenyl	4-pyridyl	4-pyridyl
3-chlorophenyl	4-pyridyl	4-pyridyl
2-chlorophenyl	4-pyridyl	4-pyridyl
4-tolyl	4-pyridyl	4-pyridyl
3-tolyl	4-pyridyl	4-pyridyl
2-tolyl	4-pyridyl	4-pyridyl
4-trifluoro- methylphenyl	4-pyridyl	4-pyridyl
3-trifluoro- methylphenyl	4-pyridyl	4-pyridyl
2,6- dichlorophenyl	4-pyridyl	4-pyridyl
2,6-dimethyl phenyl	4-pyridyl	4-pyridyl
3,4- dichlorophenyl	4-pyridyl	4-pyridyl
3,4-dimethyl phenyl	4-pyridyl	4-pyridyl
2,4- dichlorophenyl	4-pyridyl	4-pyridyl
2,4-dimethyl phenyl	4-pyridyl	4-pyridyl
Phenyl	2-amino-4- pyridyl	4-pyridyl
4-fluorophenyl	2-amino-4- pyridyl	4-pyridyl
3-fluorophenyl	2-amino-4- pyridyl	4-pyridyl
2-fluorophenyl	2-amino-4- pyridyl	4-pyridyl

4-chlorophenyl	2-amino-4-pyridyl	4-pyridyl
3-chlorophenyl	2-amino-4-pyridyl	4-pyridyl
2-chlorophenyl	2-amino-4-pyridyl	4-pyridyl
4-tolyl	2-amino-4-pyridyl	4-pyridyl
3-tolyl	2-amino-4-pyridyl	4-pyridyl
2-tolyl	2-amino-4-pyridyl	4-pyridyl
4-trifluoromethylphenyl	2-amino-4-pyridyl	4-pyridyl
3-trifluoromethylphenyl	2-amino-4-pyridyl	4-pyridyl
2,6-dichlorophenyl	2-amino-4-pyridyl	4-pyridyl
2,6-dimethylphenyl	2-amino-4-pyridyl	4-pyridyl
3,4-dichlorophenyl	2-amino-4-pyridyl	4-pyridyl
3,4-dimethylphenyl	2-amino-4-pyridyl	4-pyridyl
2,4-dichlorophenyl	2-amino-4-pyridyl	4-pyridyl
2,4-dimethylphenyl	2-amino-4-pyridyl	4-pyridyl
Phenyl	2-acetamido-4-pyridyl	4-pyridyl
4-fluorophenyl	2-acetamido-4-pyridyl	4-pyridyl
3-fluorophenyl	2-acetamido-4-pyridyl	4-pyridyl
2-fluorophenyl	2-acetamido-4-pyridyl	4-pyridyl
4-chlorophenyl	2-acetamido-4-pyridyl	4-pyridyl
3-chlorophenyl	2-acetamido-4-pyridyl	4-pyridyl
2-chlorophenyl	2-acetamido-4-pyridyl	4-pyridyl
4-tolyl	2-acetamido-4-pyridyl	4-pyridyl
3-tolyl	2-acetamido-4-pyridyl	4-pyridyl
2-tolyl	2-acetamido-4-pyridyl	4-pyridyl
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	4-pyridyl
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	4-pyridyl
2,6-dichlorophenyl	2-acetamido-4-pyridyl	4-pyridyl

2,6-dimethylphenyl	2-acetamido-4-pyridyl	4-pyridyl
3,4-dichlorophenyl	2-acetamido-4-pyridyl	4-pyridyl
3,4-dimethylphenyl	2-acetamido-4-pyridyl	4-pyridyl
2,4-dichlorophenyl	2-acetamido-4-pyridyl	4-pyridyl
2,4-dimethylphenyl	2-acetamido-4-pyridyl	4-pyridyl
Phenyl	2-amino-4-pyrimidinyl	4-pyridyl
4-fluorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
3-fluorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
2-fluorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
4-chlorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
3-chlorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
2-chlorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
4-tolyl	2-amino-4-pyrimidinyl	4-pyridyl
3-tolyl	2-amino-4-pyrimidinyl	4-pyridyl
2-tolyl	2-amino-4-pyrimidinyl	4-pyridyl
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	4-pyridyl
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	4-pyridyl
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	4-pyridyl
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	4-pyridyl
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	4-pyridyl
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	4-pyridyl
Phenyl	4-pyridyl	4-methyl sulfinylphenyl
4-fluorophenyl	4-pyridyl	4-methyl sulfinylphenyl
3-fluorophenyl	4-pyridyl	4-methyl sulfinylphenyl
2-fluorophenyl	4-pyridyl	4-methyl sulfinylphenyl
4-chlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
3-chlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
2-chlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
4-tolyl	4-pyridyl	4-methyl sulfinylphenyl

3-tolyl	4-pyridyl	4-methyl sulfinylphenyl
2-tolyl	4-pyridyl	4-methyl sulfinylphenyl
4-trifluoro-methylphenyl	4-pyridyl	4-methyl sulfinylphenyl
3-trifluoro-methylphenyl	4-pyridyl	4-methyl sulfinylphenyl
2,6-dichlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
2,6-dimethyl phenyl	4-pyridyl	4-methyl sulfinylphenyl
3,4-dichlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
3,4-dimethyl phenyl	4-pyridyl	4-methyl sulfinylphenyl
2,4-dichlorophenyl	4-pyridyl	4-methyl sulfinylphenyl
2,4-dimethyl phenyl	4-pyridyl	4-methyl sulfinylphenyl
Phenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
4-fluorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
3-fluorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2-fluorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
4-chlorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
3-chlorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2-chlorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
4-tolyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
3-tolyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2-tolyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
4-trifluoro-methylphenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
3-trifluoro-methylphenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2,6-dichlorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2,6-dimethyl phenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
3,4-dichlorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
3,4-dimethyl phenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2,4-dichlorophenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl
2,4-dimethyl phenyl	2-amino-4-pyridyl	4-methyl sulfinylphenyl

Phenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
4-fluorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
3-fluorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2-fluorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
4-chlorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
3-chlorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2-chlorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
4-tolyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
3-tolyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2-tolyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2,6-dichlorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2,6-dimethylphenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
3,4-dichlorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
3,4-dimethylphenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2,4-dichlorophenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
2,4-dimethylphenyl	2-acetamido-4-pyridyl	4-methyl sulfinylphenyl
Phenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
4-fluorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
3-fluorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
2-fluorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
4-chlorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
3-chlorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
2-chlorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
4-tolyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
3-tolyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl

2-tolyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	4-methyl sulfinylphenyl
Phenyl	4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	4-pyridyl	2,6-dichlorobenzyl
4-tolyl	4-pyridyl	2,6-dichlorobenzyl
3-tolyl	4-pyridyl	2,6-dichlorobenzyl
2-tolyl	4-pyridyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	4-pyridyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	4-pyridyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2,6-dimethylphenyl	4-pyridyl	2,6-dichlorobenzyl
3,4-dichlorophenyl	4-pyridyl	2,6-dichlorobenzyl
3,4-dimethylphenyl	4-pyridyl	2,6-dichlorobenzyl
2,4-dichlorophenyl	4-pyridyl	2,6-dichlorobenzyl
2,4-dimethylphenyl	4-pyridyl	2,6-dichlorobenzyl
Phenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl

3-chlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-tolyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-tolyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2-tolyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2,6-dimethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3,4-dichlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
3,4-dimethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2,4-dichlorophenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
2,4-dimethylphenyl	2-amino-4-pyridyl	2,6-dichlorobenzyl
Phenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
4-fluorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
3-fluorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2-fluorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
4-chlorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
3-chlorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2-chlorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
4-tolyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
3-tolyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2-tolyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2,6-dimethylphenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl

3,4-dichlorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
3,4-dimethylphenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2,4-dichlorophenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
2,4-dimethylphenyl	2-acetamido-4-pyridyl	2,6-dichlorobenzyl
Phenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
4-fluorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-fluorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2-fluorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
4-chlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-chlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2-chlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
4-tolyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-tolyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2-tolyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	2,6-dichlorobenzyl
Phenyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
4-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
3-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
2-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
4-chlorophenyl	4-pyridyl	2-(4-fluorophenyl)ethylamino

3-chlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2-chlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
4-tolyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3-tolyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2-tolyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
4-trifluoro- methylphenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3-trifluoro- methylphenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2,6- dichlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2,6-dimethyl phenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3,4- dichlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
3,4-dimethyl phenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2,4- dichlorophenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
2,4-dimethyl phenyl	4-pyridyl	2-(4-fluorophenyl) ethylamino
Phenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
4-fluorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
3-fluorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
2-fluorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
4-chlorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
3-chlorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
2-chlorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
4-tolyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
3-tolyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
2-tolyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
4-trifluoro- methylphenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
3-trifluoro- methylphenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
2,6- dichlorophenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino
2,6-dimethyl phenyl	2-amino-4- pyridyl	2-(4-fluorophenyl) ethylamino

3,4-dichlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl) ethylamino
3,4-dimethyl phenyl	2-amino-4-pyridyl	2-(4-fluorophenyl) ethylamino
2,4-dichlorophenyl	2-amino-4-pyridyl	2-(4-fluorophenyl) ethylamino
2,4-dimethyl phenyl	2-amino-4-pyridyl	2-(4-fluorophenyl) ethylamino
Phenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
4-fluorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
3-fluorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2-fluorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
4-chlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
3-chlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2-chlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
4-tolyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
3-tolyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2-tolyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
4-trifluoromethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
3-trifluoromethylphenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2,6-dimethyl phenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
3,4-dimethyl phenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2,4-dichlorophenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
2,4-dimethyl phenyl	2-acetamido-4-pyridyl	2-(4-fluorophenyl) ethylamino
Phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
3-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
4-chlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino

3-chlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2-chlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
4-tolyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
3-tolyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2-tolyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
4-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
3-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2,6-dimethyl phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
3,4-dimethyl phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
2,4-dimethyl phenyl	2-amino-4-pyrimidinyl	2-(4-fluorophenyl) ethylamino
Phenyl	4-pyridyl	3-phenyl-propylamino
4-fluorophenyl	4-pyridyl	3-phenyl-propylamino
3-fluorophenyl	4-pyridyl	3-phenyl-propylamino
2-fluorophenyl	4-pyridyl	3-phenyl-propylamino
4-chlorophenyl	4-pyridyl	3-phenyl-propylamino
3-chlorophenyl	4-pyridyl	3-phenyl-propylamino
2-chlorophenyl	4-pyridyl	3-phenyl-propylamino
4-tolyl	4-pyridyl	3-phenyl-propylamino
3-tolyl	4-pyridyl	3-phenyl-propylamino
2-tolyl	4-pyridyl	3-phenyl-propylamino
4-trifluoro-methylphenyl	4-pyridyl	3-phenyl-propylamino
3-trifluoro-methylphenyl	4-pyridyl	3-phenyl-propylamino
2,6-dichlorophenyl	4-pyridyl	3-phenyl-propylamino
2,6-dimethyl phenyl	4-pyridyl	3-phenyl-propylamino
3,4-dichlorophenyl	4-pyridyl	3-phenyl-propylamino
3,4-dimethyl phenyl	4-pyridyl	3-phenyl-propylamino
2,4-dichlorophenyl	4-pyridyl	3-phenyl-propylamino
2,4-dimethyl phenyl	4-pyridyl	3-phenyl-propylamino
Phenyl	2-amino-4-pyridyl	3-phenyl-propylamino

4-fluorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
3-fluorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
2-fluorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
4-chlorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
3-chlorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
2-chlorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
4-tolyl	2-amino-4-pyridyl	3-phenyl-propylamino
3-tolyl	2-amino-4-pyridyl	3-phenyl-propylamino
2-tolyl	2-amino-4-pyridyl	3-phenyl-propylamino
4-trifluoromethylphenyl	2-amino-4-pyridyl	3-phenyl-propylamino
3-trifluoromethylphenyl	2-amino-4-pyridyl	3-phenyl-propylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
2,6-dimethylphenyl	2-amino-4-pyridyl	3-phenyl-propylamino
3,4-dichlorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
3,4-dimethylphenyl	2-amino-4-pyridyl	3-phenyl-propylamino
2,4-dichlorophenyl	2-amino-4-pyridyl	3-phenyl-propylamino
2,4-dimethylphenyl	2-amino-4-pyridyl	3-phenyl-propylamino
Phenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
4-fluorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
3-fluorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2-fluorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
4-chlorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
3-chlorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2-chlorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
4-tolyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
3-tolyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2-tolyl	2-acetamido-4-pyridyl	3-phenyl-propylamino

4-trifluoro-methylphenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
3-trifluoro-methylphenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
3,4-dimethylphenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2,4-dichlorophenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
2,4-dimethylphenyl	2-acetamido-4-pyridyl	3-phenyl-propylamino
Phenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
3-fluorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2-fluorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
4-chlorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
3-chlorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2-chlorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
4-tolyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
3-tolyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2-tolyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
4-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
3-trifluoro-methylphenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	3-phenyl-propylamino
Phenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino

4-fluorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
3-fluorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2-fluorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
4-chlorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
3-chlorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2-chlorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
4-tolyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
3-tolyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2-tolyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
4-trifluoromethylphenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
3-trifluoromethylphenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2,6-dichlorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2,6-dimethylphenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
3,4-dichlorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
3,4-dimethylphenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2,4-dichlorophenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
2,4-dimethylphenyl	4-pyridyl	(1-methyl-3-phenyl)propylamino
Phenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-fluorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-fluorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2-fluorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-chlorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-chlorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2-chlorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-tolyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-tolyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2-tolyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino

4-trifluoro-methylphenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-trifluoro-methylphenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,6-dimethylphenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
3,4-dichlorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
3,4-dimethylphenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,4-dichlorophenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,4-dimethylphenyl	2-amino-4-pyridyl	(1-methyl-3-phenyl)propylamino
Phenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-fluorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-fluorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2-fluorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-chlorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-chlorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2-chlorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-tolyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-tolyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2-tolyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
4-trifluoro-methylphenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
3-trifluoro-methylphenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
3,4-dichlorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
3,4-dimethylphenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,4-dichlorophenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
2,4-dimethylphenyl	2-acetamido-4-pyridyl	(1-methyl-3-phenyl)propylamino
Phenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino

4-fluorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
3-fluorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2-fluorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
4-chlorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
3-chlorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2-chlorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
4-tolyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
3-tolyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2-tolyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
3-trifluoromethylphenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2,6-dichlorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
3,4-dimethylphenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2,4-dichlorophenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
2,4-dimethylphenyl	2-amino-4-pyrimidinyl	(1-methyl-3-phenyl)propylamino
4-fluorophenyl	4-pyridyl	4-fluorobenzylamino
4-fluorophenyl	2-acetamido-4-pyridyl	4-fluorobenzylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	4-fluorobenzylamino
4-fluorophenyl	4-pyridyl	(2-(4-fluorophenyl)-1-methyl-ethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-(4-fluorophenyl)-1-methyl-ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-(4-fluorophenyl)-1-methyl-ethyl)amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-2-(4-fluorophenyl)-ethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(1,1-dimethyl-2-(4-fluorophenyl)-ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(1,1-dimethyl-2-(4-fluorophenyl)-ethyl)amino
4-fluorophenyl	4-pyridyl	2-(4-fluorophenyl)-2-methyl-ethylamino

4-fluorophenyl	2-acetamido-4-pyridyl	(2-(4-fluorophenyl)-2-methyl-ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-(4-fluorophenyl)-2-methyl-ethyl)amino
4-fluorophenyl	4-pyridyl	(2-methyl-2-phenylethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-methyl-2-phenylethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-methyl-2-phenylethyl)amino
4-fluorophenyl	4-pyridyl	methyl-(2-phenylethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	methyl-(2-phenylethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	methyl-(2-phenylethyl)amino
4-fluorophenyl	4-pyridyl	(2-(4-trifluoromethylphenyl)ethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-(4-trifluoromethylphenyl)ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-(4-trifluoromethylphenyl)ethyl)amino
4-fluorophenyl	4-pyridyl	2-(4-tolyl)ethylamino
4-fluorophenyl	2-acetamido-4-pyridyl	2-(4-tolyl)ethylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	2-(4-tolyl)ethylamino
4-fluorophenyl	4-pyridyl	(2-(3-fluorophenyl)ethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-(3-fluorophenyl)ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-(3-fluorophenyl)ethyl)amino
4-fluorophenyl	4-pyridyl	(2-(2-fluorophenyl)ethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-(2-fluorophenyl)ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-(2-fluorophenyl)ethyl)amino
4-fluorophenyl	4-pyridyl	methyl-(2-(2-pyridyl)ethyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	methyl-(2-(2-pyridyl)ethyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	methyl-(2-(2-pyridyl)ethyl)amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-3-phenyl-propyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(1,1-dimethyl-3-phenyl-propyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(1,1-dimethyl-3-phenyl-propyl)amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-propyl)amino

4-fluorophenyl	2-acetamido-4-pyridyl	(3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	4-pyridyl	(3-(4-fluorophenyl)-1-methyl-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-(4-fluorophenyl)-1-methyl-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(4-fluorophenyl)-1-methyl-propyl) amino
4-fluorophenyl	4-pyridyl	(1,1-dimethyl-3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(1,1-dimethyl-3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(1,1-dimethyl-3-(4-fluorophenyl)-propyl) amino
4-fluorophenyl	4-pyridyl	(3-(2-fluorophenyl)-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-(2-fluorophenyl)-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(2-fluorophenyl)-propyl) amino
4-fluorophenyl	4-pyridyl	(3-methyl-3-phenyl-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-methyl-3-phenyl-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-methyl-3-phenyl-propyl) amino
4-fluorophenyl	4-pyridyl	(2-methyl-3-phenyl-propyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(2-methyl-3-phenyl-propyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2-methyl-3-phenyl-propyl) amino
4-fluorophenyl	4-pyridyl	(3,3-dimethylbutyl) amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3,3-dimethylbutyl) amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3,3-dimethylbutyl) amino
4-fluorophenyl	4-pyridyl	isoamylamino
4-fluorophenyl	2-acetamido-4-pyridyl	isoamylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	isoamylamino
4-fluorophenyl	4-pyridyl	amylamino
4-fluorophenyl	2-acetamido-4-pyridyl	amylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	amylamino
4-fluorophenyl	4-pyridyl	(2,5-dimethyl)pentylamino
4-fluorophenyl	2-acetamido-4-pyridyl	(2,5-dimethyl)pentylamino
4-fluorophenyl	2-amino-4-pyrimidinyl	(2,5-dimethyl)pentylamino

4-fluorophenyl	4-pyridyl	piperazinyl
4-fluorophenyl	2-acetamido-4-pyridyl	piperazinyl
4-fluorophenyl	2-amino-4-pyrimidinyl	piperazinyl
4-fluorophenyl	4-pyridyl	(3-(3-fluorophenyl)-propyl)amino
4-fluorophenyl	2-acetamido-4-pyridyl	(3-(3-fluorophenyl)-propyl)amino
4-fluorophenyl	2-amino-4-pyrimidinyl	(3-(3-fluorophenyl)-propyl)amino
benzyl	4-pyridyl	3-phenylpropylamino
benzyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
2-thienyl	4-pyridyl	3-phenylpropylamino
2-thienyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
cyclohexyl	4-pyridyl	3-phenylpropylamino
cyclohexyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
tert-butyl	4-pyridyl	3-phenylpropylamino
tert-butyl	4-pyridyl	2-(4-fluorophenyl)ethylamino
4-fluorophenyl	4-piperidinyl	3-phenylpropylamino
4-fluorophenyl	4-piperidinyl	2-(4-fluorophenyl)ethylamino
4-fluorophenyl	4-pyranyl	3-phenylpropylamino
4-fluorophenyl	4-pyranyl	2-(4-fluorophenyl)ethylamino
Phenyl	4-pyridyl	3-phenyl-2-amino-propylamino
4-fluorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
3-fluorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
2-fluorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
4-chlorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
3-chlorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
2-chlorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
4-tolyl	4-pyridyl	3-phenyl-2-amino-propylamino
3-tolyl	4-pyridyl	3-phenyl-2-amino-propylamino
2-tolyl	4-pyridyl	3-phenyl-2-amino-propylamino
4-trifluoromethylphenyl	4-pyridyl	3-phenyl-2-amino-propylamino
3-trifluoromethylphenyl	4-pyridyl	3-phenyl-2-amino-propylamino

2,6-dichlorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
2,6-dimethylphenyl	4-pyridyl	3-phenyl-2-amino-propylamino
3,4-dichlorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
3,4-dimethylphenyl	4-pyridyl	3-phenyl-2-amino-propylamino
2,4-dichlorophenyl	4-pyridyl	3-phenyl-2-amino-propylamino
2,4-dimethylphenyl	4-pyridyl	3-phenyl-2-amino-propylamino
Phenyl	4-pyridyl	3-phenyl-3-amino-propylamino
4-fluorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
3-fluorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
2-fluorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
4-chlorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
3-chlorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
2-chlorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
4-tolyl	4-pyridyl	3-phenyl-3-amino-propylamino
3-tolyl	4-pyridyl	3-phenyl-3-amino-propylamino
2-tolyl	4-pyridyl	3-phenyl-3-amino-propylamino
4-trifluoromethylphenyl	4-pyridyl	3-phenyl-3-amino-propylamino
3-trifluoromethylphenyl	4-pyridyl	3-phenyl-3-amino-propylamino
2,6-dichlorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
2,6-dimethylphenyl	4-pyridyl	3-phenyl-3-amino-propylamino
3,4-dichlorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
3,4-dimethylphenyl	4-pyridyl	3-phenyl-3-amino-propylamino
2,4-dichlorophenyl	4-pyridyl	3-phenyl-3-amino-propylamino
2,4-dimethylphenyl	4-pyridyl	3-phenyl-3-amino-propylamino
3-fluorophenyl	4-pyridyl	(S)-tetrahydroisoquinol-3-ylmethylenamino
2-fluorophenyl	2-amino-4-pyridyl	(S)-3-benzylpiperazinyl
3-chlorophenyl	2-acetamido-4-pyridyl	(S)-2-N-isopropylamino-3-phenylpropylamino

2-chlorophenyl	2-amino-4-pyrimidinyl	(S)-2-N-glycylamino-3-phenylpropylamino
4-tolyl	4-pyridyl	(S)-2-amino-3-phenylpropylamino
3-tolyl	2-amino-4-pyridyl	(R)-2-amino-3-phenylpropylamino
2-tolyl	2-acetamido-4-pyridyl	3-amino-3-phenylpropylamino
4-trifluoromethylphenyl	2-amino-4-pyrimidinyl	(S)-2-amino-3-(2-fluorophenyl)propylamino
3-trifluoromethylphenyl	4-pyridyl	(S)-2-amino-3-(2-methylphenyl)propylamino
2,6-dichlorophenyl	2-amino-4-pyridyl	3-amino-3-(2-fluorophenyl)propylamino
2,6-dimethylphenyl	2-acetamido-4-pyridyl	3-amino-3-(2-methylphenyl)propylamino
3,4-dichlorophenyl	2-amino-4-pyrimidinyl	2-amino-2-methyl-3-phenylpropylamino
3,4-dimethylphenyl	4-pyridyl	3-amino-2-methyl-3-phenylpropylamino
3-fluorophenyl	2-amino-4-pyridyl	(S)-2-amino-3-phenylpropylamino
2-fluorophenyl	2-acetamido-4-pyridyl	(S)-2-amino-3-(2-fluorophenyl)propylamino
3-chlorophenyl	2-amino-4-pyrimidinyl	(S)-2-amino-3-(2-methylphenyl)propylamino
2-chlorophenyl	4-pyridyl	(S)-2-N-isopropylamino-3-phenylpropylamino
4-tolyl	2-amino-4-pyridyl	(S)-2-N-glycylamino-3-phenylpropylamino
3-tolyl	2-acetamido-4-pyridyl	2-amino-2-methyl-3-phenylpropylamino
2-tolyl	2-amino-4-pyrimidinyl	(R)-2-amino-3-phenylpropylamino
4-trifluoromethylphenyl	4-pyridyl	3-amino-3-phenylpropylamino
3-trifluoromethylphenyl	2-amino-4-pyridyl	3-amino-3-(2-fluorophenyl)propylamino
2,6-dichlorophenyl	2-acetamido-4-pyridyl	3-amino-3-(2-methylphenyl)propylamino
2,6-dimethylphenyl	2-amino-4-pyrimidinyl	3-amino-2-methyl-3-phenylpropylamino
3,4-dichlorophenyl	4-pyridyl	(S)-tetrahydroisoquinol-3-ylmethylenamino
3,4-dimethylphenyl	4-pyridyl	(S)-3-benzylpiperazinyl

Additional preferred compounds are listed in the Examples, *infra*.

As utilized herein, the following terms shall have the following meanings:

"Alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing preferably 1-15 carbon atoms (C_1 - C_{15}), more preferably 1-8 carbon atoms (C_1 - C_8), even more preferably 1-6 carbon atoms (C_1 - C_6), yet more preferably 1-4 carbon atoms (C_1 - C_4), still more preferably 1-3 carbon atoms (C_1 - C_3), and most preferably 1-2 carbon atoms (C_1 - C_2). Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like.

"Hydroxyalkyl", alone or in combination, means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical. Examples of such radicals include hydroxymethyl, 1-, 2-hydroxyethyl, 1-, 2-, 3-hydroxypropyl, 1,3-dihydroxy-2-propyl, 1,3-dihydroxybutyl, 1,2,3,4,5,6-hexahydroxy-2-hexyl and the like.

"Alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C_2 - C_{15}), more preferably 2-8 carbon atoms (C_2 - C_8), even more preferably 2-6 carbon atoms (C_2 - C_6), yet more preferably 2-4 carbon atoms (C_2 - C_4), and still more preferably 2-3 carbon atoms (C_2 - C_3). Examples of such alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like.

"Alkoxy", alone or in combination, means a radical of the type "R-O-" wherein "R" is an alkyl radical as defined above and "O" is an oxygen atom. Examples of such alkoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

"Alkoxy carbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-O-" is an alkoxy radical as defined above and "C(O)" is a carbonyl radical.

"Alkoxy carbonylamino", alone or in combination, means a radical of the type "R-O-C(O)-NH-" wherein "R-O-C(O)" is an alkoxy carbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.

"Alkylthio", alone or in combination, means a radical of the type "R-S-" wherein "R" is an alkyl radical as defined above and "S" is a sulfur atom. Examples of such alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio and the like.

"Alkylsulfinyl", alone or in combination, means a radical of the type "R-S(O)-" wherein "R" is an alkyl radical as defined above and "S(O)" is a mono-oxygenated sulfur atom. Examples of such alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, isopropylsulfinyl, n-butylsulfinyl, iso-butylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl and the like.

"Alkylsulfonyl", alone or in combination, means a radical of the type "R-S(O)₂-" wherein "R" is an alkyl radical as defined above and "S(O)₂" is a di-oxygenated

sulfur atom. Examples of such alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, iso-butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like.

5

"Aryl", alone or in combination, means a phenyl or biphenyl radical, which is optionally benzo fused or heterocyclo fused and which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, alkanoylamino, amido, amidino, alkoxycarbonylamino, N-alkylamidino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, N-alkylamido, N,N-dialkylamido, aralkoxycarbonylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, oxo and the like.

10

15

20

25

Examples of aryl radicals are phenyl, o-tolyl, 4-methoxyphenyl, 2-(tert-butoxy)phenyl, 3-methyl-4-methoxyphenyl, 2-CF₃-phenyl, 2-fluorophenyl, 2-chlorophenyl, 3-nitrophenyl, 3-aminophenyl, 3-acetamidophenyl, 2-amino-3-(aminomethyl)phenyl, 6-methyl-3-acetamidophenyl, 6-methyl-2-aminophenyl, 6-methyl-2,3-diaminophenyl, 2-amino-3-methylphenyl, 4,6-dimethyl-2-aminophenyl, 4-hydroxyphenyl, 3-methyl-4-hydroxyphenyl, 4-(2-methoxyphenyl)phenyl, 2-amino-1-naphthyl, 2-naphthyl, 3-amino-2-naphthyl, 1-methyl-3-amino-2-naphthyl, 2,3-diamino-1-naphthyl, 4,8-dimethoxy-2-naphthyl and the like.

30

35

"Aralkyl" and "arylalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2-phenylethyl, dibenzylmethyl, hydroxyphenylmethyl, methylphenylmethyl, diphenylmethyl, dichlorophenylmethyl, 4-methoxyphenylmethyl and the like.

- "Aralkoxy", alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2-phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4-methoxyphenylmethoxy and the like.
- 10 "Aralkoxycarbonyl", alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-O-" is an aralkoxy radical as defined above and "-C(O)-" is a carbonyl radical.
- 15 "Alkanoyl", alone or in combination, means a radical of the type "R-C(O)-" wherein "R" is an alkyl radical as defined above and "-C(O)-" is a carbonyl radical. Examples of such alkanoyl radicals include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl, butyryl, 20 valeryl, 4-methylvaleryl, and the like.
- "Alkanoylamino", alone or in combination, means a radical of the type "R-C(O)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
- 25 "Aminocarbonyl", alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di-substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
- 30 "Aminosulfonyl", alone or in combination, means an amino substituted sulfonyl radical.
- 35

"Benzo", alone or in combination, means the divalent radical $C_6H_4=$ derived from benzene. "Benzo fused" forms a ring system in which benzene and a cycloalkyl or aryl group have two carbons in common, for example tetrahydronaphthylene and the like.

"Bicyclic" as used herein is intended to include both fused ring systems, such as naphthyl and β -carbolinyl, and substituted ring systems, such as biphenyl, phenylpyridyl and diphenylpiperazinyl.

"Cycloalkyl", alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic, bicyclic or tricyclic carbocyclic alkyl radical, preferably monocyclic, containing preferably 5-12 carbon atoms (C_5-C_{12}), more preferably 5-10 carbon atoms (C_5-C_{10}), even more preferably 5-7 carbon atoms (C_5-C_7), which is optionally benzo fused or heterocyclo fused and which is optionally substituted as defined herein with respect to the definition of aryl. Examples of such cycloalkyl radicals include cyclopentyl, cyclohexyl, dihydroxycyclohexyl, ethylenedioxycyclohexyl, cycloheptyl, octahydronaphthyl, tetrahydronaphthyl, octahydroquinolinyl, dimethoxytetrahydronaphthyl, 2,3-dihydro-1H-indenyl, azabicyclo[3.2.1]octyl and the like.

"Heteroatoms" means nitrogen, oxygen and sulfur heteroatoms.

"Heterocyclo fused" forms a ring system in which a heterocyclyl or heteroaryl group of 5-6 ring members and a cycloalkyl or aryl group have two carbons in common, for example indole, isoquinoline, tetrahydroquinoline, methylenedioxybenzene and the like.

"Heterocyclyl" means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4, more preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring. "Heterocyclyl" is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N-oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 ring carbon atoms and more preferably 5-6 ring carbon atoms, and benzo fused ring systems. "Heterocyclyl" radicals may optionally be substituted on at least one, preferably 1-4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidino, N-alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals. More preferably, "heterocyclyl", alone or in combination, is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals. Examples of such heterocyclyl radicals include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, 4-benzyl-piperazin-1-yl, pyrimidinyl, tetrahydrofuryl, pyrazolidonyl, pyrazolinyl, pyridazinonyl, pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone derivatives, 2,3-dihydroindolyl, tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-1-

oxo-isoquinolinyl, 2,3-dihydrobenzofuryl, benzopyranyl, methylenedioxyphenyl, ethylenedioxyphenyl and the like.

"Heteroaryl" means a monocyclic or bicyclic, preferably
5 monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3, even more preferably 1-2, nitrogen, oxygen or sulfur atom ring members and having preferably 5-6 ring members in each ring, which is optionally saturated carbocyclic
10 fused, preferably 3-4 carbon atoms (C₃-C₄) to form 5-6 ring membered rings and which is optionally substituted as defined above with respect to the definitions of aryl. Examples of such heteroaryl groups include imidazolyl, 1-benzyloxycarbonylimidazol-4-yl, pyrrolyl,
15 pyrazolyl, pyridyl, 3-(2-methyl)pyridyl, 3-(4-trifluoromethyl)pyridyl, pyrimidinyl, 5-(4-trifluoromethyl)pyrimidinyl, pyrazinyl, triazolyl, furyl, thienyl, oxazolyl, thiazolyl, indolyl, quinolinyl, 5,6,7,8-tetrahydroquinolyl,
20 5,6,7,8-tetrahydroisoquinolinyl, quinoxalinyl, benzothiazolyl, benzofuryl, benzimidazolyl, benzoxazolyl and the like.

"Heteroaralkyl" and "heteroarylalkyl," alone or in
25 combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3-furylpropyl, 2-pyrrolyl propyl, chloroquinolinylmethyl, 2-thienylethyl, pyridylmethyl,
30 1-imidazolylethyl and the like.


"Halogen" and "halo", alone or in combination, means fluoro, chloro, bromo or iodo radicals.

35 "Haloalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical,

more preferably fluoro or chloro radicals. Examples of such haloalkyl radicals include 1,1,1-trifluoroethyl, chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl,

5 bis(trifluoromethyl)methyl and the like.

"4(3H)-pyrimidinone" (A) and "4-hydroxy-pyrimidine" (B) are names of two tautomers of the same compound which may be used interchangeably. It is intended that the
10 use of one of these terms inherently includes the other.



"Pharmacologically acceptable salt" means a salt prepared by conventional means, and are well known by
15 those skilled in the art. The "pharmacologically acceptable salts" include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid,
20 acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like. When compounds of the invention include an acidic function such as a carboxy
25 group, then suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like. For additional examples of "pharmacologically acceptable
30 salts," see *infra* and Berge et al, *J. Pharm. Sci.* 66, 1 (1977).

- "Cytokine" means a secreted protein that affects the functions of other cells, particularly as it relates to the modulation of interactions between cells of the immune system or cells involved in the inflammatory response. Examples of cytokines include but are not limited to interleukin 1 (IL-1), preferably IL-1 β , interleukin 6 (IL-6), interleukin 8 (IL-8) and TNF, preferably TNF- α (tumor necrosis factor- α).
- 10 "TNF, IL-1, IL-6, and/or IL-8 mediated disease or disease state" means all disease states wherein TNF, IL-1, IL-6, and/or IL-8 plays a role, either directly as TNF, IL-1, IL-6, and/or IL-8 itself, or by TNF, IL-1, IL-6, and/or IL-8 inducing another cytokine to be
- 15 released. For example, a disease state in which IL-1 plays a major role, but in which the production of or action of IL-1 is a result of TNF, would be considered mediated by TNF.
- 20 "Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide,
- 25 N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
- "Protecting group" generally refers to groups well known
- 30 in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein
- 35 where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl

alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, durenyl and the like.

10 Examples of cycloalkenylalkyl or substituted cycloalkylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an

20 aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic

25 groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an

30 addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also suitable groups


35 for protecting hydroxy and mercapto groups, such as tert-butyl.

Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, 5 triethylsilyl, tri-isopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of 10 aminoalcohol compounds can lead to a N,N,O-tri-silyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or 15 in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-buty-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with 20 imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well 25 known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.

Protecting groups are removed under conditions which will not affect the remaining portion of the 30 molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a 35 suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic

or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.

The symbols used above have the following meanings:



10

Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as

20

25

arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as

5 imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid

10 prodrugs, their preparation and use.

Compounds according to the invention can be synthesized according to one or more of the following methods. It should be noted that the general procedures are shown as it relates to preparation of compounds

15 having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R). In addition, the compounds having one stereochemistry


20 (e.g., (R)) can often be utilized to produce those having opposite stereochemistry (i.e., (S)) using well-known methods, for example, by inversion.

Pyrimidines:


A general method for the preparation of compounds


25 of formula I involves the condensation of an 1,3-dicarbonyl intermediate IV with an N-C-N containing structure such as an amidine V, a guanidine VI or urea VII (Scheme 1; for a review of synthetic methods see D.J. Brown, *Heterocyclic Compounds: the Pyrimidines*,

30 Chapter 3, 1994, John Wiley & Sons).

Scheme 1


Additionally, as a 1,3-dicarbonyl synthon, a b-dimethylamino-a,b-unsaturated ketone IX can be reacted
5 with amidines V or guanidines VI as described (G.B. Bennett et al., J. Med. Chem. 21, 623-628, 1978).
(Scheme 2). Such b-dimethylamino-a,b-unsaturated ketones IX can be prepared by aminoformylation of an
active methylene ketone VIII with Brederick's reagent,
10 namely, bis(dimethylamino)methoxymethane (H. Brederick et al., Chem. Ber. 101, 41-50 (1968); G. B. Bennett et al., J. Org. Chem. 43, 221-225 (1977)).

Scheme 2






- According to this approach, Scheme 3 illustrates the conversion of 2-(4-fluorophenyl)-1-(4-pyridyl)ethanone (VIII; Sheldrake, *Synthetic Communications* 23, 1967 (1993)) into the enamine IX. Intermediate IX may be condensed with a variety of amidines V and guanidines VI to provide 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines I.
- Further ketones VIII may be prepared (e.g., according to Sheldrake, *Synthetic communications* 23, 1967-1971 (1993)), by employing other heteroaryl carboxaldehydes as the starting material, such as 2-methylpyridine-4-carboxaldehyde, 2,6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, *Chem. Ber.* 88, 1276-1283 (1955)), quinoline-4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6-methylpyrimidine-4-carboxaldehyde, 2-methylpyrimidine-4-carboxaldehyde, 2,6-dimethylpyrimidine-4-carboxaldehyde (Bredereck et al., *Chem. Ber.* 97, 3407-3417 (1964)). Furthermore, 2-nitropyridin-4-carboxaldehyde may be prepared from 2-nitro-4-methylpyridine (Stanonis, *J. Org. Chem.* 22, 475 (1957)) by oxidation of the methyl group (Venemalm et al., *Tet. Lett.* 34, 5495-5496 (1993)). Its further

conversion via a ketone VIII would lead to a 2-nitro-4-pyridyl derivative I (Scheme 4). Catalytic reduction of the nitro group to an amino group would provide a derivative of I with R^1 represented by a 2-amino-4-pyridyl group. Conventional acetylation of the amino group then leads to the 2-acetamido-4-pyridyl derivative.

Scheme 4

As displayed in Scheme 5, intermediate IX may also be condensed with urea VII to give the 2(1H)-pyrimidinone derivative X. X is transformed into chloride XI by reaction with a halogenating agent such as phosphorous oxychloride. Treatment of chloride XI with primary and secondary amines, thiolates or alcoholates allows the preparation of further pyrimidines I with R^1 represented by a substituted N, S or O groups, as recited above. Likewise, hydrazines may be reacted with chloride XI to provide 2-hydrazino substituted pyrimidines I.




5

Palladium or nickel catalyzed cross couplings of chloride XI with arylboronic acids or arylzinc halides provide compounds of formula I wherein R^1 is aryl or heteroaryl.

10

Scheme 6 illustrates the reaction of intermediate IX with guanidine VI to give 2-amino substituted I. 2-Amino I is a useful intermediate for further acylations


For the synthesis of 4-hydroxy-pyrimidines II, the approach displayed in Scheme 7 may be followed (for a review of synthetic methods see: D.J. Brown, Heterocyclic Compounds: the Pyrimidines, *supra*). This approach involves the cyclization reaction between an acrylic acid ester XII and an amidine V followed by oxidation of the resulting dihydropyrimidinone XIII to give II.



Accordingly, further compounds of formula II may be obtained in which R¹² is any other heteroaryl ring within the definition of R¹² by the appropriate choice of starting material. Such starting materials include but are not limited to 2-methylpyridine-4-carboxaldehyde, 2,6-dimethylpyridine-4-carboxaldehyde (Mathes and Sauermilch, *Chem. Ber.* 88, 1276-1283 (1955)), quinoline-4-carboxaldehyde, pyrimidine-4-carboxaldehyde, 6-methylpyrimidine-4-carbox-aldehyde, 2-methylpyrimidine-4-carboxaldehyde, 2,6-dimethylpyrimidine-4-carboxaldehyde (Bredereck et al., *Chem. Ber.* 97, 3407-3417

(1964)). The use of 2-nitropyridine-4-carboxaldehyde would lead to a derivative of formula II with R^{12} represented by a 2-nitro-4-pyridyl group. Catalytic reduction of the nitro to an amino group would provide the 2-amino-4-pyridyl derivative of II. The approach displayed in Scheme 8 is applicable to the use of other aryl acetic acids leading to compounds of formula II with different aryl groups as R^{11} .

Scheme 8




10

Another approach (Scheme 9) leading to 5,6-diaryl-4-hydroxy-pyrimidines involves the cyclization of the β -keto ester XIV with thiourea to give the thiouracil derivative XV. XV can be S-monomethylated to XVI. Reaction of XVI with primary and secondary amines leads to 2-amino substituted 4-hydroxy-pyrimidines II. Further 2-thioether derivatives of II with $R^1 = SR^{21}$ can be obtained, for example by alkylation of XV with alkyl halides. Treatment of XV or XVI with Raney nickel and H_2 provides compounds of structure II wherein R^1 is H.

20


Scheme 9



Although Scheme 9 illustrates syntheses in which R^{12} is 4-pyridyl, this approach may be equally applied to any other heteroaryl ring within the definition of R^{12} by the appropriate choice of the starting material. Such starting materials include but are not limited to ethyl 2-methyl isonicotinate (Efimovsky and Rumpf, *Bull. Soc. Chim. FR.* 648-649 (1954)), methyl pyrimidine-4-carboxylate, methyl 2-methylpyrimidine-4-carboxylate, methyl 6-methylpyrimidine-4-carboxylate and methyl 2,6-dimethylpyrimidine-4-carboxylate (Sakasi et al., *Heterocycles* 13, 235 (1978)). Likewise, methyl 2-nitroisonicotinate (Stanonis, *J. Org. Chem.* 22, 475 (1957)) may be reacted with an aryl acetic acid ester followed by cyclization of the resultant β -keto ester with thiourea analogously to Scheme 9. Subsequent catalytic reduction of the nitro group to an amino group


would give a 4-hydroxy-pyrimidine II in which R^{12} is represented by a 2-amino-4-pyridyl group (Scheme 10).

Scheme 10



- 5 Furthermore, methyl 2-acetamido isonicotinate (Scheme 11) may be reacted analogously to Scheme 9 after appropriate protection of the amide nitrogen with e.g. a tert-butyldimethylsilyloxymethyl group (Benneche et al., *Acta Chem. Scand. B* 42 384-389 (1988)), a tert-
- 10 butyldimethylsilyl group, a benzyloxymethyl group, a benzyl group or the like (P_1).


Scheme 11



- 15 Removal of the protecting group P_1 of the resulting pyrimidine II with a suitable reagent (e.g., tetrabutylammonium fluoride in the case where P_1 is t-butyldimethyl-silyloxymethyl) would then lead to a pyrimidine II with R^{12} represented by a 2-acetamido-4-pyridyl group. Needless to say, ethyl p-fluorophenyl acetate may be substituted by any alkyl arylacetate in the procedure illustrated in Scheme 9 thus providing
- 20 compounds of formula II with different R^{11} aryl substituents.

- In a further process, compounds of pyrimidines II
- 25 may be prepared by coupling a suitable derivative of XVIII (L is a leaving group, such as halogen radical and

the like, and P² is a protecting group, such as benzyl and the like) with an appropriate aryl equivalent.




XVIII

- 5 Such aryl/heteroaryl couplings are well known to those skilled in the art and involve an organic-metallic component for reaction with a reactive derivative, e.g., a halogeno derivative, of the second compound in the presence of a catalyst. The metallo-organic species may
- 10 be provided either by the pyrimidinone in which case the aryl component provides the reactive halogen equivalent or the pyrimidinone may be in the form of a reactive 5-halogeno derivative for reaction with a metallo organic aryl compound. Accordingly, 5-bromo and 5-iodo
- 15 derivatives of XVIII (L = Br, I) may be treated with arylalkyl tin compounds, e.g., trimethylstannylbenzene, in an inert solvent such as tetrahydrofuran in the presence of a palladium catalyst, such as di(triphenylphosphine)palladium(II)dichloride. (Peters
- 20 et al., *J. Heterocyclic Chem.* 27, 2165-2173, (1990). Alternatively, the halogen derivative of XVIII may be converted into a trialkyltin derivative (L = Bu₃Sn) by reaction with e.g. tributylstannyl chloride following lithiation with butyllithium and may then be reacted
- 25 with an aryl halide in the presence of a catalyst. (Sandosham and Undheim, *Acta Chem. Scand.* 43, 684-689 (1989). Both approaches would lead to pyrimidines II in which R¹¹ is represented by aryl and heteroaryl groups.
- 30 As reported in the literature (Kabbe, *Lieb. Ann. Chem.* 704, 144 (1967); German Patent 1271116 (1968)) and displayed in Scheme 12, 5-aryl-2,6-dipyridyl-4-hydroxy-pyrimidines II may be prepared in a one step synthesis by reaction of the cyanopyridine with an arylacetyl

ester, such as ethyl phenylacetate in the presence of sodium methoxide.


Scheme 12



5 Analogously, as reported (Kabbe, *supra*) and displayed in Scheme 13, 4-amino-5-(aryl)-2,6-dipyridylpyrimidines XIX are obtained in a one step synthesis by reaction of cyanopyridine with arylacetonitrile, such as 4-fluorophenylacetonitrile.

10


Scheme 13



XIX


Modification at the 4-position (R^2 of formula I) of pyrimidine II is possible by conversion into the chloro derivative XX by reaction with phosphorous oxychloride (Scheme 14). A 4-alkoxy derivative XXI may be prepared from chloro derivative XX by nucleophilic substitution with alkoxide. Alternatively, in stead of the chloro group, other leaving groups, such as tosylates, mesylates and the like, can be used. Also, such leaving groups can also be displaced by amino, thiolates, alcoholates, and the like nucleophiles. For example, the chloro derivative XX may be reduced by catalytic hydrogenation to give a pyrimidine I where R^2 is H, or may be reacted with an alkyl or aryl boronic acid or an alkyl or aryl zinc halide to provide a pyrimidine I where R^2 is alkyl or aryl.

Scheme 14



In Scheme 15, compounds of the present invention of formula XXX can be readily prepared by reacting the methylthio intermediate XXXI with the amine $\text{NHR}^{\text{R}^{21}}$, for example by heating the mixture preferably at a temperature greater than 100°C , more preferably $150-210^\circ\text{C}$. Alternatively, compounds of formula XXX can be readily prepared by reacting the methylsulfonyl intermediate XXXII with the amine $\text{NHR}^{\text{R}^{21}}$, for example by heating the mixture preferably at a temperature greater than 40°C , more preferably $50-210^\circ\text{C}$.

Scheme 15




Amines of formula $\text{NHR}^{\text{R}^{21}}$ are commercially available or can be readily prepared by those skilled in the art from commercially available starting materials. For example, an amide, nitro or cyano group can be reduced under reducing conditions, such as in the presence of a reducing agent like lithium aluminum hydride and the like, to form the corresponding amine. Alkylation and acylation of amino groups are well known in the art. Chiral and achiral substituted amines can be prepared from chiral amino acids and amino acid amides (for example, alkyl, aryl, heteroaryl, cycloalkyl, arylalkyl,

- heteroarylalkyl, cycloalkylalkyl and the like substituted glycine, β -alanine and the like) using methods well known in the art, such as H. Brunner, P. Hankofer, U. Holzinger, B. Treitinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, 1990; M. Freiburger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698, 1960; Dornow and Fust, Chem. Ber. 87, 984, 1954; M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459, 1982; W. Wheeler and D. O'Bannon, Journal of Labelled Compounds and Radiopharmaceuticals XXXI, 306, 1992; and S. Davies, N. Garrido, O. Ichihara and I. Walters, J. Chem. Soc., Chem. Commun. 1153, 1993.

The following Examples are presented for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that modifications and variations of the compounds disclosed herein can be made without violating the spirit or scope of the present invention.

EXAMPLES**Example 1**


- 10 *General procedure for the preparation of 2-substituted*
 5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines
a. 3-(Dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridyl)-
 3-propene-1-one:
 (According to Bennett et al., J. Org. Chem. 43, 221
15 (1977)).



- A mixture of 2-(4-fluorophenyl)-1-(4-pyridinyl)ethanone (300 mg, 1.39 mmol) and bis(dimethylamino)methoxymethane (300 mmol, 1.95 mmol) was heated at 110°C for 1.5 h under argon. It was evaporated and the yellow, crystallizing residue dried in an oil pump vacuum before used in the succeeding reaction. MS (m/z): 270.8 (M+H)⁺; C₁₆H₁₃FN₂O requir. 270.3. ¹H-NMR (CDCl₃): d 8.57, 7.25 (2m, each 2H, Pyrid.), 7.36 (s, 1H, CH=), 7.13, 6.99 (2m, each 2H, PhF), 3.00 (bs, 6H, 2CH₃).
- 20
25

b. General procedure:

(According to Bennett et al., J. Med. Chem. 21, 623 (1978)).



A solution of 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one (1.39 mmol) in absol. ethanol (9 ml) was transferred into a solution of the $R^1\text{-C(NH)NH}_2$ (1.67 mmol) in ethanol (2 ml) prepared from sodium (1.67 mmol) and the amidine or guanidine hydrochloride (1.67 mmol). After heating under reflux for 1.5 to 24 h, it was evaporated and the resulting material was applied either directly to a column of silica gel (1-5% methanol/dichloromethane) or was taken up in dichloromethane followed by washing with water, drying of the organic solution and evaporation prior to column chromatography.



The following pyrimidines were prepared according to this general procedure by reacting 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one with amidines:


1-1 5-(4-Fluorophenyl)-2-methyl-4-(4-pyridyl)-pyrimidine: MS (m/z): 266.0 (M+H)⁺; $C_{16}H_{12}FN_3$ requir. 265.3. ¹H-NMR (CDCl₃): δ 8.70 (d, 1H, H-6, Pyrim.), 8.59, 7.32 (2m, each 2H, Pyrid.), 7.20-7.00 (m, 4H, PhF), 2.88 (s, 3H, CH₃).

$R_1 = \text{CH}_3$ -


1-2 5-(4-Fluorophenyl)-2-isopropyl-4-(4-pyridyl)-pyrimidine: MS (m/z): 294.4 (M+H)⁺; $C_{18}H_{16}FN_3$ requir. 293.4. ¹H-NMR (CDCl₃): δ 8.73 (s, 1H, H-6, Pyrim.), 8.60, 7.35 (2m, each 2H, Pyrid.), 7.20-7.04 (m, 4H, PhF), 3.37 (m, 1H, CH(CH₃)₂), 1.50, 1.47 (2s, each 3H, 2CH₃).

$R_1 = (\text{CH}_3)_2\text{CH-}$


- 1-3 2-tert-Butyl-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 307.8 (M+H)⁺; C₁₉H₁₈FN₃ requir. 307.4. ¹H-NMR (CDCl₃): δ 8.72 (s, 1H, H-6, Pyrim.), 8.59, 7.38 (2m, each 2H, Pyrid.), 7.21-7.06 (m, 4H, PhF), 1.52 (s, 9H, 3CH₃).
 5 R₁ = (CH₃)₃C-
- 1-4 2-(1-Chloro-2-methoxyethyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 344.2 (M+H)⁺; C₁₈H₁₅ClFN₃O requir. 343.8. ¹H-NMR (CDCl₃): δ 8.81 (s, 1H, H-6, Pyrim.), 8.61, 7.35 (2m, each 2H, Pyrid.), 7.22-7.08 (m, 4H, PhF), 5.29 (dd, 1H, CHCl), 4.31, 4.04 (2dd, each 1H, CH₂O), 3.47 (s, 3H, CH₃O).
 10 R₁ = CH₃OCH₂CH(Cl)-
- 1-5 2-(Cyclopropyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 292.0 (M+H)⁺; C₁₈H₁₄FN₃ requir. 291.3. ¹H-NMR (CDCl₃): δ 8.60 (s, 1H, H-6, Pyrim.), 8.57, 7.32 (2d, each 2H, Pyrid.), 7.16-7.00 (m, 4H, PhF), 2.32 (m, 1H, -CH-), 1.2, 1.1 (2m, each 2H, 2CH₂).
 15 R₁ = 
- 20 1-6 2-(Adamant-1-yl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 386.0 (M+H)⁺; C₂₅H₂₄FN₃ requir. 385.5. ¹H-NMR (CDCl₃): δ 8.76 (s, 1H, H-6, Pyrim.), 8.61, 7.51 (2m, each 2H, Pyrid.), 7.22-7.08 (m, 4H, PhF), ~1.9-1.5 (broad, 15H, CH₂, CH).
 25 R₁ = 
- 1-7 2-Benzyl-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 342.2 (M+H)⁺; C₂₂H₁₆FN₃ requir. 341.4. ¹H-NMR (CDCl₃): δ 8.71 (s, 1H, H-6, Pyrim.), 8.60, 7.48 (2m, each 2H, Pyrid.), 7.42-7.04 (m, 9H, PhF, Ph), 4.42 (s, 2H, CH₂Ph).
 30




- 1-8 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 410.2 (M)⁺; C₂₂H₁₄Cl₂FN₃ requir. 410.3. ¹H-NMR (CDCl₃): d 8.68 (s, 1H, H-6, Pyrim.), 8.57 (d, 2H, Pyrid.), 7.44-7.03 (m, 9H, Pyrid., PhF, PhCl₂), 4.93 (s, 2H, CH₂).




- 1-9 5-(4-Fluorophenyl)-2-phenoxyethyl-4-(4-pyridyl)-pyrimidine: MS (m/z): 358.2 (M+H)⁺; C₂₂H₁₆FN₃O requir. 357.4. ¹H-NMR (CDCl₃): d 8.83 (s, 1H, H-6, Pyrim.), 8.60 (m, 2H, Pyrid.), 7.36-6.98 (m, 11H, Pyrid., PhF, Ph), 5.43 (s, 2H, CH₂).




- 1-10 5-(4-Fluorophenyl)-2-phenylthiomethyl-4-(4-pyridyl)-pyrimidine: MS (m/z): 374.2 (M+H)⁺; C₂₂H₁₆FN₃S requir. 373.5. ¹H-NMR (CDCl₃): d 8.72 (s, 1H, H-6, Pyrim.), 8.56, 7.49 (2m each 2H, Pyrid.), 7.32-7.02 (m, 9H, PhF, Ph), 4.50 (s, 2H, CH₂).




- 1-11 5-(4-Fluorophenyl)-2-phenyl-4-(4-pyridyl)-pyrimidine: MS (m/z): 328.2 (M+H)⁺; C₂₁H₁₄FN₃ requir. 327.4. ¹H-NMR (CDCl₃): d 8.85 (s, 1H, H-6, Pyrim.), 8.63, 7.4 (2m, each 2H, Pyrid.), 8.56, 7.6-7.5, 7.25-7.05 (m, 9H, PhF, Ph).




- 1-12 5-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 344.2 (M+H)⁺; C₂₁H₁₄FN₃O requir. 343.4. ¹H-NMR (DMSO-d₆): δ 10.2 (bs, 1H, OH), 8.90 (s, 1H, H-6, Pyrim., Pyrim.), 8.60, 7.42 (2m, each 2H, Pyrid.), 8.35, 7.40-6.92 (m, 8H, PhF, PhOH).




- 1-13 5-(4-Fluorophenyl)-2-(4-aminophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 343.2 (M+H)⁺; C₂₁H₁₃FN₃ requir. 342.4. ¹H-NMR (CDCl₃): δ 8.75 (s, 1H, H-6, Pyrim.), 8.60, 7.41 (2m, each 2H, Pyrid.), 8.40, 7.22-6.79 (m, 8H, PhF, Ph), 4.00 (bs, 2H, NH₂).



- 1-14 5-(4-Fluorophenyl)-2-(3-pyridyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 329.0 (M+H)⁺; C₂₀H₁₁FN₃ requir. 328.4. ¹H-NMR (CDCl₃): δ 9.80 (bs, H-2, 3-Pyrid.), 8.90 (s, 1H, H-6, Pyrim.), 8.84, 8.80 (2m, each 1H, 3-Pyrid.), 8.66, 7.45 (2m, each 2H, 4-Pyrid.), 7.50 (m, 1H, 3-Pyrid.), 7.28-7.10 (m, 4H, PhF).




- 1-15 5-(4-Fluorophenyl)-2-(2-pyridyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 329.0 (M+H)⁺; C₂₀H₁₁FN₃ requir. 328.4. ¹H-NMR (CDCl₃): δ 9.01 (s, 1H, H-6, Pyrim.), 8.92, 8.66, 7.94, 7.48 (4m, each 1H, 2-Pyrid.), 8.66, 7.47 (2m, each 2H, 4-Pyrid.), 7.26, 7.14 (2m, each 2H, PhF).



- 1-16 5-(4-Fluorophenyl)-2-(2-pyrazinyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 330.2 (M+H)⁺; C₁₉H₁₂FN₃ requir.


329.3. $^1\text{H-NMR}$ (CDCl_3): 9.84 (m, 1H, H-3, Pyraz.), 9.01 (s, 1H, H-6, Pyrim.), 8.84, 8.76 (2m, each 1H, H-5, H-6, Pyraz.), 8.65, 7.44 (2m, each 2H, Pyrid.), 7.26, 7.13 (2m, each 2H, PhF).



5


1-17 5-(4-Fluorophenyl)-2-(2-methylthiazol-4-yl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 349.0 (M+H)⁺; $\text{C}_{19}\text{H}_{13}\text{FN}_4\text{S}$ requir. 348.4. $^1\text{H-NMR}$ (CDCl_3): d 8.90 (s, 1H, H-6, Pyrim.), 8.63, 7.42 (2m, each 2H, Pyrid.), 8.32 (s, 1H, H-5, Thiaz.), 7.22, 7.10 (2m, each 2H, PhF), 2.88 (s, 3H, CH_3).

10



1-18 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-thienyl)-pyrimidine: MS (m/z): 334.2 (M+H)⁺; $\text{C}_{19}\text{H}_{12}\text{FN}_3\text{S}$ requir.

15 333.4. $^1\text{H-NMR}$ (CDCl_3): d 8.74 (s, 1H, H-6, Pyrim.), 8.63, 7.41 (2m, each 2H, Pyrid.), 8.13, 7.55 (2m, each 1H, Thioph.), 7.20 (m, 3H, PhF, Thioph.), 7.10 (m, 2H, PhF).



20 The following pyrimidines were prepared according to the general procedure by reacting 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one with guanidines:

1-19 2-Amino-5-(4-fluorophenyl)-4-(4-pyridyl)-

25 pyrimidine: MS (m/z): 267.0 (M+H)⁺; $\text{C}_{15}\text{H}_{11}\text{FN}_4$ requir.

266.3. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$): d 8.54, 7.26 (2m, each 2H, Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.22-7.12 (m, 4H, PhF), 6.97 (s, 2H, NH_2).

R1 = NH_2 -

1-20 2-Ethylamino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 295.0 (M+H)⁺; C₁₇H₁₅FN₄ requir. 294.3. ¹H-NMR (CDCl₃): δ 8.56, 7.32 (m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.12-6.99 (m, 4H, PhF), 5.33 (unresolv.t, 1H, NH), 3.58 (m, 2H, CH₂), 1.32 (t, 3H, CH₃).

R1 = CH₃CH₂-NH-


1-21 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-sulfoethylamino)-pyrimidine: MS (m/z): 375.2 (M+H)⁺; C₁₇H₁₅FN₄O₂S requir. 374.4. ¹H-NMR (DMSO-d₆): δ 8.51, 7.25 (2d, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.32 (t, 1H, NH), 7.2-7.1 (m, 4H, PhF), 3.62 (q, 2H, CH₂N), 2.72 (t, 2H, CH₂).

R1 = HO₂S-CH₂-CH₂-NH-


1-22 2-(2-Diethylaminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 365.8 (M+H)⁺; C₂₁H₂₄FN₅ requir. 365.5. ¹H-NMR (CDCl₃): δ 8.55, 7.28 (2m, each 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.08, 7.01 (2m, each 2H, PhF), 5.95 (bs, 1H, NH), 3.60 (q, 2H, CH₂N), 2.76 (t, 2H, CH₂), 2.65 (q, 4H, 2CH₂CH₃), 1.08 (t, 6H, 2CH₃).

R1 = (CH₃CH₂)₂NCH₂CH₂NH-


1-23 (4-Fluorophenyl)-4-(4-pyridyl)-2-(thioureido)-pyrimidine: MS (m/z): 326.2 (M+H)⁺; C₁₆H₁₂FN₃S requir. 325.4. ¹H-NMR (DMSO-d₆): δ 10.84, 10.11, 9.20 (3s, each 1H, NH, SH), 8.75 (s, 1H, H-6, Pyrim.), 8.59, 7.32 (2m, each 2H, Pyrid.), 7.28, 7.21 (2m, each 2H, PhF).




1-24 2-(2,6-Dichlorophenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 410.8 (M)⁺; C₂₁H₁₃Cl₂FN₄ requir. 411.3. ¹H-NMR (CDCl₃): δ 8.54, 7.30 (2m, each 2H, Pyrid.), 8.45 (s, 1H, H-6, Pyrim.), 7.45 (d, 2H, PhCl₂), 7.21 (t, 1H, PhCl₂), 7.12, 7.04 (2m, each 2H, PhF).




- 1-25 2-(2,6-Dimethylphenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 371.0 (M+H)⁺; C₂₃H₁₉FN₄ requir. 370.4. ¹H-NMR (CDCl₃): d 8.56, 7.32 (2d, each 2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.20 (s, 3H, PhCl₂), 7.11, 7.04 (2m, each 2H, PhF), 6.66 (s, 1H, NH), 2.20 (s, 6H, 2CH₃).



- 10 1-26 5-(4-Fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 373.0 (M+H)⁺; C₂₂H₁₇FN₄O requir. 372.4. ¹H-NMR (CDCl₃): d 8.62, 7.40 (2m, each 2H, Pyrid.), 8.60 (m, 1H, PhOMe), 8.52 (s, 1H, H-6, Pyrim.), 7.99 (s, 1H, NH), 7.18-6.94 (m, 7H, PhF, PhOMe), 3.96 (s, 3H, CH₃O).



- 15 1-27 5-(4-Fluorophenyl)-2-(4-fluorophenylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 361.0 (M+H)⁺; C₂₂H₁₄F₂N₄ requir. 360.4. ¹H-NMR (CDCl₃): d 8.58, 7.32 (m, 2H, Pyrid.), 8.46 (s, 1H, H-6, Pyrim.), 7.62 (m, 2H, PhF), 7.24 (bs, 1H, NH), 7.13-7.00 (m, 6H, PhF).




20


- 1-28 2-(4-Ethylphenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 371.2 (M+H)⁺; C₂₃H₁₉FN₄ requir. 370.4. ¹H-NMR (CDCl₃): d 8.61, 7.41 (2m, each 2H, Pyrid.), 8.49 (s, 1H, H-6, Pyrim.), 7.60, 7.23 (2d,

107


each 2H, PhEth), -7.28 (NH), 7.13, 7.06 (2m, each 2H, PhF), 2.67 (q, 2H, CH₂), 1.27 (t, 3H, CH₃).




- 1-29 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(3-trifluoromethylphenylamino)-pyrimidine: MS (m/z): 411.0 (M+H)⁺; C₂₂H₁₄F₃N₄ requir. 410.4. ¹H-NMR (CDCl₃): δ 8.60, 7.35 (2m, each 2H, Pyrid.), 8.52 (s, 1H, H-6, Pyrim.), 8.23, 7.73, 7.46 (s, dd, t, each 1H, PhCF₃), 7.44 (s, 1H, NH), 7.31 (dd, 1H, PhCF₃), 7.13, 7.05 (2m, each 2H, PhF).



- 1-30 2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 357.0 (M+H)⁺; C₂₂H₁₇FN₄ requir. 356.4. ¹H-NMR (CDCl₃): δ 8.55, 7.28 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.44-7.28 (m, 5H, Ph), 7.09, 7.02 (2m, each 2H, PhF), 5.71 (t, 1H, NH), 4.75 (d, 1H, CH₂).



- 1-31 5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 371.0 (M+H)⁺; C₂₃H₁₉FN₄ requir. 370.4. ¹H-NMR (CDCl₃): δ 8.56 (m, 2H, Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.38-7.22 (m, 7H, Ph, Pyrid.), 7.08, 7.02 (2m, each 2H, PhF), 5.32 (t, 1H, NH), 3.80 (q, 2H, CH₂N), 2.92 (t, 2H, CH₂).




25

108


1-32 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-pyrimidine: MS (m/z): 321.2 (M+H)⁺; C₁₃H₁₁FN₃ requir.

320.4. ¹H-NMR (CDCl₃): δ 8.54, 7.32 (2d, each 2H, Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.06, 7.00 (2m, each 2H, PhF), 3.68, 2.05 (2m, each 4H, 4CH₂).




1-33 5-(4-Fluorophenyl)-2-morpholino-4-(4-pyridyl)-pyrimidine: MS (m/z): 337.2 (M+H)⁺; C₁₅H₁₇FN₃O requir.

336.4. ¹H-NMR (CDCl₃): δ 8.56, 7.31 (2m, each 2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.10, 7.03 (2m, each 2H, PhF), 3.94, 3.83 (2m, each 4H, 4CH₂).




1-34 2-(3,5-Dimethylpyrazolyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 346.0 (M+H)⁺; C₂₀H₁₆FN₅ requir.

345.4. ¹H-NMR (CDCl₃): δ 8.80 (s, 1H, H-6, Pyrim.), 8.60, 7.35 (2m, each 2H, Pyrid.), 7.18, 7.08 (2m, each 2H, PhF), 6.08 (s, 1H, Pyraz.), 2.70, 2.30 (2s, each 3H, 2CH₃).




1-35 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(3,5-bis(trifluoromethyl)benzenesulfamoyl)-pyrimidine: MS


(m/z): 542.8 (M+H)⁺; C₂₃H₁₃F₅N₄O₂S requir. 542.4. ¹H-NMR (DMSO-d₆): δ 8.63 (s, 1H, H-6, Pyrim.), 8.56 (m, 2H, Pyrid.), 8.49, 8.43 (2s, 2H, 1H, Ph(CF₃)₂), 7.26-7.15 (m, 6H, PhF, Pyrid.).



- 1-36 2-(4-Aminobenzenesulfamoyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 421.8 (M+H)⁺; C₂₁H₁₆FN₅O₂S requir. 421.5. ¹H-NMR (DMSO-d₆): d 8.58 (s, 1H, H-6, Pyrim.), 8.575 (m, 2H, Pyrid.), 7.64, 6.56 (2d, each 2H, PhNH₂), 7.28-7.15 (m, 6H, PhF, Pyrid.), 5.99 (s, 2H, NH₂).




- 1-37 2-(2-Dimethylaminoethylthio)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine was prepared according to the general procedure by reacting 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one with S-(2-dimethylaminoethyl)isothiourrea. MS (m/z): 355.2 (M+H)⁺; C₁₉H₁₉FN₄S requir. 354.5. ¹H-NMR (CDCl₃): d 8.59, 7.32 (2m, each 2H, Pyrid.), 8.58 (s, 1H, H-6, Pyrim.), 7.16, 7.08 (2m, each 2H, PhF), 3.40, 2.76 (2m, each 2H, 2CH₃), 2.37 (s, 6H, 2CH₃).



Example 2

- 20 General procedure for the preparation of 2-N substituted 2-amino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines
a. 5-(4-Fluorophenyl)-4-(4-pyridyl)-2(1H)-pyrimidinone:




- 25 Urea (0.67 g, 11.15 mmol) was added to a stirred ethanolic 0.62 N sodium ethoxide solution (15 ml). An ethanolic solution (60 ml) of 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridinyl)-3-propene-1-one (9.29

mmol) was added and the mixture was refluxed overnight. It was evaporated followed by column chromatography (5% methanol/dichloromethane to 100% methanol). Crystals (presumably urea) obtained on treating the resultant product with dichloromethane/methanol were filtered. The filtrate was evaporated and the remainder rechromatographed on a column of silica gel (chloroform/methanol/water = 70:20:1) to yield the title compound as a yellowish foam.

MS (m/z): 268.2 (M+H)⁺; C₁₅H₁₀FN₃O requir. 267.3. ¹H-NMR (DMSO-d₆): δ 8.55, 7.24 (2m, each 2H, Pyrid.), 8.22 (bs, 1H, H-6, Pyrim.), 7.20-7.10 (m, 4H, PhF).

b. 2-Chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine:




A mixture of 5-(4-fluorophenyl)-4-(4-pyridyl)-2-(1H)-pyrimidinone (2.41 mmol) and phosphorus oxychloride (3 ml) was heated at reflux for 45 min. It was evaporated to dryness at a bath temperature of >50° C. The flask was cooled in an ice-bath and ice-water was added. If the pH value was found still acidic, then the mixture was neutralized with aqueous 5% ammonium hydroxide. It was extracted with dichloromethane, followed by washing of the organic solution with aqueous sodium chloride, drying and evaporation to yield the title compound as a yellowish foam which was used without further purification.

MS (m/z): 286.1 (M+H)⁺; C₁₅H₁₀ClFN₃ requir. 285.7. ¹H-NMR (CDCl₃): δ 8.68 (s, 1H, H-6, Pyrim.), 8.62, 7.42 (2m, each 2H, Pyrid.), 7.23-7.10 (m, 4H, PhF).

Alternatively, 2-chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine (MS (m/z): 282 (M+H)⁺; C₁₆H₁₂ClN₃ requir. 281.7) and 2-chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine (MS (m/z): 336.0 (M)⁺; C₁₆H₉ClF₃N₃ requir. 335.7) have been synthesized by the same reaction sequence, but starting from 2-(3-methylphenyl)-1-(4-pyridinyl)ethanone (prepared according to: I. Lantos et al., J. Org. Chem. 53, 4223-4227, 1988) and 1-(4-pyridinyl)-2-(3-trifluoromethylphenyl)ethanone (prepared according to: P.W. Sheldrake, Synth. Commun. 23 (24), 1967-1971, 1993); and WO 97/12876). Also, thionyl chloride/*N,N*-dimethylformamide (excess/3 equivalents, reflux) can be used instead of phosphorus oxychloride.

15 c. General procedure:




Typically, a mixture of 2-chloro-5-(4-fluoro phenyl)-4-(4-pyridyl)-pyrimidine (50-120 mg, 0.18-0.42 mmol) and the amine, HNR⁵R²¹, (0.5-5.5 mmol) was heated at 50-100°C for 5-60 min (thin layer chromatography check). The mixture was applied directly to a column of silica gel which was developed with dichloromethane/methanol or dichloromethane/methanol/conc. ammonium hydroxide.


25 An alternate procedure using ethanol as a solvent was used in case of Examples 2-6, 2-11, 2-12, 2-20 and 2-26 as described.

The following pyrimidines were prepared according to this procedure using the appropriate amine and
30 substituted 2-chloropyrimidine:


- 2-1 2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 310.2 (M+H)⁺; C₁₇H₁₆FN₅-HCl requir. 309.4+36.5. ¹H-NMR (CD₃OD): d 8.84, 8.10 (2m, each 2H, Pyrid.), 8.58 (s, 1H, H-6, Pyrim.), 7.28, 7.15 (2m, each 2H, PhF), 3.83 (t, 2H, CH₂), 3.27 (t, 2H, CH₂).
R1 = NH₂CH₂CH₂NH-
- 2-2 2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 324.0 (M+H)⁺; C₁₈H₁₈FN₅-HCl requir. 323.4+36.5. ¹H-NMR (CD₃OD): d 8.85, 8.10 (m, 2H, Pyrid.), 8.54 (s, 1H, H-6, Pyrim.), 7.27, 7.14 (2m, each 2H, PhF), 3.84, 3.68 (2t, each 2H, 2CH₂N), 2.18 (m, 2H, CH₂).
R1 = NH₂CH₂CH₂CH₂NH-
- 2-3 2-(4-Aminobutylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 338.0 (M+H)⁺; C₁₉H₂₀FN₅-HCl requir. 337.4+36.5. ¹H-NMR (CD₃OD): d 8.80, 8.05 (2m, each 2H, Pyrid.), 8.50 (s, 1H, H-6, Pyrim.), 7.25, 7.14 (2m, each 2H, PhF), 3.58 (bt, 2H, CH₂), 3.02 (bt, 1H, CH₂), 1.80 (m, 4H, 2CH₂).
R1 = NH₂CH₂CH₂CH₂CH₂NH-
- 2-4 2-(2-Dimethylaminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 338.2 (M+H)⁺; C₁₉H₂₀FN₅ requir. 337.4. ¹H-NMR (CDCl₃): d 8.57, 7.30 (2m, each 2H, Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.10, 7.03 (2m, each 2H, PhF), 6.00 (t, 1H, NH), 3.66 (q, 2H, CH₂), 2.71 (t, 2H, CH₂), 2.41 (s, 6H, 2CH₃).
R1 = (CH₃)₂NCH₂CH₂NH-
- 2-5 5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 386 (M+H)⁺; C₂₃H₂₀FN₅ requir. 385.5. ¹H-NMR (CDCl₃): d 8.57, 7.28 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.18 (t, 2H, Ph), 7.08, 7.02 (2m, each 2H, PhF), 6.73 (t, 1H, Ph), 6.64 (d, 2H, Ph), 5.62 (bt, 1H, NH), 3.80 (q, 2H, CH₂), 3.47 (t, 2H, CH₂).




- 2-6 5-(4-Fluorophenyl)-2-(2-(4-fluorophenylamino)-ethyldiamino)-4-(4-pyridyl)-pyrimidine: A solution of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (103 mg, 0.36 mmol) and N-(4-fluorophenyl)ethyldiamine (1 ml) in ethanol (1 ml) was heated to reflux for 3 h. Evaporation was followed by column chromatography (3% methanol/dichloromethane) to provide the title compound as a yellowish solid. MS (m/z): 404.2 (M+H)⁺; C₂₃H₁₉F₂N₅, requir. 403.4. ¹H-NMR (CDCl₃): 8.60 7.31 (2m, each 2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.11-7.02 (2m, each 2H, PhF), 6.90, 6.60 (t, dd, each 2H, PhF), 5.62 (t, 1H, NH), 3.82 (q, 2H, CH₂), 3.44 (t, 2H, CH₂).




- 15 2-7 5-(4-Fluorophenyl)-2-(4-methylbenzylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 371.2 (M+H)⁺; C₂₃H₁₉FN₄, requir. 370.4. ¹H-NMR (CDCl₃): d 8.55, 7.34 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.30, 7.18 (2d, each 2H, PhMe), 7.08, 7.02 (2m, each 2H, PhF), 5.69 (bs, 1H, NH), 4.69 (d, 2H, CH₂), 2.36 (s, 3H, CH₃).




- 2-8 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)-ethyldiamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 389.2 (M+H)⁺; C₂₃H₁₈F₂N₅, requir. 388.4. ¹H-NMR (CDCl₃): d 8.57 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.32-7.20, 7.12-6.98 (2m, 10H, 2PhF, Pyrid.), 5.37 (bt, 1H, NH), 3.79 (q, 2H, CH₂N), 2.97 (t, 2H, CH₂).



- 2-9 2-(2-(4-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 405.0 (M+H)⁺; C₂₃H₁₈ClFN₄ requir. 404.9. ¹H-NMR (CDCl₃): δ 8.56 (bs, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.29 (m, d, 4H, Pyrid., PhCl), 7.20 (d, 2H, PhCl), 7.08, 7.02 (2m, each 2H, PhF), 5.35 (t, 1H, NH), 3.78 (q, CH₂N), 2.96 (t, 2H, CH₂).




- 10 2-10 2-(2-(4-Bromophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 449.0 (M)⁺; C₂₃H₁₈BrFN₄ requir. 449.3. ¹H-NMR (CDCl₃): δ 8.58, 7.47 (m, 2H, Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.29, 7.17 (2d, each 2H, PhCl), 7.10, 7.02 (2d, each 2H, PhF), 5.34 (t, 1H, NH), 3.80 (q, 2H, CH₂N), 2.97 (t, 2H, CH₂).




- 2-11 5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)-ethylamino)-4-(4-pyridyl)-pyrimidine: A mixture of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (61 mg, 0.21 mmol), tyramine hydrochloride (186 mg, 1.01 mmol) and sodium hydrogencarbonate (90 mg, 1.07 mmol) in aqueous ethanol (1 ml) was heated to reflux for 1 h. Solvent evaporation and subsequent column chromatography (5% methanol/dichloromethane) provided the title
- 25 compound as a yellow solid. MS (m/z): 387.2 (M+H)⁺; C₂₃H₁₉FN₄O requir. 386.4. ¹H-NMR (DMSO-d₆): δ 9.12 (bs, 1H, OH), 8.54, 7.26 (2m, each 2H, Pyrid.), 8.38 (s, 1H, H-6, Pyrim.), 7.52 (t, 1H, NH), 7.20-7.10 (m, 4H, PhF), 7.05,

115


6.69 (2d, each 2H, PhOH), 3.52 (q, 2H, CH₂N), 2.78 (t, 2H, CH₂):



- 2-12 2-(2-(4-Aminophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: A solution of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (71 mg, 0.25 mmol) and 2-(4-aminophenyl)ethanamine (0.5 ml, 3.80 mmol) in ethanol (1.5 ml) was heated to reflux for 20 min. Evaporation and subsequent chromatography on a column of silica gel (2% methanol/dichloromethane) provided the title compound as a yellow syrup. MS (m/z): 386.4 (M+H)⁺; C₂₃H₂₀FN₄ requir. 385.5. ¹H-NMR (CDCl₃): d 8.56, 7.32 (2m, each 2H, Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.12-6.99 (m, 6H, PhF, PhNH₂), 6.68 (d, 2H, PhNH₂), 5.37 (t, 1H, NH), 3.75 (q, 2H, CH₂N), 2.88 (t, 2H, CH₂).




- 2-13 5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)-ethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 389.2 (M+H)⁺; C₂₃H₁₈F₂N₄ requir. 388.4. ¹H-NMR (CDCl₃): 8.57 (m, 2H, Pyrid.), 8.35 (s, 1H, H-6, Pyrim.), 7.34-7.20, 7.14-7.00 (2m, 10H, 2PhF, Pyrid.), 5.42 (bt, 1H, NH), 3.82 (q, 2H, CH₂N), 3.05 (t, 2H, CH₂).




- 2-14 2-(2-(2-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 405.0 (M+H)⁺; C₂₃H₁₆ClFN₄ requir. 404.9. ¹H-NMR (CDCl₃): d 8.57 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.40-7.00

116


(m, 10H, PhF, PhCl₂, Pyrid.), 5.44 (bt, 1H, NH), 3.84 (q, 2H, CH₂N), 3.15 (t, 2H, CH₂).



- 2-15 5-(4-Fluorophenyl)-2-(2-(2-methoxyphenyl)-ethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 401.2 (M+H)⁺; C₂₄H₂₁FN₄O requir. 400.5 ¹H-NMR (CDCl₃): δ 8.56, 7.30 (2m, each 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.24, 7.08, 7.02, 6.92 (4m, each 2H, PhF, PhOMe), 5.50 (bt, 1H, NH), 3.87 (s, 3H, CH₃), 3.78 (q, 2H, CH₂N), 3.02 (t, 2H, CH₂).




- 2-16 2-(2-(2,4-Dichlorophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 439.0 (M)⁺; C₂₃H₁₇Cl₂FN₄ requir. 439.3. ¹H-NMR (CDCl₃): 8.56 (bs, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.37 (s, 1H, PhCl), 7.30 (bd, 2H, Pyrid.), 7.22-7.15 (m, 2H, PhCl), 7.08, 7.05 (2m, each 2H, PhF), 5.40 (t, 1H, NH), 3.80 (q, 2H, CH₂N), 3.10 (t, 2H, CH₂).




- 2-17 2-(2-(2,6-Dichlorophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 439.0 (M)⁺; C₂₃H₁₇Cl₂FN₄ requir. 439.3. ¹H-NMR (CDCl₃): 8.57 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.35 (d, 2H, PhCl), 7.11 (m, 3H, PhF, PhCl), 7.03 (m, 2H, PhF), 5.45 (t, 1H, NH), 3.86 (q, 2H, CH₂N), 3.38 (t, 2H, CH₂).


117



- 2-18 5-(4-Fluorophenyl)-2-(2-(3-methoxyphenyl)-ethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 401.2 (M+H)⁺; C₂₄H₂₁FN₄O requir. 400.5. ¹H-NMR (CDCl₃): d 8.56 (m, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.32-7.22, 7.11-6.98, 6.89-6.77 (3m, 10H, PhF, PhOMe, Pyrid.), 5.38 (t, 1H, NH), 3.82 (m, 5H, CH₂N, CH₃), 2.96 (t, 2H, CH₂).




- 2-19 2-(2-(3-Chlorophenyl)-ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 405.4 (M+H)⁺; C₂₃H₁₈ClFN₄ requir. 404.9. ¹H-NMR (CDCl₃): d 8.60 (d, 2H, Pyrid.), 8.38 (s, 1H, H-6, Pyrim.), 7.32-7.24 (m, 5H, Pyrid., PhCl), 7.18 (m, 1H, PhCl), 7.11, 7.04 (2m, each 2H, PhF), 5.35 (t, 1H, NH), 3.83 (q, 2H, CH₂N), 3.00 (t, 2H, CH₂).



- 2-20 5-(4-Fluorophenyl)-2-((2-hydroxy-2-phenyl)-ethylamino)-4-(4-pyridyl)-pyrimidine: A mixture of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (87 mg, 0.31 mmol) and 2-amino-1-phenylethanol (300 mg, 2.19 mmol) in ethanol (2 ml) was heated to reflux for 2 h. Evaporation and subsequent chromatography on a column of silica gel (4% methanol/dichloromethane) provided the title compound as as yellow foam. MS (m/z): 387.0 (M+H)⁺; C₂₃H₁₉FN₄O requir. 386.4. ¹H-NMR (CDCl₃): d 8.58 (d, 2H, Pyrid.), 8.38 (s, 1H, H-6, Pyrim.), 7.47 (d, 2H,


Ph), 7.41 (t, 2H, Ph), 7.34 (t, 1H, Ph), 7.28 (d, 2H, Pyrid.), 7.10, 7.02 (2m, 2H, PhF), 5.72 (t, 1H, NH), 5.06 (m CHOH), 4.02-3.92 (m, 2H, OH, 1CH₂), 3.72 (ddd, 1H, 1CH₂).



5


2-21 5-(4-Fluorophenyl)-2-(methyl-(2-phenylethyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 385.0 (M+H)⁺; C₂₄H₂₁FN₄, requir. 384.5. ¹H-NMR (CDCl₃): d 8.57, 7.35 (2m, each 2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.34-7.21 (m, 5H, Ph), 7.10, 7.03 (2m, each 2H, PhF), 3.96 (t, 2H, CH₂N), 3.23 (s, 3H, CH₃), 3.00 (t, 2H, CH₂).

10



2-22 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 385.2 (M+H)⁺; C₂₄H₂₁FN₄, requir. 384.5. ¹H-NMR (CDCl₃): d 8.56 (m, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.34-7.20 (m, 7H, Ph, Pyrid.), 7.08, 7.01 (2m, each 2H, PhF), 5.38 (t, 1H, NH), 3.58 (q, 2H, CH₂N), 2.78 (t, 2H, CH₂), 2.03 (m, 2H, CH₂).


15




20

2-23 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 399.0 (M+H)⁺; C₂₅H₂₃FN₄, requir. 398.5. ¹H-NMR (CDCl₃): d 8.56 (m, 2H, Pyrid.), 8.32 (s, 1H, H-6, Pyrim.), 7.32-7.17 (m, 7H, Pyrid., Ph), 7.09-7.02 (2m, each 2H, PhF), 5.16 (d, 1H, NH), 4.28 (m, 1H, CH), 2.77 (m, 2H, CH₂), 1.94 (m, 2H, CH₂), 1.34 (d, 3H, CH₃).


25




- 2-24 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 375.0 (M+H)⁺; C₂₂H₁₉FN₅ requir. 374.4. ¹H-NMR (CDCl₃): δ 8.57, 7.26 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.56 (s, 1H, Imid.), 7.16-6.96 (m, 6H, PhF, Imid.), 5.38 (bt, 1H, NH), 4.12 (t, 2H, CH₂N), 3.56 (q, 2H, CH₂NH), 2.20 (m, 2H, CH₂).



- 10 2-25 5-(4-Fluorophenyl)-2-((4-phenyl-n-butyl)-amino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 399.0 (M+H)⁺; C₂₅H₂₃FN₄ requir. 398.5. ¹H-NMR (CDCl₃): δ 8.56 (m, 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.33-7.17 (m, 7H, Ph, Pyrid.), 7.08, 7.02 (2m, each 2H, PhF), 5.33 (bt, 1H, NH), 3.56 (q, 2H, CH₂N), 2.71 (t, 2H, CH₂), 1.76 (m, 4H, 2CH₂).




- 20 2-26 5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-pyrimidine: A mixture of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (71 mg, 0.25 mmol) and piperazine (214 mg, 2.48 mmol) in ethanol (1 ml) was heated to reflux for 5 min. Evaporation and subsequent chromatography on a column of silica gel (5% methanol/dichloromethane) provided the title compound as
 25 as yellow solid. MS (m/z): 336.2 (M+H)⁺; C₁₉H₁₈FN₅ requir. 335.4. ¹H-NMR (CDCl₃): δ 8.54, 7.29 (2m, each 2H, Pyrid.), 8.37 (s, 1H, H-6, Pyrim.), 7.08, 7.00 (2m, each 2H, PhF), 3.95 (t, 4H, 2CH₂), 3.01 (t, 4H, 2CH₂).



2-27 5-(4-Fluorophenyl)-2-(1-piperidinyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 335.2 (M+H)⁺; C₂₀H₁₅FN₅, requir.


334.4. ¹H-NMR (CDCl₃): δ 8.55, 7.30 (2m, each 2H,

- 5 Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.08, 7.01 (2m, 2H, PhF), 3.91 (t, 4H, 2CH₂N), 1.74, 1.68 (2m, 6H, 3CH₂).




2-28 5-(4-Fluorophenyl)-2-(4-methyl-1-piperazinyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 350.0 (M+H)⁺; C₂₀H₂₀FN₅,

- 10 requir. 349.4. ¹H-NMR (CDCl₃): δ 8.58, 7.32 (2m, each 2H, Pyrid.), 8.40 (s, 1H, H-6, Pyrim.), 7.10, 7.04 (2m, each 2H, PhF), 4.00 (t, 4H, 2CH₂), 2.57 (t, 4H, 2CH₂), 2.42 (s, 3H, CH₃).




- 15 2-29 5-(4-Fluorophenyl)-2-(4-phenyl-1-piperazinyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 412.2 (M+H)⁺; C₂₅H₂₁FN₅, requir. 411.5. ¹H-NMR (CDCl₃): δ 8.58 (bd, 2H, Pyrid.), 8.42 (s, 1H, H-6, Pyrim.), 7.38-7.30 (m, 4H, Pyrid., Ph), 7.15-7.00 (m, 6H, PhF, Ph), 6.94 (t, 1H, Ph), 4.13
- 20 (t, 4H, 2CH₂), 3.33 (t, 4H, 2CH₂).




2-30 5-(4-Fluorophenyl)-2-(2-morpholinoethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 380.4 (M+H)⁺; C₂₁H₂₂FN₅O


- 25 requir. 379.4. ¹H-NMR (CDCl₃): δ 8.58, 7.30 (2m, each 2H, Pyrid.), 8.38 (s, 1H, H-6, Pyrim.), 7.10, 7.03 (2m, each 2H, PhF), 5.91 (bs, 1H, NH), 3.79 (bs, 4H, 2CH₂), 3.66 (bs, 2H, CH₂), 2.71 (bs, 2H, CH₂), 2.59 (bs, 4H, 2CH₂).




- 2-31 5-(4-Fluorophenyl)-2-(2-piperidinoethylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 378.2 (M+H)⁺; C₂₂H₂₂FN₅, requir. 377.5 ¹H-NMR (CDCl₃): δ 8.54, 7.27 (2d, each 2H, Pyrid.), 8.34 (s, 1H, H-6, Pyrim.), 7.06, 7.00 (2m, each 2H, PhF), 6.04 (bt, 1H, NH), 3.66 (q, 2H, CH₂NH), 2.74 (t, 2H, CH₂), 2.61 (bs, 4H, 2CH₂), 1.68 (m, 4H, 2CH₂), 1.50 (m, 2H, CH₂).



- 10 2-32 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-pyrrolidinoethylamino)-pyrimidine: MS (m/z): 364.0 (M+H)⁺; C₂₁H₂₂FN₅, requir. 363.4 ¹H-NMR (CDCl₃): δ 8.55, 7.28 (2m, each 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.08, 7.02 (2m, each 2H, PhF), 6.28 (t, 1H, NH), 3.86 (q, 2H, CH₂NH), 3.18 (t, 2H, CH₂N), 3.10 (bs, 4H, 2CH₂N), 2.02 (bs, 4H, 2CH₂).




- 20 2-33 5-(4-Fluorophenyl)-2-(3-morpholinopropylamino)-4-(4-pyridyl)-pyrimidine: MS (m/z): 394.2 (M+H)⁺; C₂₂H₂₄FN₅O, requir. 393.5. ¹H-NMR (CDCl₃): δ 8.54, 7.27 (2m, each 2H, Pyrid.), 8.33 (s, 1H, H-6, Pyrim.), 7.06, 7.00 (2m, each 2H, PhF), 6.00 (t, 1H, NH), 3.76 (t, 4H, 2CH₂O), 3.60 (q, 2H, CH₂NH), 2.52 (t, 2H, CH₂N), 2.50 (m, 4H, CH₂N), 1.86 (m, 2H, CH₂).



25


2-34 5-(4-Fluorophenyl)-2-(3-(2-pyrrolidinon-1-yl)-propylamino)-4-(4-pyridyl)-pyrimidine:

MS (m/z): 392.2 (M+H)⁺; C₂₂H₂₂FN₅O requir. 391.5. ¹H-NMR (CDCl₃): δ 8.58, 7.30 (m, 2H, Pyrid.), 8.36 (s, 1H, H-6, Pyrim.), 7.10, 7.04 (m, 2H, PhF), 5.88 (t, 1H, NH), 3.56 (q, 2H, CH₂NH), 3.48, 3.45 (2t, each 2H, 2CH₂), 2.46 (t, 2H, CH₂), 2.08 (m, 2H, CH₂), 1.90 (m, 2H, CH₂).




2-35 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:

MS (m/z): 400.1 (M+H)⁺; C₂₄H₂₂FN₅ requir. 399.5 (free base).




2-36 2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride:

2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and (S)-1,2-benzylethyldiamine were reacted according to the General Procedure, Step C (70°C for 75 min) to give the title compound. MS (m/z): 450.4 (M+H)⁺; C₂₅H₂₂F₃N₅ requir. 4449.5 (free base).




2-37 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:


2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and (S)-1,2-benzylethyldiamine were reacted according to the General Procedure, Step C (100°C for 20 min) to give the title compound. MS (m/z): 396.2 (M+H)⁺; C₂₅H₂₅N₅ requir. 395.5 (free base).




- 2-38 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: 2-Chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine and (S)-2-N,N-dimethylamino-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 45 min) to give the title compound. MS (m/z): 427.8 (M+H)⁺; C₂₆H₂₆FN, requir. 427.5.



- 2-39 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine: 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and (S)-2-N,N-dimethylamino-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 424.2 (M+H)⁺; C₂₇H₂₇FN, requir. 423.6.




- 2-40 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: 2-Chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine and 1-phenyl-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 4001. (M+H)⁺; C₂₄H₂₂FN, requir. 399.5 (free base).




- 2-41 2-((3-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and 1-phenyl-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 1

124


h) to give the title compound. MS (m/z): 450.3 (M+H)⁺; C₂₅H₂₂F₃N₃, requir. 449.5 (free base).




- 2-42 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
 5 hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and 1-(2-fluorophenyl)-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to
 10 give the title compound. MS (m/z): 468.4 (M+H)⁺; C₂₅H₂₁F₄N₃, requir. 467.5 (free base).




- 2-43 2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:
 15 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and 1-phenyl-1,3-propanediamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 396.1 (M+H)⁺; C₂₅H₂₅N₃, requir. 395.5 (free base).




- 20 2-44 2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and 2-amino-2-methyl-3-phenylpropylamine were reacted
 25 according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 410.2 (M+H)⁺; C₂₆H₂₇N₃, requir. 409.5 (free base).




- 2-45 2-((3-Hydroxy-3-phenylpropyl)-amino) 5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine: 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and 3-hydroxy-3-phenylpropylamine were reacted according to the General Procedure, Step C (100°C for 30 min) to give the title compound. MS (m/z): 397.2 (M+H)⁺; C₂₅H₂₄N₄O requir. 396.5.




- 10 2-46 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and (1R,2R)-2-methyl-1-phenyl-1,3-propanediamine were reacted according to
15 the General Procedure, Step C (50°C for 1 h) to give the title compound. MS (m/z): 464.4 (M+H)⁺; C₂₆H₂₄F₃N₅ requir. 463.5 (free base).




- 20 2-47 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and (1S,2S)-2-methyl-1-phenyl-1,3-propanediamine were reacted according to
25 the General Procedure, Step C (90°C for 45 min) to give the title compound. MS (m/z): 464.1 (M+H)⁺; C₂₆H₂₄F₃N₅ requir. 463.5 (free base).




2-48 2-((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and (S)-2-benzylpiperazine were reacted according to the General Procedure, Step C (70°C for 30 min) to give the title compound. MS (m/z): 475.5 (M+H)⁺; C₂₇H₂₄F₃N₅ requir. 476.1 (free base).



10 2-49 4-(4-Pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethyl)amino)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: 2-Chloro-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine and (S)-tetrahydroisoquinol-3-ylmethylamine were reacted according to the General Procedure, Step C (50°C for 1.5 h) to give the title compound. MS (m/z): 462.4 (M+H)⁺; C₂₆H₂₂F₃N₅ requir. 461.5 (free base).




20 2-50 5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethyl)amino)-pyrimidine hydrochloride: 2-Chloro-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine and (S)-tetrahydroisoquinol-3-ylmethylamine were reacted according to the General Procedure, Step C (100°C for 45 min) to give the title compound. MS (m/z): 408.2 (M+H)⁺; C₂₆H₂₅N₅ requir. 407.5 (free base).



Example 3

General procedure for the preparation of
2-acylamino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidines



The chlorocarbonyl $R-C(O)Cl$ (0.57 mmol) was added dropwise to a solution of 2-amino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine (0.38 mmol) in pyridine (3 ml) at ice-bath temperature. It was stirred for 3 h at room temperature, monitored by thin layer chromatography, poured into ice-water, extracted with dichloromethane, dried and evaporated. The crude product can be purified by silica gel column chromatography (hexane-acetone) and recrystallized from a suitable solvent such as ethyl acetate.

The following compounds were prepared using the appropriate acid chloride according to this procedure:

3-1 2-Acetamido-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 309.0 (M+H)⁺; $C_{17}H_{13}FN_4O$ requir.
308.3. ¹H-NMR (CDCl₃): δ 8.63 (s, 1H, H-6, Pyrim.), 8.60, 7.29 (2m, each 2H, Pyrid.), 8.26 (bs, 1H, NH), 7.14, 7.08 (2m, each 2H, PhF), 2.58 (s, 3H, CH₃CO).
 $R = CH_3-$

3-2 2-Butyramido-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 337.2 (M+H)⁺; $C_{19}H_{17}FN_4O$ requir.
336.4. ¹H-NMR (CDCl₃): δ 8.64, (s, 1H, H-6, Pyrim.), 8.60, 7.31 (2m, each 2H, Pyrid.), 8.17 (bs, 1H, NH), 7.14, 7.08 (2m, each 2H, PhF), 2.80 (t, 2H, CH₂CO), 1.82 (m, 2H, CH₂), 1.06 (t, 3H, CH₃).

R = $\text{CH}_2\text{CH}_2\text{CH}_2-$


3-3 5-(4-Fluorophenyl)-2-pivalamido-4-(4-pyridyl)-pyrimidine: MS (m/z): 351.0 (M+H)⁺; $\text{C}_{20}\text{H}_{19}\text{FN}_4\text{O}$ requir.

350.4. ¹H-NMR (CDCl_3): δ 8.69 (s, 1H, H-6, Pyrim.),
 5 8.60, 7.35 (2m, each 2H, Pyrid.), 8.25 (bs, 1H, NH),
 7.15, 7.08 (2m, each 2H, PhF), 1.4 (s, 9H, 3CH₃).

R = $(\text{CH}_2)_3\text{C}-$


3-4 2-Benzamido-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine: MS (m/z): 371.0 (M+H)⁺; $\text{C}_{22}\text{H}_{15}\text{FN}_4\text{O}$ requir.

10 370.4. ¹H-NMR (CDCl_3): δ 8.75 (s, 2H, NH, H-6, Pyrim.),
 8.61, 7.36 (2m, each 2H, Pyrid.), 8.00, 7.63, 7.55 (d,
 t, t, 2H, 1H, 2H, Ph), 7.18, 7.10 (2m, each 2H, PhF).



3-5 5-(4-Fluorophenyl)-2-phenylacetamido-4-(4-pyridyl)-pyrimidine: MS (m/z): 385.0 (M+H)⁺; $\text{C}_{23}\text{H}_{17}\text{FN}_4\text{O}$ requir.


15 384.4. ¹H-NMR (CDCl_3): δ 8.66 (s, 1H, H-6, Pyrim.),
 8.59, 7.28 (2m, each 2H, Pyrid.), 8.21 (bs, 1H, NH),
 7.43-7.30 (m, 5H, Ph), 7.14, 7.08 (2m, each 2H, PhF),
 4.13 (s, 2H, CH₂).



20


3-6 5-(4-Fluorophenyl)-2-hydrocinnamamido-4-(4-pyridyl)-pyrimidine: MS (m/z): 399.2 (M+H)⁺; $\text{C}_{24}\text{H}_{19}\text{FN}_4\text{O}$ requir.

398.4. ¹H-NMR (CDCl_3): δ 8.60 (s, 1H, H-6, Pyrim.),
 8.54 (m, 2H, Pyrid.), 8.20 (bs, 1H, NH), 7.31-
 25 7.16 (m, 7H, Ph, Pyrid.), 7.11, 7.05 (2m, each 2H, PhF),
 3.20, 3.09 (2t, each 2H, 2CH₂).



Example 4

General procedure for the preparation of 2-substituted
5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidones



- 5 a. 2-(4-Fluorophenyl)-3-(4-pyridyl)-acrylic acid: A mixture of 4-fluorophenylacetic acid (9 g, 58.4 mmol), 4-pyridinecarboxaldehyde (5.6 ml, 58.6 mmol), pyridine (6 ml) and acetic anhydride (6 ml) was heated at 150°C for 1 h followed by evaporation and co-distillation with
- 10 water. The resulting material crystallized on addition of ethanol. The solids were filtered and washed with ethanol and ethyl acetate to provide the title compound. MS (m/z): 244.0 (M+H)⁺; C₁₄H₁₀FNO₂, requir. 243.2 ¹H-NMR (DMSO-d₆): δ 8.43, 6.98 (2d, each 2H, Pyrid.), 7.73 (s, 1H, CH=), 7.21 (d, 4H, PhF).

- b. Ethyl 2-(4-fluorophenyl)-3-(4-pyridyl)-acrylate: Conc. sulfuric acid (2.2 ml) was added carefully to a suspension of 2-(4-fluorophenyl)-3-(4-pyridyl)-acrylic acid (6.7 g, 27.5 mmol) in ethanol (120 ml) and the
- 20 mixture was heated at reflux for 24 h. The solvent was evaporated, the remainder was taken up in dichloromethane and the organic solution was washed with aqueous sodium hydrogencarbonate and water, followed by drying and evaporation. Flash column chromatography on

130

silica gel (hexane-acetone = 2:1) provided the pure title compound. MS (m/z): 271.8 (M+H)⁺; C₁₆H₁₄FN₂O₂ requir. 271.3 ¹H-NMR (CDCl₃): 8.44, 6.88 (2m, each 2H, Pyrid.), 7.72 (s, 1H, CH=), 7.16, 7.06 (2m, each 2H, PhF), 4.28 (q, 2H, CH₂), 1.28 (t, 3H, CH₃).

c. General procedure: A stirred mixture of ethyl 2-(4-fluorophenyl)-3-(4-pyridyl)-acrylate (357 mg, 1.38 mmol), the amidine hydrochloride (2.61 mmol) and sodium methoxide (250 mg, 4.62 mmol) in ethanol (5 ml) was heated in a sealed tube at 120°C for 3 h. It was neutralized with 2N hydrochloric acid prior to evaporation. The residue was taken up in acetic acid (25 ml) and treated with sodium nitrite (670 mg, 9.71 mmol) at 44°C for 20 min. After evaporation, the resultant product was taken up in dichloromethane and the solution was washed with aqueous sodium hydrogencarbonate and water before drying and evaporation. The product was purified by recrystallization from methanol. If the crude product of nitrite oxidation was water soluble, as was found for 5-(4-fluorophenyl)-2-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone, then no aqueous work up was done, but the material obtained on evaporation was applied to a column of silica gel (5% methanol/dichloromethane) prior to recrystallization.

The following compounds were prepared accordingly using the appropriate amidine hydrochloride:

4-1 5-(4-Fluorophenyl)-2-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 282.2 (M+H)⁺; C₁₆H₁₂FN₂O requir. 281.3 ¹H-NMR (DMSO-d₆): d 8.46 (m 2H, Pyrid.), 7.2-7.03 (m, 6H, PhF, Pyrid.). 2.38 (s, 3H, CH₃).

R1 = CH₃-


4-2 5-(4-Fluorophenyl)-2-isopropyl-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 310.0 (M+H)⁺; C₁₈H₁₆FN₂O requir. 309.4 ¹H-NMR (DMSO-d₆): 8.45 (m, 2H, Pyrid.), 7.21-7.03

131


(m, 6H, PhF, Pyrid.), 2.90 (m, 1H, CH(CH₃)₂), 1.26, 1.24 (2s, each 3H, 2CH₃).

R1 = (CH₃)₂CH-

- 4-3 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 426.0 (M)⁺; C₂₂H₁₄Cl₂FN₃O requir. 426.3 ¹H-NMR (DMSO-d₆): δ 8.37 (m, 2H, Pyrid.), 7.50 (d, 2H, PhCl₂), 7.35 (t, 1H, PhCl₂), 7.18-7.08 (m, 4H, PhF), 6.96 (m, 2H, Pyrid.), 4.36 (s, 2H, CH₂).



- 4-4 5-(4-Fluorophenyl)-2-phenyl-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 344.2 (M+H)⁺; C₂₁H₁₄FN₃O requir. 343.4 ¹H-NMR (DMSO-d₆): δ 8.49 (d, 2H, Pyrid.), 8.20 (d, 2H, Ph), 7.66-7.50 (m, 3H, Pyrid., Ph), 7.32-7.11 (m, 6H, PhF, Ph).




- 4-5 5-(4-Fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (293 mg, 1.02 mmol), 4-phenylbutanecarboxamide (315 mg, 1.79 mmol) and pyridinium p-toluenesulfonate (10 mg) were suspended in p-xylene (10 ml). With efficient stirring, the mixture was heated to reflux using a Dean-Stark apparatus with continuous removal of water. After 16 h, the solvent was evaporated and the product purified by column chromatography on silica gel (3% methanol/dichloromethane) followed by recrystallization from acetone. MS (m/z): 400.3 (M+H)⁺; C₂₅H₂₂FN₃O requir. 399.5
- R1 = Ph(CH₂)₄-

30

Example 5

General procedure for the preparation of
5-(4-fluorophenyl)-6-(4-pyridyl)-2-thioalkyl-4(3H)-
pyrimidinones


5 Step A. Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-
propionate:



(According to: Legrand and Lozac'h, Bull. Soc. Chim.
Fr., 79-81 (1955)).

- 10 A mixture of ethyl 4-fluorophenylacetate (13 g,
71.35 mmol), ethyl isonicotinate (10.7 ml, 71.4 mmol)
and sodium spheres (1.64 g, 71.34 mmol) was heated at
90-95_ C under argon. The mixture started to reflux and
gradually turned into a solid. After 2.5 h, the mixture
15 was neutralized with dil. acetic acid with cooling
followed by extraction with dichloromethane. The
organic solution was washed with water, dried and
evaporated. Flash chromatography on a column of silica
gel (hexane-acetone = 4:1, 3:1, 2:1) provided the title
20 compound as an oil. MS (m/z): 287.8 (M+H)⁺; C₁₆H₁₄FNO₃,
requir. 287.3 ¹H-NMR (CDCl₃), (ketone : enole = 1 :
0.33): δ 13.50 (s, 0.3H, OH-E), 8.81 (m, 2H, Pyrid.-K),
8.48 (m, 0.66 H, Pyrid.-E), 7.72 (m, 2H, Pyrid.-K), 7.38
(m, 2H, PhF-K), 7.14-7.04 (m, 2H, PhF-K; ~0.65H, Pyrid.-
25 E; ~0.65H, PhF-E), 6.96 (t, 0.64H, PhF-E), 5.51 (s, 1H,
CH-K), 4.23-4.2- (m, CH₂-K,E), 1.26 (t, CH₃-K,E).

Step B. 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil:



133

A stirred mixture of ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (22.3 g, 77.6 mmol) and thiourea (5.9 g, 77.6 mmol) was reacted at 190_ C under argon for 40 min. The reaction mixture was allowed to reach room temperature, taken up in acetone and the precipitate was filtered to provide the title compound. MS (m/z): 300.2 (M+H)⁺; C₁₅H₁₀FN₂OS requir. 299.3 ¹H-NMR (DMSO-d₆): δ 12.74, 12.65 (2s, 2H), 8.51 (m, 2H, Pyrid.), 7.26 (m, 2H, Pyrid.), 7.09 and 7.03 (2m, each 2H, PhF).


Alternatively, ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (2.87 g, 10 mmol) and thiourea (2.28 g, 30 mmol) were suspended in anhydrous p-xylene (50 ml) with very efficient stirring. To the mixture pyridinium p-toluenesulfonate (100 mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.2 ml). Reaction mixture was cooled and a dark brown solid was filtered using a Buchner funnel. The collected solid was suspended in acetone (25 ml) and filtered. The acetone washed product contained a trace of thiourea, which was removed by trituration with hot water (20-30 ml). The product was filtered and airdried.

Step C. General procedure:


The arylalkyl bromide (0.36 mmol) was added dropwise to a stirring mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (100 mg, 0.33 mmol) and potassium carbonate (46 mg, 0.33 mmol) in *N,N*-dimethylformamide (4.6 ml). Stirring was continued for 3h followed by evaporation. Flash chromatography on a column of silica gel (hexane-acetone = 3:1, 2:1, 1:1) and recrystallization from hot methanol provided the target compound.

The following compounds were obtained using the appropriate arylalkyl bromide according to the above procedure:


- 5-1 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 404.2 ($M+H$)⁺; $C_{23}H_{18}FN_3OS$ requir. 403.4. ¹H-NMR (DMSO- d_6): δ 13.08 (bs, 0.7H), 8.49 (m, 2H, Pyrid.), 7.30-7.06 (m, 11H, Pyrid., Ph, PhF), 3.41 (dd, 2H, CH_2S), 3.00 (t, 2H, CH_2).



- 5-2 5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 418.0 ($M+H$)⁺; $C_{24}H_{20}FN_3OS$ requir. 417.5. ¹H-NMR (DMSO- d_6): δ 13.10 (bs, 0.7H), 8.47 (m, 2H, Pyrid.), 7.29-7.06 (m, 11H, Pyrid., Ph, PhF), 3.18 (t, 2H, CH_2S), 2.71 (t, 2H, CH_2Ph), 2.03 (m, 2H, CH_2).




- 5-3 5-(4-Fluorophenyl)-2-(2-phenoxyethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 420.0 ($M+H$)⁺; $C_{23}H_{18}FN_3O_2S$ requir. 419.5. ¹H-NMR (DMSO- d_6): δ 13.20 (bs, 0.7H), 8.46 (m, 2H, Pyrid.), 7.24-7.07 (m, 8H, Pyrid., PhF, Ph), 6.95 (d, 2H, Ph), 6.92 (t, overlapped, 1H, Ph), 4.30 (t, 2H, CH_2O), 3.58 (t, 2H, CH_2S).



20


- 5-4 5-(4-Fluorophenyl)-2-(2-phenylaminoethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 419.0 ($M+H$)⁺; $C_{23}H_{19}FN_4OS$ requir. 418.5. ¹H-NMR (DMSO- d_6): δ 13.20 (bs, 0.8H), 8.48, 7.22 (2m, each 2H, Pyrid.), 7.16, 7.10 (2m, each 2H, PhF), 6.89 (t, 2H, Ph), 6.54 (d, 2H, Ph), 6.48 (t, 1H, Ph), 5.90 (bs, 0.6H, NH), 3.43-3.25 (m, 2 CH_2).



Example 6


General procedure for the preparation of 2-N substituted
2-amino-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-
pyrimidinones:

5 Step A. 5-(4-Fluorophenyl)-2-methylthio-6-(4-pyridyl)-
4(3H)-pyrimidinone:



Methyl iodide (90 ml, 1.44 mmol) was added dropwise
to a stirred mixture of 5-(4-fluorophenyl)-6-(4-
10 pyridyl)-2-thiouracil (430 mg, 1.44 mmol) and potassium
carbonate (198 mg, 1.43 mmol) in *N,N*-dimethylformamide
(13 ml) at ice-bath temperature. After 40 min, it was
evaporated and the crude product purified by flash
chromatography on a column of silica gel (hexane-acetone
15 = 2:1, 1:1, 1:2) to provide the title compound as a
solid. MS (*m/z*): 314.2 (*M*+*H*)⁺; C₁₆H₁₂FN₃OS requir. 313.3.
¹H-NMR (DMSO-*d*₆): δ 13.10 (bs), 8.47, 7.22 (2m, each 2H,
Pyrid.), 7.16, 7.10 (2m, each 2H, PhF), 2.56 (s, 3H,
CH₃).

20 Step B. General procedure:




A mixture of 5-(4-fluorophenyl)-2-methylthio-6-(4-
pyridyl)-4(3H)-pyrimidinone (100 mg, 0.32 mmol) and an
amine HNR⁵R²¹ (1 mmol) was heated at 180°C for 2 h. The
25 resulting product was purified by flash chromatography
on a column of silica gel (hexane-acetone or methanol-


dichloromethane or dichloromethane-methanol-conc. ammonium hydroxide) to provide the target compound.

The following compounds were prepared using the general procedure outlined above and an appropriate amine:

- 5 6-1 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 421.2 (M+H)⁺; C₂₃H₁₈ClFN₄O requir. 420.9. ¹H-NMR (DMSO-d₆): δ 11.24 (bs), 8.44, 7.16 (2m, each 2H, Pyrid.), 7.43, 7.38 (2dd, each 1H, PhCl), 7.30, 7.26 (2dt, each 1H, PhCl), 7.10-7.00 (m, 2H, PhF), 6.74 (bs, 1H, NH), 3.60 (q, 2H, CH₂N), 3.03 (t, 2H, CH₂).




- 15 6-2 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 401.2 (M+H)⁺; C₂₄H₂₁FN₄O requir. 400.5. ¹H-NMR (DMSO-d₆): δ 11.16 (bs), 8.44, 7.14 (2m, each 2H, Pyrid.), 7.32-7.01 (m, 9H, Ph, PhF), 6.78 (bs, NH), 3.36 (q, 2H, CH₂N), 2.67 (t, 2H, CH₂Ph), 1.89 (m, 2H, CH₂).




20

- 6-3 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: A reaction time of 15 h at 180°C was required. MS (m/z): 415.0 (M+H)⁺; C₂₅H₂₃FN₄O requir. 414.5. ¹H-NMR (CDCl₃): δ 8.48 (m, 2H, Pyrid.), 7.28-7.08 (m, 9H, Pyrid., Ph, PhF), 6.94 (m, 2H, PhF), 5.67 (bs, 1H, NH), 4.08 (m, 1H, CHCH₃), 2.61 (t, 2H, CH₂Ph), 1.67 (m, 2H, CH₂), 1.08 (d, 3H, CH₃).


25



- 5 6-4 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 391.0 ($M+H$)⁺; $C_{21}H_{19}FN_5O$ requir. 390.4. ¹H-NMR (DMSO- d_6): δ 11.24 (bs), 8.42, 7.12 (2m, each 2H, Pyrid.), 7.62, 7.18 (2s, each 1H, Imid.), 7.08-6.99 (m, 4H, PhF), 6.88 (s, 1H, Imid.), 4.02 (t, 2H, CH_2N), 3.28 (overlapped by water signal, CH_2NH), 2.00 (m, 2H, CH_2).



- 10 6-5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: The reaction was done at 170°C for 7 h. MS (m/z): 416.1 ($M+H$)⁺; $C_{26}H_{22}FN_5O$ requir. 415.5.



15

Example 7


5-(4-Fluorophenyl)-2-hydrazino-6-(4-pyridyl)-4(3H)-pyrimidinone

- A mixture of 5-(4-fluorophenyl)-6-(4-pyridyl)-2-thiouracil (500 mg, 1.66 mmol) and hydrazine hydrate (800 ml, ~14 mmol) was heated at 120°C for 60 min. It was evaporated and the reaction product was recrystallized from hot methanol to provide the title compound. MS (m/z): 298.0 ($M+H$)⁺; $C_{15}H_{12}FN_5O$ requir. 297.3. ¹H-NMR (DMSO- d_6): δ 8.41, 7.12 (2m, each 2H, Pyrid.), 7.05, 7.00 (2m, each 2H, PhF).
- 25 $R^1 = NH-NH_2$


Example 8

General procedure for the preparation of 5-aryl-2,6-dipyridyl-(3H)-pyrimidinones


8-1




8-2



8-3



8-4



These compounds were prepared according to the literature (Kabbe, *supra*; German Patent 1271116 (1968)) as follows:

A stirred mixture of the ethyl phenylacetate (3.13 mmol), cyanopyridine (6.24 mmol) and sodium methoxide (3.5 mmol) in n-butanol (1.2 ml) was heated at 110°C for 2h. The reaction mixture was concentrated and dissolved in water (4 ml), followed by the addition of aqueous sat. ammonium chloride (2 ml). The precipitate was filtered and recrystallized from hot methanol.

The following compounds were prepared according to this procedure using the appropriate starting materials:

8-1 5-Phenyl-2,6-bis-(4-pyridyl)-4-(3H)pyrimidinone: MS (m/z): 327.2 ($M+H$)⁺; $C_{20}H_{13}N_3O$ requir. 326.4. ¹H-NMR (DMSO- d_6): δ 8.78, 8.47, 8.13 (3m, each 2H, Pyrid.), 7.40-7.14 (m, 7H, Ph, Pyrid.).


8-2 5-(4-Fluorophenyl)-2,6-bis-(4-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 345.2 ($M+H$)⁺; $C_{20}H_{11}FN_3O$ requir. 344.4 ¹H-NMR (DMSO- d_6): δ 8.80, 8.49, 8.13 (3m, each 2H, Pyrid.), 7.40-7.08 (m, 6H, PhF, Pyrid.).

8-3 2,5,6-Tris-(4-pyridyl)-4(3H)-pyrimidinone was prepared according to the general procedure by reacting ethyl 4-pyridylacetate and 4-cyanopyridine in the presence of sodium methoxide. MS (m/z): 328.2 ($M+H$)⁺; $C_{19}H_{11}N_5O$ requir. 327.4 ¹H-NMR (DMSO- d_6): 8.65, 8.45, 8.35, 8.18, 7.25, 7.13 (6m, each 2H, Pyrid.).

8-4 5-(4-Fluorophenyl)-2,6-bis-(3-pyridyl)-4(3H)-pyrimidinone: MS (m/z): 345.2 ($M+H$)⁺; $C_{20}H_{11}FN_3O$ requir. 344.4 ¹H-NMR (DMSO- d_6): δ 9.34, 8.77, 8.54, 8.48, 7.78, 7.60, 7.34 (7m, 3x1H, 2H, 3x1H, Pyrid.), 7.26, 7.15 (2m, each 2H, PhF).

Example 9

4-Amino-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-pyrimidine



25

4-Amino-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-pyrimidine was prepared according to the literature (Kabbe, *supra*):


Sodium methoxide (180 mg, 3.33 mmol) was added to a stirred solution of 4-cyanopyridine (650 mg, 6.24 mmol)

30

140

and 4-fluorophenylacetonitrile (375 mmol, 3.12 mmol) in n-butanol (1.5 ml). The mixture was stirred for 20 min at room temperature before heating it at 110°C for 1.5 h. It was allowed to reach room temperature and ethanol (2.5 ml) was added. The precipitate was filtered and recrystallized from acetic acid/water (3.5/10 ml) to provide the title compound. MS (m/z): 344.2 (M+H)⁺; C₂₀H₁₄FN₅ requir. 343.4 ¹H-NMR (DMSO-d₆): 8.76, 8.47, 8.22 (3m, each 2H, Pyrid.), 7.4-7.16 (m, 6H, PhF, Pyrid.).

10


Example 10**4-Methoxy-5-phenyl-2,6-bis-(4-pyridyl)-pyrimidine**

A mixture of 5-phenyl-2,6-bis-(4-pyridyl)-4(3H)-pyrimidinone (360 mg, 1.10 mmol) and phosphorus oxychloride (2 ml) was heated at reflux for 1.5 h. Work-up was done as described for the preparation of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine. To a solution of the crude 4-chloro-5-phenyl-2,6-bis-(4-pyridyl)-pyrimidine (250 mg, 0.73 mmol) in methanol (5 ml) was added methanolic 0.5 N sodium methoxide (1.45 ml, 0.73 mmol) and it was heated at reflux for 1 h. After evaporation, the resultant material was partitioned between ethyl acetate and water. The organic solution was washed with water, dried and evaporated. Chromatography of the crude product on a column of silica gel (ethyl acetate) provided the title compound. MS (m/z): 341.2 (M+H)⁺; C₂₁H₁₆N₄O requir. 340.4 ¹H-NMR (CDCl₃): 8.82, 8.54, 8.40 (3m, each 2H, Pyrid.), 7.40-7.18 (m, 7H, Ph, Pyrid.), 4.15 (s, 3H, CH₃O).

Example 11


Procedure for the preparation of 5-(4-Fluorophenyl)-2,4-bis-(4-pyridyl)-pyrimidine

Step A. 4-Chloro-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-pyrimidine:



A mixture of 5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-4(3H)-pyrimidinone (760 mg, 2.21 mmol) in phosphorus oxychloride (3 ml) was heated at reflux for 1 h. Work-up was done as described for the preparation of 2-chloro-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine. A portion (290 mg) of the resulting product (495 mg) was purified by flash chromatography (ethyl acetate, trace triethylamine) on silica gel. MS (m/z): 363.2 ($M+H$)⁺; C₂₀H₁₂ClFN₄ requir. 362.8 ¹H-NMR (CDCl₃): d 8.84, 8.60, 8.38, 7.30 (4m, each 2H, Pyrid.), 7.22, 7.13 (2m, each 2H, PhF).

Step B. 5-(4-Fluorophenyl)-2,4-bis-(4-pyridyl)-pyrimidine:



20

A stirred mixture of 4-chloro-5-(4-fluorophenyl)-2,6-bis-(4-pyridyl)-pyrimidine (99 mg, 0.27 mmol) and 10% palladium-on-carbon (70 mg) in ethanol (10 ml) was hydrogenated under an atmosphere of hydrogen for 28 h. Filtration and evaporation of the solvent was followed by flash chromatography (ethyl acetate) on a column of

25


142

silica gel to provide the title compound. MS (m/z): 329.2 ($M+H$)⁺; $C_{20}H_{15}FN_4$ requir. 328.4. ¹H-NMR ($CDCl_3$): δ 8.91 (s, 1H, H-6, Pyrim.), 8.83, 8.65, 8.40, 7.45 (4m, each 2H, Pyrid.), 7.30-7.06 (m, 4H, PhF).

5

Example 12

Procedure for the preparation of 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride



- 10 12-1 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-
(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
hydrochloride: Ethyl chloroformate (86 μ l, 0.901 mmol)
 was added at ice-bath temperature to a stirring mixture
 of N-(tert.-butoxycarbonyl)glycine (160 mg, 0.911 mmol)
 15 and 4-methylmorpholine (110 μ l, 1.00 mmol) in
 tetrahydrofuran (10 ml). After 40 min, a solution 2-
 (((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-
 trifluoromethylphenyl)-pyrimidine (409 mg, 0.911 mmol)
 in tetrahydrofuran (15 ml) was added at ice-bath
 20 temperature. Within 1 h, the mixture was allowed to
 reach room temperature. It was diluted with dichloro-
 methane, washed with aqueous sodium hydrogencarbonate,
 followed by drying of the organic solution and
 evaporation. The resulting material was purified on a
 25 column of silica gel (5% methanol/dichloromethane), then
 dissolved in methanol (2 ml) and 4N hydrogen
 chloride/dioxane (2 ml) was added. After 1 h at room
 temperature, it was evaporated and the remainder taken
 up in dichloromethane followed by washing with aqueous
 30 sodium hydrogencarbonate, drying of the organic solution
 and evaporation. Column chromatography on silica gel
 (dichloromethane - methanol - conc. ammonium hydroxide =

143


95 : 5 : 0; 90 : 10 : 0.6) provided the title compound as the free base which was converted into the hydrochloride by the addition of 4N hydrogen chloride/dioxane (85 μ l) to its methanolic solution (3 ml) followed by evaporation. MS (m/z): 507.4 (M+H)⁺; C₂₇H₂₅F₃N₆O requir. 506.5 (free base).

The following compound was prepared using the above procedure and the appropriate starting materials:

10 12-2 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride:
MS (m/z): 453.2 (M+H)⁺; C₂₇H₂₈N₆O requir. 452.6 (free base).

Example 13

15 *Procedure for the preparation of (S)-1,2-Benzylethyldiamine*




(S)-1,2-Benzylethyldiamine: The diamine was prepared according to the literature (H. Brunner, P. Hankofer, U. Holzinger, B. Treittinger and H. Schoenenberger, Eur. J. Med. Chem. **25**, 35-44, (1990)) by reduction of L-phenylalanine amide with lithium aluminium hydride. The (R)-enantiomer was prepared in the same manner from D-phenylalanine amide.

25

Example 14

Procedure for the preparation of 2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone

144




2-(((S)-2-Acetamido-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone:

A solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone (25 mg, 0.058 mmol) and acetic anhydride (200 ml) in methanol (2 ml) was kept at room temperature for 1 h. Evaporation followed by chromatography of the resultant product on a column of silica gel (10% methanol/dichloromethane) provided the title compound.

MS (m/z): 472.3 (M+H)⁺; C₂₇H₂₆FN₅O₂ requir. 471.5.

Example 15

Procedure for the preparation of 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride




2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: Sodium triacetoxyborohydride (184 mg, 0.868 mmol) was added to a stirring mixture of 2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine (300 mg, 0.668 mmol) and acetone (50 μ l, 0.675 mmol) in 1,2-dichloroethane (4 ml). After 16 h, the reaction was quenched by the addition of sat. aq. sodium hydrogencarbonate, followed by extraction with dichloromethane, drying of the organic solution and evaporation. Chromatography on a


column of silica gel (5% methanol/chloroform) provided the title compound as a free base which was converted into the monohydrochloride by the addition of 6N hydrochloric acid (73 μ l) to its methanolic solution (3 ml) and subsequent evaporation. MS (m/z): 491.7 (M)⁺; $C_{28}H_{28}F_3N_5$ requir. 491.6 (free base).

The following compounds were prepared using the above procedure and the appropriate starting materials:


- 10 15-2 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine hydrochloride: MS (m/z): 532.0 ($M+H$)⁺; $C_{31}H_{22}F_3N_5$ requir. 531.6 (free base).



- 15 15-3 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 439.1 ($M+H$)⁺; $C_{28}H_{31}N_5$ requir. 437.6 (free base).




- 20 15-4 2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 452.1 ($M+H$)⁺; $C_{29}H_{33}N_5$ requir. 451.6 (free base).



- 25 15-5 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 478.3 ($M+H$)⁺; $C_{31}H_{33}N_5$ requir. 477.7 (free base).


146



15-6 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine

hydrochloride: MS (m/z): 442.1 (M+H)⁺; C₂₇H₂₈FN₅ requir.


5 441.6 (free base).



15-7 5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine


hydrochloride: MS (m/z): 442.2 (M+H)⁺; C₂₇H₂₈FN₅ requir.

10 441.6 (free base).



Example 16

Procedure for the preparation of 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride



5

- Step A: 4-(4-Pyridyl)-2(1H)-pyrimidinone:** A mixture of 4-acetylpyridine (25 ml, 226.0 mmol) and bis(dimethylamino)methoxymethane (44 ml, 293.8 mmol) was heated at 85°C for 30 min followed by evaporation to dryness to recover a solid of 3-(dimethylamino)-1-(4-pyridyl)-3-propen-1-one. Its ethanolic solution (200 ml) was transferred into ethanolic 1.13 N sodium ethoxide (200 ml) containing urea (16.3 g, 271 mmol). The mixture was heated to reflux overnight, then cooled down to ice-bath temperature. The precipitate was filtered, dissolved in a minimal amount of water and the aqueous solution was washed with dichloromethane. The title compound was precipitated from the aqueous solution by neutralization with 6N hydrochloric acid and filtered. More material was obtained from the original reaction filtrate which was concentrated, diluted with a minimal amount of water and washed with dichloromethane. The aqueous solution was neutralized with 6N hydrochloric acid and the precipitate filtered. MS (m/z): 174.1 (M+H)⁺; C₁₄H₁₃N₃O requir. 173.2.
- 10
- 15
- 20
- 25

- Step B: 2-Chloro-4-(4-pyridyl)-pyrimidine: With ice-bath cooling under argon, 4-(4-pyridyl)-2(1H)-pyrimidinone (13.45 g, 77.7 mmol) and thionyl chloride (92 ml) were combined. *N,N*-Dimethylformamide (13.2 ml, 170.5 mmol) was added slowly and the mixture was heated to reflux for 1 h. It was evaporated and co-distilled with toluene. At 0°C, water was added to the remainder, then 10% ammonium hydroxide until neutral followed by extraction with dichloromethane. Drying of the organic solution was followed by evaporation and the resultant solid was recrystallized from acetone. MS (*m/z*): 192.1, 194.0 (*M*+*H*)⁺; C₈H₆ClN₂, requir. 191.6.
- Step C: 2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine: A mixture of 2-chloro-4-(4-pyridyl)-pyrimidine (4.5 g, 23.7 mmol) and (S)-1,2-benzylethylenediamine (8.0 g, 53.3 mmol) was heated at 100°C for 25 min. Column chromatography on silica gel (dichloromethane - methanol - conc. ammonium hydroxide = 95 : 5 : 0.4) provided the title compound. MS (*m/z*): 306.5 (*M*+*H*)⁺; C₁₈H₁₉N₃, requir. 305.4.
- Step D: 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-bromo-4-(4-pyridyl)-pyrimidine: Bromine (787 µl, 15.28 mmol) was added to a stirring solution of 2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine (2.33 g, 7.64 mmol) in chloroform (25 ml). Stirring was continued for 2 d. The mixture was partitioned between dichloromethane and aqueous sodium hydrogencarbonate. The organic solution was washed with brine, dried and evaporated. The resultant product was purified on a column of silica gel (dichloromethane - methanol - conc. ammonium hydroxide = 92 : 8 : 0.6). MS (*m/z*): 384.0, 386.0 (*M*+*H*)⁺; C₁₈H₁₈BrN₃, requir. 384.3.
- Step E: 2-(((S)-2-Amino-3-phenylpropyl)amino)-5-(3-chloro-4-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: A mixture of 2-((2(S)-amino-3-phenylpropyl)amino)-5-bromo-4-(4-pyridyl)-pyrimidine (204 mg,

0.53 mmol), aqueous 2M sodium carbonate (1.66 ml, 3.32 mmol) and 3-chloro-4-fluorobenzene boronic acid (103 mg, 0.637 mmol) in toluene (5 ml) was stirred for 10 min under argon. The mixture was thoroughly degassed (10
5 times), before the addition of tetrakis (triphenylphosphine) palladium(0) (18 mg, 0.016 mmol). After heating at reflux for 16 h, the reaction mixture was diluted with toluene and washed with brine. The organic solution was dried and evaporated. Subsequent
10 column chromatography on silica gel (dichloromethane - méthanol - conc. ammonium hydroxide = 95 : 5 : 04) provided the title compound which was converted into the hydrochloride by the addition of 6N hydrochloric acid (64 µl) to its methanolic solution (2 ml) followed by
15 evaporation. MS (m/z): 434.1 (M)⁺; C₂₄H₂₂ClFN₃, requir. 433.9 (free base).

The following compounds were prepared according to Step E of this procedure by using the appropriate boronic acid and 5-bromopyrimidine:

20 16-2 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-fluorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 400.1 (M+H)⁺; C₂₄H₂₂FN₃, requir. 399.5 (free base).

25 16-3 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-isopropylphenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 424.2 (M+H)⁺; C₂₇H₂₉N₃, requir. 423.6 (free base).

30 16-4 5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 439.1 (M+H)⁺; C₂₆H₂₄N₄O requir. 438.5 (free base).

35 16-5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-chlorophenyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 416.3 (M+H)⁺; C₂₄H₂₂ClN₃, requir. 415.9 (free base).

16-6 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-4-(4-pyridyl)-pyrimidine hydrochloride:


MS (m/z): 438.3 ($M+H$)⁺; C₂₆H₂₃N₅S requir. 437.6 (free base).

16-7 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-(4-pyridyl)-pyrimidine hydrochloride: MS (m/z): 432.5 ($M+H$)⁺; C₂₈H₂₃N₅ requir. 431.5 (free base).

10

Example 17

Procedure for the preparation of (S)-2-Benzylpiperazine




(S)-2-Benzylpiperazine: At ice-bath temperature, lithium aluminium hydride (1.6 g, 42.16 mmol) was added in portions to a stirring mixture of (S)-2-benzyl piperazine-3,6-dione (3.0 g, 14.70 mmol) and tetrahydrofuran (80 ml). After 30 min at ice-bath temperature, the mixture was refluxed for 4 h with stirring. The reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. It was filtered and the solids were washed several times with dichloromethane. The combined filtrates were evaporated to leave a white solid. MS (m/z): 177.1 ($M+H$)⁺; C₁₁H₁₆N₂ requir. 176.3.

25

Example 18

Procedure for the preparation of (S)-2-N,N-Dimethylamino-3-phenylpropylamine



(S)-2-N,N-Dimethylamino-3-phenylpropylamine: Sodium triacetoxyhydride (13.0 g, 61.3 mmol) was added to a


30

151

stirring mixture of phenylalanine amide (3.6 g, 21.9 mmol) and 37% formaldehyde solution (4.4 ml, 58.7 mmol) in 1,2-dichloroethane (77 ml). After stirring for 2 h, the reaction was quenched by the addition of sat. aqu. sodium hydrogencarbonate. Then potassium hydroxide pellets were added followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting (S)-2-N,N-dimethylamino-3-phenylpropylamide was reduced with lithium aluminium hydride according to the literature (H. Brunner, P. H  nkofer, U. Holzinger, B. Treitinger and H. Schoenenberger, Eur. J. Med. Chem. 25, 35-44, (1990)) to provide the title compound.

Example 19

15 Procedure for the preparation of 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride



20 Step A. 5-(4-Fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone: A mixture of 5-(4-fluorophenyl)-3-methyl-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (400 mg, 1.22 mmol) and Oxone[®] (potassium peroxymonosulfate, 2.3 g, 3.74 mmol) in methanol (100 ml) and water (45 ml) was stirred for 13 h. The solvent was concentrated to about 50 ml, followed by extraction with dichloromethane, drying of the organic solution and evaporation. The resulting white solid was used without purification in the next step.

Step B. 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-
amino)-5-(4-fluorophenyl-3-methyl-6-(4-pyridyl)-4(3H)-
pyrimidinone hydrochloride: A mixture of crude 5-(4-
fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-
4(3H)-pyrimidinone (430 mg, 1.19 mmol) and (S)-2-N,N-
dimethylamino-3-phenylpropylamine (600 mmol, ~3.4 mmol)
was stirred at room temperature for 1h and then briefly
warmed at 50°C. Column chromatography on silica gel (3-
5% methanol/chloroform) provided the title compound as a
free base which was converted into the monohydrochloride
by the addition of 4N hydrochloric acid/dioxane (160
mmol, 0.64 mmol) to its methanolic solution (4 ml) and
subsequent evaporation. MS (m/z): 458.0 (M+H)⁺;
C₂₇H₂₈FN₅O requir. 457.5 (free base).

15

Example 20

5-(4-fluorophenyl)-6-(4-(2-acetamido)-pyridyl)-2-
thioalkyl-4(3H)-pyrimidinones

Step A. Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-
acetamido)-pyridyl))-propionate:
A solution of 2-chloroisonicotinic acid (25.0g, 0.16
mol) in 65 mL of concentrated ammonium hydroxide was
warmed to 205 Celsius in a steel bomb for 72 h. After
cooling to 23 C, the solution was acidified to a pH of 1
using 6N HCl and subsequently filtered to remove
unreacted starting material. The solution was
concentrated to one fourth the original volume (approx
200 mL) in vacuo, and carefully adjusted to a pH of 6
using 1 N NaOH. After storing the cloudy solution at 0
C for 20 h, the desired 2-aminoisonicotinic acid was
filtered off. To a suspension of 2-aminoisonicotinic
acid in ethanol (600 mL) was added 47.1 mL of 4 N
anhydrous HCl in dioxane. After warming to achieve
reflux for 20 h, an additional 47.1 mL of 4 N anhydrous
HCl in dioxane was added and the reaction was warmed to
reflux for an additional 20 h. Concentration with a

stream of nitrogen in the hood was followed by further concentration in vacuo, the remaining solid was diluted with saturated bicarbonate (200 mL), extracted with ethyl acetate (2 x 200mL), dried (Na₂SO₄). After
5. concentration in vacuo, the desired ethyl 2-aminoisonicotinate was obtained. To a solution of ethyl 2-aminoisonicotinic acid in pyridine (45 mL) at 0 C under an argon atmosphere was added acetyl chloride dropwise over 5 min. After 2 h at 0 C, the reaction was
10. poured into over ice 300 g, extracted with ethyl acetate (2' x 300 mL), washed with water (2 x 100 ml) followed by brine (2 x 100 mL), and dried (Na₂SO₄). After concentration in vacuo, the residue was purified by application of flash chromatography (step gradient
15. ethyl acetate: hexane 1:4 then ethyl acetate: hexane 1:1) to afford ethyl 2-acetamidoisonicotinate.

To a solution of diisopropylamine (14.15 mL, 101 mmol) and THF (40 mL) at -78 C was added n-butyl lithium (38.1 mL, 95 mmol) dropwise over 5 min. After
20. 10 min, ethyl 4-fluorophenylacetate (17.3 g, 95 mmol) was added in 40 mL of dry THF. After 10 min, ethyl 2-acetamidoisonicotinate (6.0 g, 29 mmol) was added in 20 ml of dry THF. The reaction was allowed to warm to 23 C overnight, and then acetic acid (95 mmol) was added in
25. one portion. The reaction was concentrated in vacuo, then partitioned repeatedly between saturated bicarbonate (200 ml) and ether (300 mL), the combined bicarbonate layers were neutralized with 10% citric acid, and extracted with ethyl acetate (2 x 300 mL).
30. The organic layers were dried (Na₂SO₄), concentrated in vacuo to afford the Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)-pyridyl)-propionate.

Step B. 5-(4-fluorophenyl)-6-(4-(2-acetamido)pyridyl))-2-thiouracil:
35.


Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-(2-acetamido)pyridyl)-propionate (1.3 g, 3.78 mmol) and

154

thiourea (863 mg, 11.3 mmol) were suspended in anhydrous p-xylene (15 ml) with very efficient stirring. To the mixture pyridinium p-toluenesulfonate (38 mg) was added and refluxed for 12-16 h using a Dean-Stark apparatus with continuous removal of water (0.1 ml). Reaction mixture was cooled and a dark brown solid was filtered using a Buchner funnel. The collected solid was suspended in acetone (25 ml) and filtered. The acetone washed product contained a trace of thiourea, which was removed by trituration with hot water (20-30 ml). The product was filtered and air dried followed by azeotroping with toluene.

Example 21

Procedure for the preparation of (S)-2-N-Ethylamino-3-phenylpropylamine




- 5 (S)-2-N-Ethylamino-3-phenylpropylamine: Acetic anhydride (1.2 ml, 12.7 mmol) was added to a stirring solution of L-phenylalanine amide (1.0 g, 6.10 mmol) in methanol (25 ml). After 1.5 h at room temperature, it was evaporated followed by drying in an oil pump vacuum.
- 10 The resultant L-N-ethylphenylalanine amide (6.1 mmol) was reduced with lithium aluminium hydride (570 mg, 15.0 mmol) in tetrahydrofuran (65 mmol) at 55°C for 4 h. The reaction mixture was poured into sat. aqu. sodium hydrogencarbonate followed by extraction with
- 15 dichloromethane, drying and evaporation. Column chromatography on silica gel (chloroform : methanol : triethylamine = 90:7:3) provided the amine as a yellowish oil. MS (m/z): 179.1 (M+H)⁺; C₁₁H₁₈N₂ requir. 178.3.

20

Example 22

Procedure for the preparation of 2-Amino-2-methyl-3-phenylpropylamine




- 25 2-Amino-2-methyl-3-phenylpropylamine: A solution of commercially available D,L-α-methyl phenylalanine methyl ester (5.0 g, 25.7 mmol) in aqu. 28% ammonium hydroxide (50 ml) was kept at room temperature for 3 d. The resulting white precipitate of D,L-α-methyl

156

phenylalanine amide was filtered and dried (2.5 g). This material (2.0 g, 11.22 mmol) was reduced with lithium aluminium hydride (1.3 g, 34.26 mmol) in boiling tetrahydrofuran for 24 h. The reaction was quenched by the addition of sodium sulfate decahydrate at ice-bath temperature. The salts were filtered off, followed by evaporation to leave the title compound as an oil. MS (m/z): 165.1 ($M+H$)⁺; C₁₀H₁₆N₂ requir. 164.2. An alternative preparation was reported by M. Freiburger and R. B. Hasbrouck, J. Am. Chem. Soc. 82, 696-698 (1960).

Example 23

Procedure for the preparation of 2-Methyl-3-phenylpropylamine




15

2-Methyl-3-phenylpropylamine: A mixture of commercially available 2-methyl-3-phenylpropylamide (4.32 g, 26.5 mmol) and lithium aluminium hydride (1.3 g, 34.3 mmol) in tetrahydrofuran (184 ml) was stirred at room temperature for 5 h. It was poured into aqu. sat. sodium sulfate and extracted with dichloromethane followed by drying of the organic solution and evaporation to provide the amine as an oil. Other syntheses have been reported, e.g. Dornow and Fust, Chem. Ber. 87, 984 (1954).

25

Example 24

Procedure for the preparation of 5-(4-Fluorophenyl)-3-methyl-2-((2-methyl-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride



5-(4-Fluorophenyl)-3-methyl-2-((2-methyl-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride:


A mixture of crude 5-(4-fluorophenyl)-3-methyl-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (520 mg, 1.45 mmol) and 2-methyl-3-phenylpropylamine (1.5 g, 10.1 mmol) was heated at 50°C for 30 min. Column chromatography on silica gel (2-5% methanol/dichloromethane; hexane-acetone= 2 : 1) provided the title compound. MS (*m/z*): 429.4 (*M*+*H*)⁺; C₂₆H₂₅FN₄O requir. 428.5 (free base).

10

15

Example 25

Procedure for the preparation of 1-Phenyl-1,3-propanediamine




20 1-Phenyl-1,3-propanediamine: 3-Phenyl-3-aminopropionic acid (S. G. Cohen and S. Y. Weinstein, J. Am. Chem. Soc. 86, 725-728, 1964) was converted into 1-phenyl-1,3-propanediamine as reported in the literature (M. Kojima and J. Fujita, Bull. Chem. Soc. Jpn. 55, 1454-1459 (1982)).

25

Analogously, 1-(2-fluorophenyl)-1,3-propanediamine,
1-(2-methylphenyl)-1,3-propanediamine and 1-(2-
chlorophenyl)-1,3-propanediamine have been prepared by
using the above procedure and the appropriate starting
5 material.

Example 26


Procedure for the preparation of 3-Ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-
pyrimidinone



3-Ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-
4(3H)-pyrimidinone: Ethyl bromide (600 ml, 8.03 mmol)
was added to a stirred mixture of 5-(4-fluorophenyl)-2-
methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (1.8 g, 5.97
15 mmol) and sodium hydride (60% oily suspension, 320 mg, 8
mmol) in *N,N*-dimethylformamide (60 ml) at room
temperature. More ethyl bromide (2x 600 ml, 2x8.03
mmol) was added after 2 and 3.5 h. After 8 h, the
reaction mixture was neutralized with acetic acid and
20 evaporated. The remainder was taken up in
dichloromethane, the organic solution was washed with
water, dried and evaporated. Flash chromatography on a
column of silica gel (hexane-acetone = 3:1, 2:1).
provided in the second main fraction the title compound
25 as a solid.

Example 27

Procedure for the preparation of 3-Ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone




5

3-Ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone: A mixture of 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (300 mg, 0.88 mmol) and Oxone[®] (potassium peroxymonosulfate, 2.54 g, 4.14 mmol) in methanol (71 ml) and water (33 ml) was stirred for 14 h. The solvent was concentrated to about 35 ml, followed by extraction with dichloromethane, drying and evaporation. The resulting white solid was used without purification in the next step.

15

Example 28

Procedure for the preparation of 2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride



20

2-(((S)-2-Amino-3-phenylpropyl)-amino)-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride: A mixture of 3-ethyl-5-(4-fluorophenyl)-2-methylthio-6-(4-pyridyl)-4(3H)-pyrimidinone (150 mg, 0.44 mmol) and (S)-1,2-benzylethylenediamine (200 ml, 1.3 mmol) was heated at 190°C for 4.5 h. Column chromatography on Iatrobeads[®] (chloroform : methanol :


25

160

triethylamine = 90 : 7 : 3) provided the title compound as a free base which was converted into the crystallizing monohydrochloride by the addition of 2N hydrochloric acid (165 ml, 0.33 mmol) and methanol (1.5 ml). Filtration provided the title compound. MS (m/z): 444.0 (M+H)⁺; C₂₆H₂₇FN₅O requir. 443.5 (free base).

Example 29

Procedure for the preparation of 3-Ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride




3-Ethyl-5-(4-fluorophenyl)-2-((2-methyl-3-phenylpropyl) amino)-6-(4-pyridyl)-4(3H)-pyrimidinone hydrochloride:

A mixture of crude 3-ethyl-5-(4-fluorophenyl)-2-methylsulfonyl-6-(4-pyridyl)-4(3H)-pyrimidinone (320 mg, 0.89 mmol) and 2-methyl-3-phenylpropylamine (600 ml, ~4 mmol) was heated at 60°C for 2 h. Column chromatography on silica gel (hexane-acetone= 2 : 1; 2-5% methanol/dichloromethane) provided the title compound. MS (m/z): 443.2 (M+H)⁺; C₂₇H₂₇FN₄O requir. 442.5.

Example 30

Procedure for the preparation of 3-(2-Methylphenyl)propylamine



25


3-(2-Methylphenyl)propylamine: Diethyl cyanomethylphosphonate (5.0 ml, 30.9 mmol) was added to a stirring suspension of sodium hydride (60% oily suspension, 1.24 g, 31 mmol) in tetrahydrofuran (50 ml)

under argon. After 30 min, 2-methylbenzaldehyde (3.6 ml, 31.1 mmol) was added and stirring continued for 1 h. The reaction was quenched by the addition of water and extracted with dichloromethane followed by drying and evaporation of the organic solution. Column chromatography (hexane; hexane : ethylacetate = 3 : 1) provided 2-(2-methylphenyl)acrylonitrile as an oil. This material (3.8 g), 10% palladium on carbon (3.8 g) and 12 N hydrochloric acid (11.8 ml, 142 mmol) in methanol (125 ml) were hydrogenated with hydrogen at atmospheric pressure for 2 d. The catalyst was removed by filtration and the solvent was evaporated. The resultant material was partitioned between dichloromethane and water. The aqueous layer was made basic with 10 N sodium hydroxide and extracted with dichloromethane, followed by drying and evaporation. The resultant material was purified on a silica gel column (chloroform : methanol : triethylamine = 85 : 10 : 5) to provide the title compound as an oil.

20

Example 31

Procedure for the preparation of 2-amino-3-(2-fluorophenyl)-propylamine



Step A. Methyl 2-amino-3-(2-fluorophenyl)propionate:

25 5g (27.3 mmol) of (D,L)-(2-fluoro-phenyl)alanine was suspended in 50 ml methanolic HCl and stirred at room temperature for 3 days. The reaction mixture was concentrated in vacuo and dried to give a yellow oil. MS (m/z): 198 (M+H)⁺; C₁₀H₁₂FNO₂, requir. 197.2.

30 Step B. 2-Amino-3-(2-fluorophenyl)propionamide: Methyl 2-amino-3-(2-fluorophenyl) propionate was suspended in 50 ml 30% ammonium hydroxide and stirred at room temperature for 18 hrs. The mixture was filtered,

162


washed with cold water and 2-amino-3-(2-fluorophenyl) propionamide was collected as a white solid. MS (m/z): 183.1 (M+H)⁺; C₉H₁₁FN₂O requir. 182.2.

Step C. 2-Amino-3-(2-fluorophenyl)-propylamine: 2-

- 5 Amino-3-(2-fluorophenyl)propionamide was added carefully to a chilled (5°) mixture of LAH (1.0g, 26.3 mmol) and 20 ml THF under argon. The reaction was then heated at reflux for 10 hrs. The reaction was cooled to 5°C and carefully treated with Na₂SO₄·10 H₂O. The resulting
10 mixture was stirred for 18 hrs, then filtered to remove the solids. The filtrate was concentrated in vacuo to give an amber oil. MS (m/z): 169 (M+H)⁺; C₉H₁₁FN₂ requir. 168.19

Example 32

- 15 *Procedure for the preparation of (1R,2R)-2-Methyl-1-phenyl-1,3-propanediamine*



Step A: Methyl (2S,3R,αS)-3-(N-benzyl-N-α-methylbenzylamino)-2-methyl-3-phenylpropionate was

- 20 prepared as reported for the 2R,3S,αR-enantiomer (S).G. Davies and I.A.S. Walters, J. Chem. Soc. Perkin Trans.I, 1129-1139 (1994).

Step B: Methyl (2S,3R)-3-amino-2-methyl-3-

- 25 phenylpropionate: A mixture of methyl (2S,3R,αS)-3-(N-benzyl-N-α-methylbenzylamino)-2-methyl-3-phenylpropionate (13.0 g, 33.55 mmol) and 10% palladium-

on-carbon (13.0 g) in glacial acetic acid (260 ml) was hydrogenated under a balloon of hydrogen for 24 h. The catalyst was removed by filtration followed by evaporation and co-distillation with toluene to provide the title compound as a white solid. MS (m/z): 194.2 ($M+H$)⁺; $C_{11}H_{13}NO$, requir. 193.3.

Step C: (2S,3R)-3-Amino-2-methyl-3-phenylpropionamide:

A solution of methyl (2S,3R)-3-amino-2-methyl-3-phenylpropionate (6.3 g, 33 mmol) in 2N methanolic ammonia (20 ml) and ammonium hydroxide (28-30%, 40 ml) was stirred at room temperature. After 4d, it was evaporated followed by chromatography on a short column of silica gel (dichloromethane - methanol - conc. ammonium hydroxide = 93 : 7 : 0.7; 90 : 10 : 0.8) to provide the amide as a white solid. MS (m/z): 179.2 ($M+H$)⁺; $C_{10}H_{14}N_2O$ requir. 178.2.

Step D: (1R,2R)-2-methyl-1-phenyl-1,3-propanediamine:


Lithium aluminium hydride (2.3 g, 60.60 mmol) was added in portions to a stirring solution of (2S,3R)-3-amino-2-methyl-3-phenylpropionamide (2.6 g, 14.59 mmol) in tetrahydrofuran (54 ml) at ice-bath temperature. After 45 min, the mixture was heated at reflux for 16 h. With ice-bath cooling, the reaction was quenched by the portionwise addition of sodium sulfate decahydrate and some methanol until hydrogen evolution ceased. The solids were removed by filtration and washed with dichloromethane. The combined filtrates were evaporated to provide the title compound. MS (m/z): 165.2 ($M+H$)⁺; $C_{10}H_{16}N_2$ requir. 164.3.

Analogously, the enantiomer (1S,2S)-2-methyl-1-phenyl-1,3-propanediamine was prepared from methyl (2R,3S,αR)-3-(N-benzyl-N-α-methylbenzylamino)-2-methyl-3-phenylpropionate. MS (m/z): 165.3 ($M+H$)⁺; $C_{10}H_{16}N_2$ requir. 164.3.

Analogously, the enantiomers (1S,2R)-2-methyl-1-phenyl-1,3-propanediamine and (1R,2S)-2-methyl-1-phenyl-1,3-propanediamine may be prepared from tert.butyl (2S,3S, α R)- and -(2R,3R, α S)-3-(N-benzyl-N- α -methylbenzylamino)-2-methyl-3-phenylpropionate (Davies et al., J. Chem. Soc. Chem. Commun. 1153-1155, 1993).

Example 33

Procedure for the preparation of 5-(4-fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone




10

5-(4-Fluorophenyl)-2-(4-phenylbutyl)-6-(4-pyridyl)-4(3H)-pyrimidinone: Ethyl 2-(4-fluorophenyl)-3-oxo-3-(4-pyridyl)-propionate (293 mg, 1.02 mmol), 4-phenylbutanecarboxamide (315 mg, 1.79 mmol) and pyridinium p-toluenesulfonate (10 mg) were suspended in p-xylene (10 ml). With efficient stirring, the mixture was heated to reflux using a Dean-Stark apparatus with continuous removal of water. After 16 h, the solvent was evaporated and the product purified by column chromatography on silica gel (3% methanol/dichloromethane) followed by recrystallization from acetone. MS (m/z): 400.3 (M+H)⁺; C₂₅H₂₂FN₃O requir. 399.5.

Example 34

Procedure for the preparation of 5-(4-fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)amino)-6-(4-pyridyl)-4(3H)-pyrimidinone




5

5-(4-Fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)amino)-6-(4-pyridyl)-4(3H)-pyrimidinone was prepared using the methods described above. MS (m/z): 401.2 ($M+H$)⁺; C₂₄H₂₁FN₄O requir. 400.5.

10











Example 35

The compounds shown in Tables I-II can be prepared using the procedures of Examples 1-33.



TABLE I

15











166



5



167



5
























TABLE II




R¹

5



10

169

**Example 36***Biological Assays*

The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF- α and IL-1- β . The second assay measured the inhibition of TNF- α and/or IL-1- β in mice after oral administration of the test compounds. The third assay, a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding. The fourth assay, a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used

to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.

Lipopolysaccharide-activated monocyte TNF production assay

5 *Isolation of monocytes*

Test compounds were evaluated in vitro for the ability to inhibit the production of TNF by monocytes activated with bacterial lipopolysaccharide (LPS). Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from a local blood bank, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol-Paque Plus (Pharmacia). PBMCs were suspended at 2×10^6 /ml in DMEM supplemented to contain 2% FCS, 10 mM, 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate (complete media). Cells were plated into Falcon flat bottom, 96 well culture plates (200 μ l/well) and cultured overnight at 37°C and 6% CO₂. Non-adherent cells were removed by washing with 200 μ l/well of fresh medium. Wells containing adherent cells (~70% monocytes) were replenished with 100 μ l of fresh medium.

Preparation of test compound stock solutions

Test compounds were dissolved in DMZ. Compound stock solutions were prepared to an initial concentration of 10 - 50 μ M. Stocks were diluted initially to 20 - 200 μ M in complete media. Nine two-fold serial dilutions of each compound were then prepared in complete medium.

30 *Treatment of cells with test compounds and activation of TNF production with lipopolysaccharide*

One hundred microliters of each test compound dilution were added to microtiter wells containing adherent monocytes and 100 μ l complete medium. Monocytes were cultured with test compounds for 60 min at which time 25 μ l of complete medium containing 30

ng/ml lipopolysaccharide from *E. coli* K532 were added to each well. Cells were cultured an additional 4 hrs. Culture supernatants were then removed and TNF presence in the supernatants was quantified using an ELISA.

5 *TNF ELISA.*

Flat bottom, 96 well Corning High Binding ELISA plates were coated overnight (4°C) with 150 µL/well of 3 µg/ml murine anti-human TNF-α MAb (R&D Systems #MAB210). Wells were then blocked for 1 hr at room temperature
10 with 200 µL/well of CaCl₂-free ELISA buffer supplemented to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, 150 mM NaCl, 2 mM CaCl₂, 0.15 mM thimerosal, pH 7.4). Plates were washed and replenished with 100 µl of test supernatants (diluted 1:3) or standards. Standards
15 consisted of eleven 1.5-fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems). Plates were incubated at room temperature for 1 hr on orbital shaker (300 rpm), washed and replenished with 100 µl/well of 0.5 µg/ml goat anti-human TNF-α (R&D
20 systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubated for 40 min, washed and replenished with 100 µl/well of alkaline phosphatase-conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 µg/ml. Plates were incubated 30 min, washed and
25 replenished with 200 µl/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a V_{max} plate reader.

Data analysis

Standard curve data were fit to a second order
30 polynomial and unknown TNF-α concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted vs. test compound concentration using a second order polynomial. This equation was then used to calculate
35 the concentration of test compounds causing a 50% reduction in TNF production.

Compounds of the invention can also be shown to inhibit LPS-induced release of IL-1 β , IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1 β , IL-6 and/or IL-8 by methods well known to those skilled in the art. In a similar manner to the above described assay involving the LPS induced release of TNF- α from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-1 β , IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-1 β , IL-6 and/or IL-8 by methods well known to those skilled in the art. Thus, the compounds of the invention may lower elevated levels of TNF- α , IL-1, IL-6, and IL-8 levels. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, and alleviating many disease states. All of the compounds are useful in the methods of treating disease states in which TNF- α , IL-1 β , IL-6, and IL-8 play a role to the full extent of the definition of TNF- α -mediated diseases described herein.

20 Inhibition of LPS-Induced TNF- α production in mice

Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection. Ninety minutes after LPS injection, blood was collected and the serum was analyzed by ELISA for TNF levels.

The following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with IC₅₀ values of 20 μ M or less:

- 30 5-(4-Fluorophenyl)-2-(4-pyridyl)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-methylthiazol-4-yl)-4-(4-pyridyl)-pyrimidine
- 35 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-thienyl)-pyrimidine

- 2-(2-Diethylaminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
5 2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(4-Aminobutylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
10 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(2,6-Dichlorophenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(2,6-Dimethylphenylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
15 5-(4-Fluorophenyl)-2-(2-methoxyphenylamino)-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(4-fluorophenylamino)-4-(4-pyridyl)-pyrimidine
20 5-(4-Fluorophenyl)-2-phenylthiomethyl-4-(4-pyridinyl)-pyrimidine
2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-pyrimidine
25 5-(4-Fluorophenyl)-2-(methyl-(2-phenylethyl)-amino)-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-((2-hydroxy-2-phenyl-ethyl)amino)-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine
30 2-(2-(4-Aminophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine
35 5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine
2-(2-(2-Chlorophenyl)ethyl-amino))-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(2-(4-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
40 2-(2-(3-Chlorophenyl)ethyl-amino))-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(2-(2,4-Dichlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine

- 2-(2-(4-Bromophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-(2-methoxyphenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine
- 5 5-(4-Fluorophenyl)-2-(2-(3-methoxyphenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-((3-phenylpropyl)amino)-4-(4-pyridyl)-pyrimidine
- 10 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-pyridyl)-pyrimidine
- 15 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-((4-phenylbutyl)-amino)-4-(4-pyridyl)-pyrimidine
- 20 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-pyrimidine
- 5-(4-Fluorophenyl)-2-morpholino-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-pyrimidine
- 25 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-pyrrolidinoethylamino)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-morpholinoethylamino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-piperidinoethylamino)-4-(4-pyridyl)-pyrimidine
- 30 5-(4-Fluorophenyl)-2-(3-(2-pyrrolidinon-1-yl)propyl-amino)-4-(4-pyridyl)-pyrimidine
- 2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone
- 35 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone
- 5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone
- 5-(4-Fluorophenyl)-2-(2-phenoxyethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone
- 40 5-(4-Fluorophenyl)-2-(2-phenylaminoethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone
- 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone
- 45 5-(4-Fluorophenyl)-2-((3-phenylpropyl)amino)-6-(4-pyridyl)-4(3H)-pyrimidinone

- 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4(3H)-pyrimidinone
- 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)amino)-6-(4-pyridyl)-4(3H)-pyrimidinone
- 5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 10 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 15 2-((3-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 20 2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 2-((3-Hydroxy-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 25 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 30 2-((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 4-(4-Pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethyl)amino)-5-(3-trifluoromethylphenyl)-pyrimidine
- 5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethyl)amino)-pyrimidine
- 35 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 40 2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine

- 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 5 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 10 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-isopropylphenyl)-4-(4-pyridyl)-pyrimidine
- 15 5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-chlorophenyl)-4-(4-pyridyl)-
- 20 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone.
- 25 The following compounds exhibit activities in the monocyte assay (LPS induced TNF release) with IC₅₀ values of 5 μ M or less:
- 2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 30 2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 35 5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)amino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-hydroxy-2-phenyl-ethyl)amino-4-(4-pyridyl)-pyrimidine
- 40 5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)ethylamino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethylamino)-4-(4-pyridyl)-pyrimidine

- 5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)ethylamino)-4-(4-pyridyl)-pyrimidine
2-(2-(2-Chlorophenyl)ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
5 2-(2-(4-Chlorophenyl)ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(2-(2,4-Dichlorophenyl)ethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
10 5-(4-Fluorophenyl)-2-(3-phenylpropyl)amino-4-(4-pyridyl)-pyrimidine
2-((S)-2-Amino-3-phenylpropyl)amino-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-pyridyl)-pyrimidine
15 5-(4-Fluorophenyl)-2-(3-imidazolylpropyl)amino-4-(4-pyridyl)-pyrimidine
5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-pyrimidine
5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-pyrimidine
20 5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone
5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-4(3H)-pyrimidinone
25 2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)-pyrimidinone
5-(4-Fluorophenyl)-2-(3-phenylpropyl)amino-6-(4-pyridyl)-4(3H)-pyrimidinone
5-(4-Fluorophenyl)-2-(1-methyl-3-phenylpropyl)amino-6-(4-pyridyl)-4(3H)-pyrimidinone
30 2-(((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
35 2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
2-(((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
40 2-((3-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine

- 2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 5 2-((3-Hydroxy-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 10 2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 4-(4-Pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethyl)amino)-5-(3-trifluoromethylphenyl)-pyrimidine
- 15 5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethylen)amino)-pyrimidine
- 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 20 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 25 2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 30 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine
- 2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine
- 35 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-fluorophenyl)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-isopropylphenyl)-4-(4-pyridyl)-pyrimidine
- 40 5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine
- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-chlorophenyl)-4-(4-pyridyl)-

- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-
4-(4-pyridyl)-pyrimidine
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-
(4-pyridyl)-pyrimidine
5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-
fluorophenyl)-6-(4-pyridyl)-4-(3H)pyrimidinone.

Compounds of the invention may be shown to have
anti-inflammatory properties in animal models of
10 inflammation, including carageenan paw edema, collagen
induced arthritis and adjuvant arthritis, such as the
carageenan paw edema model (C. A. Winter et al Proc.
Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F.
Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds.,
15 Antiinflammatory Agents, Chemistry and Pharmacology,
Vol. 13-II, Academic, New York, 1974, p. 33) and
collagen induced arthritis (D. E. Trentham et al J. Exp.
Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature
(New Biol.) (1980), Vol 283, p 666).

20

¹²⁵I-Glucagon Binding Screen with CHO/hGLUR Cells

The assay is described in WO 97/16442, which is
incorporated herein by reference in its entirety.

Reagents

- 25 The reagents can be prepared as follows: (a)
prepare fresh 1M o-Phenanthroline (Aldrich) (198.2 mg/ml
ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c)
Protease Inhibitor Mix (1000X): 5 mg leupeptin, 10 mg
benzamidine, 40 mg bacitracin and 5 mg soybean trypsin
30 inhibitor per ml DMSO and store aliquots at -20°C; (d)
250 µM human glucagon (Peninsula): solubilize 0.5 mg
vial in 575 µl 0.1N acetic acid (1 µl yields 1 µM final
concentration in assay for non-specific binding) and
store in aliquots at -20°C; (e) Assay Buffer: 20mM Tris
35 (pH 7.8), 1 mM DTT and 3 mM o-phenanthroline; (f) Assay
Buffer with 0.1% BSA (for dilution of label only; 0.01%
final in assay): 10 µl 10% BSA (heat-inactivated) and
990 µl Assay Buffer; (g) ¹²⁵I-Glucagon (NEN, receptor-

grade, 2200 Ci/mmol): dilute to 50,000 cpm/25 μ l in assay buffer with BSA (about 50pM final concentration in assay).

Harvesting of CHO/hGLUR Cells for Assay

- 5 1. Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme-free Dissociation Fluid (Specialty Media, Inc.).
2. Add 10 ml Enzyme-free Dissoc. Fluid and hold for about 4 min. at 37°C.
- 10 3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
4. Resuspend pellet in Assay Buffer at 75000 cells per 100 μ l.

- 15 Membrane preparations of CHO/hGLUR cells can be used in place of whole cells at the same assay volume. Final protein concentration of a membrane preparation is determined on a per batch basis.

Assay

- 20 The determination of inhibition of glucagon binding can be carried out by measuring the reduction of I^{125} -glucagon binding in the presence of compounds of Formula I. The reagents are combined as follows:

	Compound/ Vehicle	250 μ M Glucagon	125 I- Glucagon	CHO/hGLUR Cells
Total Binding	--/5 μ l	--	25 μ l	100 μ l
+ Compound	5 μ l/--	--	25 μ l	100 μ l
Nonspecific Binding	--/5 μ l	1 μ l	25 μ l	100 μ l

25

The mixture is incubated for 60 min. at 22°C on a shaker at 275 rpm. The mixture is filtered over pre-soaked (0.5% polyethylimine (PEI)) GF/C filtermat using an

Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8). The radioactivity in the filters is determined by a gamma-scintillation counter.

- 5 Thus, compounds of the invention may also be shown to inhibit the binding of glucagon to glucagon receptors.

Cyclooxygenase Enzyme Activity Assay

- 10 The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2. THP-1 cells are routinely cultured in RPMI complete media supplemented
15 with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM-10%FBS); all cell incubations are at 37°C in a humidified environment containing 5% CO₂.

20

COX-1 Assay

- In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA), and
25 incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5×10^6 cells/mL and plated in 96-well culture plates at a density of 5×10^5 cells/mL. Test compounds are diluted
30 in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours. Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.

35

COX-2 Assay

For the COX-2 assay, subconfluent HOSC are trypsinized and resuspended at 3×10^6 cells/mL in MEM-FBS containing 1 ng human IL-1b/mL, plated in 96-well tissue culture plates at a density of 3×10^4 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-1b/mL, and the cells incubated for 18-22 hours. Following replacement of media with 190 mL MEM, 10 mL of test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours. The supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.

COX Activity Determined

After incubation with arachidonic acid, the reactions are stopped by the addition of 1 N HCl, followed by neutralization with 1 N NaOH and centrifugation to pellet cell debris. Cyclooxygenase enzyme activity in both HOSC and THP-1 cell supernatants is determined by measuring the concentration of PGE₂ using a commercially available ELISA (Neogen #404110). A standard curve of PGE₂ is used for calibration, and commercially available COX-1 and COX-2 inhibitors are included as standard controls.

Accordingly, the compounds of the invention or a pharmaceutical composition thereof are useful for prophylaxis and treatment of rheumatoid arthritis; Pagets disease; osteoporosis; multiple myeloma; uveitis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis;

ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster, all of which are sensitive to TNF- α and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.

The compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1. The compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety).

Because of their ability to lower TNF- α and IL-1 concentrations or inhibit glucagon binding to its receptor, the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.

The methods of the invention comprise administering an effective dose of a compound of the invention, a pharmaceutical salt thereof, or a pharmaceutical composition of either, to a subject (i.e., an animal, preferably a mammal, most preferably a human) in need of a reduction in the level of TNF- α , IL-1, IL-6, and/or IL-8 levels and/or reduction in plasma glucose levels and/or which subject may be suffering from rheumatoid arthritis; Pagets disease; osteoporosis; multiple

myeloma; uveitis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome
5 (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; Alzheimer's disease;
10 stroke; myocardial infarction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection, or which subject is infected by HIV-1, HIV-2, HIV-3,
15 cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), or herpes zoster.

In another aspect, this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a
20 medicament for the treatment either acutely or chronically of a TNF- α , IL-1 β , IL-6, and/or IL-8 mediated disease state, including those described previously. Also, the compounds of this invention are useful in the manufacture of an analgesic medicament and a medicament
25 for treating pain disorders, such as hyperalgesia. The compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.

30 In still another aspect, this invention provides a pharmaceutical composition comprising an effective TNF- α , IL-1 β , IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically
35 acceptable carrier or diluent, and if desired other active ingredients. The compounds of the invention are administered by any suitable route, preferably in the

form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest
5 the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.

For the treatment of TNF- α , IL-1 β , IL-6, and IL-8 mediated diseases and/or hyperglycemia, the compounds of
10 the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes,
15 subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.

The dosage regimen for treating a TNF- α , IL-1, IL-6, and IL-8 mediated diseases and/or hyperglycemia with the compounds of this invention and/or compositions of
20 this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular compound employed. Thus, the dosage regimen
25 may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1 mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for
30 all methods of use disclosed herein.

The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans
35 and other mammals.

For oral administration, the pharmaceutical composition may be in the form of, for example, a

capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.

Injectable preparations, such as sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable non-irritating excipient such as cocoa butter and polyethylene glycols that are solid at ordinary

temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg
5 administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more
10 than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions,
15 ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose.

For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration.
20 The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinyl-
25 pyrrolidone, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil,
30 cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate
35 alone or with a wax, or other materials well known in the art.

The pharmaceutical compositions may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The pharmaceutical compositions may be
5 subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

Solid dosage forms for oral administration may
10 include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also
15 comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

20 Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as
25 wetting, sweetening, flavoring, and perfuming agents.

Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The
30 optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric,
35 diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed

by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. The salts include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides

like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

Examples of acids that may be employed to form pharmaceutically acceptable acid addition salts include
5 such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium,
10 calcium or magnesium or with organic bases.


While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When
15 administered as a combination, the therapeutic agents can be formulated as separate compositions that are given at the same time or different times, or the therapeutic agents can be given as a single composition.

The foregoing is merely illustrative of the
20 invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.

25 From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various
30 usages and conditions.

WHAT IS CLAIMED IS:

1. A compound of formula



5 or a pharmaceutically acceptable salt thereof, wherein

wherein R₁ and R₂ are each independently -Z-Y, provided
that (1) the total number of aryl, heteroaryl,
cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-
10 3; and (2) the combined total number of aryl,
heteroaryl, cycloalkyl and heterocyclyl radicals in R₁
and R₂ is 0-4;

wherein each Z is independently a

- 15 (1) bond;
(2) alkyl, alkenyl or alkynyl radical optionally
substituted by (a) 1-3 radicals of amino, alkylamino,
dialkylamino, alkanoylamino, alkoxycarbonylamino,
alkylsulfonylamino, hydroxy, alkoxy, alkylthio or halo,
20 and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl
optionally substituted by 1-3 radicals of amino,
alkylamino, dialkylamino, alkanoylamino,
alkoxycarbonylamino, alkylsulfonylamino, hydroxy,
alkoxy, alkylthio, halo, alkyl or haloalkyl;
25 (3) heterocyclyl radical optionally substituted by 1-3
radicals of amino, alkylamino, dialkylamino,
alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino,
hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
(4) aryl or heteroaryl radical optionally substituted by
30 1-3 radicals of amino, alkylamino, dialkylamino,
alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino,
hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or
haloalkyl;

each Y is independently a

- (1) hydrogen radical;
- (2) halo or nitro radical;
- 5 (3) $-C(O)-R_{20}$ or $-C(NR_5)-NR_5R_{21}$ radical;
- (4) $-OR_{21}$, $-O-C(O)-R_{21}$, $-O-C(O)-NR_5R_{21}$ or $-O-C(O)-NR_{22}-S(O)_2-R_{20}$ radical;
- (5) $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$, $-S(O)_2-NR_5R_{21}$, $-S(O)_2-NR_{22}-C(O)-R_{21}$, $-S(O)_2-NR_{22}-C(O)-OR_{20}$ or $-S(O)_2-NR_{22}-C(O)-$
- 10 NR_5R_{21} radical; or
- (6) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$, $-NR_{22}-C(O)-OR_{20}$, $-NR_{22}-C(O)-NR_5R_{21}$, $-NR_{22}-C(NR_5)-NR_5R_{21}$, $-NR_{22}-S(O)_2-R_{20}$ or $-NR_{22}-S(O)_2-NR_5R_{21}$ radical;
- 15 wherein each R_5 is independently
- (1) hydrogen radicals;
- (2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, $-SO_3H$ or halo;
- 20 or
- (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclalkyl, cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; and
- 25

wherein each R_{20} is independently

- (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo or aralkoxy, aralkylthio, aralkylsulfonyl, cycloalkyl, heterocyclyl,
- 30 aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,
- 35

alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halo, alkyl or haloalkyl;

- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkyl or haloalkyl; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;

each R₂₁ is independently hydrogen radical or R₂₀;

15

each R₂₂ is independently

- (1) hydrogen radical;
- (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or
- (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl; provided when Z is a bond and Y is -NR₂₂-
- C(O)-NH₂, then R₂₂ is other than an optionally substituted aryl radical; and

30

R₁₁ and R₁₂ are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of

35

- (1) R₃₀;
- (2) halo or cyano radicals;

- (3) $-C(O)-R_{30}$, $-C(O)-OR_{29}$, $-C(O)-NR_{31}R_{32}$ or $-C(NR_{31})-NR_{31}R_{32}$ radicals;
- (4) $-OR_{29}$, $-O-C(O)-R_{29}$, $-O-C(O)-NR_{31}R_{32}$ or $-O-C(O)-NR_{33}-S(O)_2-R_{30}$ radicals;
- 5 (5) $-SR_{29}$, $-S(O)-R_{30}$, $-S(O)_2-R_{30}$, $-S(O)_2-NR_{31}R_{32}$, $-S(O)_2-NR_{33}-C(O)-R_{30}$, $-S(O)_2-NR_{33}-C(O)-OR_{30}$ or $-S(O)_2-NR_{33}-C(O)-NR_{31}R_{32}$ radicals; or
- (6) $-NR_{31}R_{32}$, $-NR_{33}-C(O)-R_{29}$, $-NR_{33}-C(O)-OR_{30}$, $-NR_{33}-C(O)-NR_{31}R_{32}$, $-NR_{33}-C(NR_{31})-NR_{31}R_{32}$, $-NR_{33}-S(O)_2-R_{30}$ or $-NR_{33}-S(O)_2-NR_{31}R_{32}$ radicals;
- 10 provided that (1) R_{11} is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and
- 15 heterocyclyl radicals substituted on each of R_{11} and R_{12} is 0-1;

wherein each R_{30} is independently

- (1) alkyl, alkenyl or alkynyl radicals optionally
- 20 substituted by 1-3 radicals of $-NR_{31}R_{31}$, $-CO_2R_{23}$, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of
- 25 amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, halo, alkyl or haloalkyl;
- (2) heterocyclyl radical optionally substituted by 1-3
- 30 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
- or
- (3) aryl or heteroaryl radicals optionally substituted
- 35 by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxy-carbonylamino, alkylsulfonylamino,

hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;

each R₂₉ is independently hydrogen radical or R₃₀;

5

each R₃₁ and R₃₂ are each independently

(1) hydrogen radicals;

(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical

10

optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino,

alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or

15

(3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical

optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino,

alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and

20

wherein each R₃₃ is independently

(1) hydrogen radical; or

(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino,

25

alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and

provided that (1) when Rⁱ and Rⁱⁱ are the same and are a

30

5- or 6-member ring having from 1-3 heteroatoms

independently selected from N, S, and O, to which ring a benzene ring is optionally fused, Rⁱⁱ is phenyl or

naphthyl optionally substituted with halo, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthiol, hydroxy, amino, C₁-C₆

35

alkylamino, or dialkylamino, or Rⁱⁱ is a 5- or 6-membered ring having from 1-3 heteroatoms independently selected from N, S, and O, to which ring a benzene ring is

optionally fused and optionally substituted with C₁-C₆ alkyl, then R² is other than OH or NH₂; (2) when R² is H, R¹¹ is phenyl and R¹² is phenyl or 4-pyridyl, then R¹ is other than H, methyl, or amino; (3) when R² is H, R¹¹ is 2-methylphenyl and R¹² is 2-pyridyl, then R¹ is other than n-propyl; and (4) when R¹¹ and R¹² are each an optionally substituted phenyl radical, then R¹ is other than an optionally substituted 2-pyridyl radical.

10

2. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein

wherein R₁ and R₂ are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ and R₂ is 0-4;

20

each Z is independently a

- (1) bond;
- (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

- alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- 5 (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl
- 10 or C₁-C₄ haloalkyl of 1-3 halo radicals;

each Y is independently a

- (1) hydrogen radical;
- (2) halo or nitro radical;
- 15 (3) -C(O)-R₂₀ or -C(NR₅)-NR₅R₂₁ radical;
- (4) -OR₂₁, -O-C(O)-R₂₁, -O-C(O)-NR₅R₂₁ or -O-C(O)-NR₂₂-S(O)₂-R₂₀ radical;
- (5) -SR₂₁, -S(O)-R₂₀, -S(O)₂-R₂₀, -S(O)₂-NR₅R₂₁, -S(O)₂-NR₂₂-C(O)-R₂₁, -S(O)₂-NR₂₂-C(O)-OR₂₀ or -S(O)₂-NR₂₂-C(O)-
- 20 NR₅R₂₁ radical; or
- (6) -NR₅R₂₁, -NR₂₂-C(O)-R₂₁, -NR₂₂-C(O)-OR₂₀, -NR₂₂-C(O)-NR₅R₂₁, -NR₂₂-C(NR₅)-NR₅R₂₁, -NR₂₂-S(O)₂-R₂₀ or -NR₂₂-S(O)₂-NR₅R₂₁ radical;

25 each R₅ is independently

- (1) hydrogen radicals;
- (2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO₃H or halo; or
- 30 (3) aryl, heteroaryl, aryl-C₁-C₄-alkyl, heteroaryl-C₁-C₄-alkyl, heterocyclyl, heterocyclyl-C₁-C₄-alkyl, C₃-C₈ cycloalkyl or C₃-C₈-cycloalkyl-C₁-C₄-alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄
- 35

alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

each R₂₀ is independently

- 5 (1) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄
- 10 alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3
- 15 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo, C₁-C₄ alkyl or
- 20 C₁-C₄ haloalkyl of 1-3 halo radicals;
- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy,
- 25 C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 30 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- 35 each R₂₁ is independently hydrogen radical or R₂₀;

each R₂₂ is independently

- (1) hydrogen radical;
- (2) C₁-C₄ alkyl radical optionally substituted by a
- 5 radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄
- 10 alkylsulfonyl, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄
- 15 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; provided when Z is a bond and Y is -NR₂₂-C(O)-NH₂, then R₂₂ is other than an
- 20 optionally substituted aryl radical;

R₁₁ and R₁₂ are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of

- (1) R₃₀;
- 25 (2) halo or cyano radicals;
- (3) -C(O)-R₃₀, -C(O)-OR₂₉, -C(O)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals;
- (4) -OR₂₉, -O-C(O)-R₂₉, -O-C(O)-NR₃₁R₃₂ or -O-C(O)-NR₃₃-S(O)₂-R₃₀ radicals;
- 30 (5) -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -S(O)₂-NR₃₃-C(O)-R₃₀, -S(O)₂-NR₃₃-C(O)-OR₃₀ or -S(O)₂-NR₃₃-C(O)-NR₃₁R₃₂ radicals; or
- (6) -NR₃₁R₃₂, -NR₃₃-C(O)-R₂₉, -NR₃₃-C(O)-OR₃₀, -NR₃₃-C(O)-NR₃₁R₃₂, -NR₃₃-C(NR₃₁)-NR₃₁R₃₂, -NR₃₃-S(O)₂-R₃₀ or -NR₃₃-S(O)₂-NR₃₁R₃₂ radicals;
- 35

provided that (1) R_{11} is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and
 5 heterocyclyl radicals substituted on each of R_{11} and R_{12} is 0-1;

each R_{30} is independently

- (1) C_1 - C_4 alkyl, C_2 - C_4 alkenyl or C_2 - C_4 alkynyl radicals
 10 optionally substituted by 1-3 radicals of $-NR_{31}R_{31}$, $-CO_2R_{23}$, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, cyano, halo or aryl- C_1 - C_4 -alkoxy, aryl- C_1 - C_4 -alkylthio, aryl- C_1 - C_4 -alkylsulfonyl, heterocyclyl, aryl or heteroaryl radicals
 15 optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 alkylsulfinyl, C_1 - C_4 alkylsulfonyl, cyano, halo, C_1 - C_4
 20 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;
- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy,
 25 C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy,
 30 C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, halo, C_1 - C_4 alkyl or C_1 - C_4 haloalkyl of 1-3 halo radicals;

each R_{29} is independently hydrogen radical or R_{30} ;

each R₃₁ and R₃₂ are each independently

- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl radical optionally substituted by an C₃-C₈ cycloalkyl, aryl, heterocyclyl or heteroaryl radical
- 5 optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
- 10 (3), aryl, heteroaryl, heterocyclyl or C₃-C₈ cycloalkyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3
- 15 halo radicals; and

each R₃₃ is independently

- (1) hydrogen radical; or
- 20 (2) C₁-C₄ alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy,
- 25 C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; and

wherein heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8

30 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is

35 radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per

ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C₃-C₄-carbocyclic-fused.

5

3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein

each Z is independently a

10 (1) bond;

(2) C₁-C₈ alkyl, C₂-C₈ alkenyl or C₂-C₈ alkynyl radical optionally substituted by (a) 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄

15 alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄20 alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or

30 (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

35

each R₅ is independently

- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, -SO₃H or halo; or
- (3) aryl, heteroaryl, aryl-C₁-C₄-alkyl, heteroaryl-C₁-C₄-alkyl, heterocyclyl, heterocyclyl-C₁-C₄-alkyl, C₃-C₈ cycloalkyl or C₃-C₈-cycloalkyl-C₁-C₄-alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄-alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

each R₂₀ is independently

- (1) C₁-C₈ alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;
- (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy,

C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

10

each R₂₁ is independently hydrogen radical or R₂₀;

each R₃₀ is independently

(1) C₁-C₄ alkyl radical optionally substituted by 1-3 radicals of

15 (a) -NR₃₁R₃₁;

(b) C₁-C₄ alkoxy-carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 radicals of amino, alkylamino, di-(C₁-C₄-alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl; or

(c) hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, or phenyl-C₁-C₄-alkoxy, phenyl-C₁-C₄-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals;

(2) C₁-C₄ haloalkyl of 1-3 halo radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄

35

alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

5 each R₂₉ is independently hydrogen radical or R₃₀;

each R₃₁ is independently

- (1) hydrogen radicals; or
 - (2) C₁-C₄ alkyl radical optionally substituted by an
- 10 phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or trifluoromethyl
- 15 radicals; and

each R₃₂ is independently

- (1) hydrogen radicals;
 - (2) C₁-C₄ alkyl radical optionally substituted by an C₃-C₆ cycloalkyl, aryl, heterocyclyl or heteroaryl radical
- 20 optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄
- 25 alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; or
 - (3) aryl, heteroaryl, heterocyclyl or C₃-C₆ cycloalkyl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄
- 30 alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, C₁-C₄ alkyl or C₁-C₄ haloalkyl of 1-3 halo radicals; and

each R₃₃ is independently hydrogen or C₁-C₄ alkyl

35 radical.

4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein

5

wherein R_1 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R_1 is 0-3;

10

Z is a

(1) bond;

(2) C_1 - C_8 alkyl or C_2 - C_8 alkenyl radical optionally substituted by (a) 1-3 radicals of amino, C_1 - C_4

alkylamino, di- $(C_1$ - C_4 alkyl)amino, C_1 - C_5 alkanoylamino,

15 $(C_1$ - C_4 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4

alkylthio or halo, and (b) 1-2 radicals of heterocyclyl,

aryl or heteroaryl optionally substituted by 1-3

radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4

alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4

20 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4

alkylthio, halo, C_1 - C_4 alkyl or C_1 - C_2 haloalkyl of 1-3

halo radicals;

(3) heterocyclyl radical optionally substituted by 1-2

radicals of amino, di- $(C_1$ - C_4 alkyl)amino, $(C_1$ - C_4

25 alkoxy)carbonylamino, hydroxy, C_1 - C_4 alkoxy, C_1 - C_4

alkylthio or C_1 - C_4 alkyl radicals; or

(4) aryl or heteroaryl radical optionally substituted by

1-3 radicals of amino, C_1 - C_4 alkylamino, di- $(C_1$ - C_4

alkyl)amino, C_1 - C_5 alkanoylamino, $(C_1$ - C_4

30 alkoxy)carbonylamino, C_1 - C_4 alkylsulfonylamino, hydroxy,

C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, cyano, halo, C_1 - C_4 alkyl

or C_1 - C_2 haloalkyl of 1-3 halo radicals;

Y is a

35 (1) hydrogen radical;

(2) halo radical;

- (3) $-C(O)-R_{20}$ or $-C(NR_5)-NR_5R_{21}$ radical;
 (4) $-OR_{21}$, $-O-C(O)-R_{21}$ or $-O-C(O)-NR_5R_{21}$ radical;
 (5) $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$ radical;
 or
 5 (6) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$, $-NR_{22}-C(O)-OR_{20}$, $-NR_{22}-C(O)-NR_5R_{21}$, $-NR_{22}-C(NR_5)-NR_5R_{21}$, $-NR_{22}-S(O)_2-R_{20}$ or $-NR_{22}-S(O)_2-NR_5R_{21}$ radical;

each R_5 is independently

- 10 (1) hydrogen radicals;
 (2) C_1-C_4 alkyl or C_2-C_5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di- $(C_1-C_4$ -alkyl)amino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, $-SO_3H$ or halo; or
 15 (3) phenyl- C_1-C_2 -alkyl, heteroaryl- C_1-C_2 -alkyl, heterocyclyl- C_1-C_2 -alkyl or C_3-C_6 -cycloalkyl- C_1-C_2 -alkyl radicals optionally substituted by 1-3 radicals of amino, di- $(C_1-C_4$ -alkyl)amino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, C_1-C_4 alkyl or C_1-C_2 haloalkyl of 1-3 halo
 20 radicals;

each R_{20} is independently

- (1) C_1-C_8 alkyl or C_2-C_5 alkenyl radicals optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino,
 25 di- $(C_1-C_4$ alkyl)amino, C_1-C_5 alkanoylamino, $(C_1-C_4$ alkoxy)carbonylamino, N- $((C_1-C_4$ alkoxy)carbonyl)-N- $(C_1-C_4$ alkyl)amino, aminocarbonylamino, hydroxy, C_1-C_4 alkoxy, C_1-C_4 alkylthio, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, halo or aryl- C_1-C_4 -alkoxy, aryl- C_1-C_4 -alkylthio, aryl- C_1-C_4 -alkylsulfonyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C_1-C_4 alkylamino,
 30 di- $(C_1-C_4$ alkyl)amino, C_1-C_5 alkanoylamino, $(C_1-C_4$ alkoxy)carbonylamino, C_1-C_4 alkylsulfonylamino, C_1-C_5

alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;

(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

5 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

10 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;

15

each R₂₁ is independently hydrogen radical or R₂₀;

each R₂₂ is independently

(1) hydrogen radical; or

20 (2) C₁-C₄ alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or
25 C₁-C₂ haloalkyl of 1-3 halo radicals;

R₂ is a radical of hydrogen, C₁-C₄ alkyl, halo, hydroxy, C₁-C₄ alkoxy, C₁-C₂ haloalkoxy of 1-3 halo radicals, thiol, C₁-C₄ alkylthio, aminosulfonyl, C₁-C₄

30 alkylaminosulfonyl, di-(C₁-C₄ alkyl)aminosulfonyl, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino or C₁-C₂ haloalkyl of 1-3 halo radicals;

35

R₁₁ and R₁₂ are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of

(1) R₃₀;

(2) halo or cyano radicals;

5 (3) -C(O)-R₃₀, -C(O)-OR₂₉, -C(O)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals; or

(4) -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂, -NR₃₃-C(O)-R₂₉ or -NR₃₃-C(O)-OR₃₀ radicals;

10 provided that (1) R₁₁ is other than a 4-pyridyl, 4-pyrimidinyl, 4-quinolyl or 6-isoquinolinyl radical optionally substituted by 1-2 substituents; and (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

15

each R₃₀ is independently

(1) C₁-C₄ alkyl radical optionally substituted by

(a) amino, C₁-C₄ alkylamino or di-(C₁-C₄-alkyl)amino radicals; or

20 (b) hydroxy, C₁-C₄ alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄

25 alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

(2) C₁-C₂ haloalkyl of 1-3 halo radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

30 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

35 each R₂₉ is independently hydrogen radical or R₃₀;

each R₃₁ is independently hydrogen or C₁-C₄ alkyl radicals; and

5 each R₃₂ is independently

(1) hydrogen radicals;

(2) C₁-C₄ alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

10 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; or

(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄

15 alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; and

each R₃₃ is independently hydrogen or methyl radical;

20 and

wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or

25 nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and

heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members,

30 wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused or saturated C₃-C₄-carbocyclic-fused.

35 5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein

Z is a

- (1) bond;
 - (2) C₁-C₄ alkyl or C₂-C₅ alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
 - (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or C₁-C₄ alkyl radicals; or
 - (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- each R₅ is independently
- (1) hydrogen radical;
 - (2) C₁-C₄ alkyl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂-alkyl)amino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo; or
 - (3) phenyl-C₁-C₂-alkyl, heteroaryl-C₁-C₂-alkyl, heterocyclyl-C₁-C₂-alkyl or C₃-C₆-cycloalkyl-C₁-C₂-alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂-alkyl)amino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, methoxy, methylthio, C₁-C₄ alkyl or trifluoromethyl radicals;

each R₂₂ is independently hydrogen or C₁-C₄ alkyl radical;

- 5 R₁₁ is an aryl radical and R₁₂ is a heteroaryl radical, wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
- (1) R₃₀;
 - (2) halo or cyano radicals;
 - 10 (3) -C(O)-R₃₀, -C(O)-OR₂₉, -C(O)-NR₃₁R₃₂ or -C(NR₃₁)-NR₃₁R₃₂ radicals; or
 - (4) -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals;
- 15 provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;

each R₃₀ is independently

- (1) C₁-C₄ alkyl radical optionally substituted by a
 - 20 phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
 - (2) trifluoromethyl radical; or
 - 25 (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, hydroxy, C₁-C₂ alkoxy, halo, C₁-C₄ alkyl or trifluoromethyl radicals;
- 30 each R₂₉ is independently hydrogen radical or R₃₀; and

each R₃₂ is independently

- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl radical or C₁-C₂ alkyl radical
- 35 substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂

alkyl)amino, acetamido, hydroxy, C₁-C₂ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; or

- (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, hydroxy, C₁-C₂ alkoxy, C₁-C₄ alkyl or trifluoromethyl radicals; and

wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo-fused.

6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein

wherein R₁ is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ is 0-2;

Z is a

- (1) bond;
- (2) C₁-C₄ alkyl or C₂-C₅ alkenyl radical optionally substituted by (a) 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio or halo, and (b) 1-2 radicals of aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂

alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals; or

- (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C₁-C₂ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, cyano, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

Y is a

- (1) hydrogen radical;
 (2) -C(O)-R₂₀ radical;
 (3) -OR₂₁, -SR₂₁, -S(O)-R₂₀, -S(O)₂-R₂₀ or -S(O)₂-NR₅R₂₁ radical; or
 (4) -NR₅R₂₁, -NR₂₂-C(O)-R₂₁, -NR₂₂-C(O)-OR₂₀, -NR₂₂-C(O)-NR₅R₂₁, -NR₂₂-S(O)₂-R₂₀ or -NR₂₂-S(O)₂-NR₅R₂₁ radical;

each R₅ is independently

- (1) hydrogen radical;
 (2) C₁-C₄ alkyl radical optionally substituted by 1-3 halo radicals; or
 (3) phenyl-C₁-C₂-alkyl or heteroaryl-C₁-C₂-alkyl, radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;

25

each R₂₀ is independently

- (1) C₁-C₈ alkyl or C₂-C₅ alkenyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or aryl-C₁-C₄-alkoxy, aryl-C₁-C₄-alkylthio, aryl-C₁-C₄-alkylsulfonyl, C₃-C₆ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino,

- di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, C₁-C₅ alkanoyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or C₁-C₂ haloalkyl of 1-3 halo radicals;
- 5 (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or
- 10 (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, acetamido, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, (C₁-C₄ alkoxy)carbonyl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or trifluoromethyl radicals;
- 15 each R₂₁ is independently hydrogen radical or R₂₀;
- R₂ is a radical of hydrogen, C₁-C₄ alkyl, halo, hydroxy, C₁-C₄ alkoxy, trifluoromethoxy, thiol, C₁-C₄ alkylthio,
- 20 amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino or trifluoromethyl;
- R₁₁ is an aryl radical and R₁₂ is a heteroaryl radical,
- 25 wherein the aryl and heteroaryl radicals are optionally substituted by 1-2 radicals of
- (1) R₃₀;
- (2) halo or cyano radicals; or
- (3) -C(O)-NR₃₁R₃₂, -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -
- 30 S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals;
- provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R₁₁ and R₁₂ is 0-1;
- 35 each R₃₀ is independently

- (1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
- (2) trifluoromethyl radical; or
- (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
- each R₂₉ is independently hydrogen radical or R₃₀;
- each R₃₁ is independently hydrogen, methyl or ethyl radicals; and
- each R₃₂ is independently
- (1) hydrogen radicals;
- (2) C₁-C₄ alkyl radical or C₁-C₂ alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or
- (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.

7. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein

R₁₁ is an aryl radical optionally substituted by 1-2 radicals of

- (1) R₃₀;
- (2) halo or cyano radicals; or
- (3) -C(O)-NR₃₁R₃₂, -OR₂₉, -SR₂₉, -S(O)-R₃₀, -S(O)₂-R₃₀, -S(O)₂-NR₃₁R₃₂, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals; and

R₁₂ is a heteroaryl radical optionally substituted by 1-2 radicals of

(1) R₃₀;

5 (2) halo or cyano radicals; or

(3) -C(O)-NR₃₁R₃₂, -OR₂₉, -SR₂₉, -NR₃₁R₃₂ or -NR₃₃-C(O)-R₂₉ radicals;

provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each
10 of R₁₁ and R₁₂ is 0-1;

R₃₀ is independently

(1) C₁-C₄ alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by
15 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

(2) trifluoromethyl radical; or

(3) aryl or heteroaryl radicals optionally substituted
20 by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;

R₂₉ is an aryl or heteroaryl radicals optionally
25 substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and

R₃₂ is independently

30 (1) hydrogen or C₁-C₄ alkyl radical; or

(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.

35

8. The compound of Claim 7 or a pharmaceutically acceptable salt thereof, wherein

wherein R₁ is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ is 0-1;

5

Z is a

(1) bond; or

(2) C₁-C₄ alkyl radical optionally substituted by 1-2 radicals of amino, di-(C₁-C₂ alkyl)amino, (C₁-C₄ alkoxy)carbonylamino, hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C₁-C₂ alkoxy, C₁-C₂ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

15

each R₅ is independently hydrogen or C₁-C₄ alkyl radical;

each R₂₀ is independently

(1) C₁-C₈ alkyl radicals optionally substituted by 1-3 radicals of amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, N-((C₁-C₄ alkoxy)carbonyl)-N-(C₁-C₄ alkyl)amino, aminocarbonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ alkylsulfinyl, C₁-C₄ alkylsulfonyl, halo or C₃-C₆ cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(C₁-C₄ alkyl)amino, C₁-C₅ alkanoylamino, (C₁-C₄ alkoxy)carbonylamino, C₁-C₄ alkylsulfonylamino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, halo, C₁-C₄ alkyl or trifluoromethyl radicals;

30

(2) heterocyclyl radical optionally substituted by 1-2 radicals of hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio or C₁-C₄ alkyl; or

35

(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C₁-C₄ alkoxy)carbonyl, amino, C₁-C₄ alkylamino, di-(C₁-C₄ alkyl)amino, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, cyano, halo, azido, C₁-C₄ alkyl or trifluoromethyl radicals;

each R₂₁ is independently hydrogen radical or R₂₀;

R₂ is a radical of hydrogen, methyl, ethyl, fluoro, chloro, hydroxy, methoxy, trifluoromethoxy, amino, methylamino, dimethylamino, acetamino or trifluoromethyl;

R₁₁ is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and

R₁₂ is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

25

9. The compound of Claim 8 or a pharmaceutically acceptable salt thereof, wherein

Z is a

30 (1) bond; or

(2) C₁-C₄ alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;

35 Y is a

(1) hydrogen radical;

- (2) $-C(O)-R_{20}$ radical;
(3) $-OR_{21}$, $-SR_{21}$, $-S(O)-R_{20}$, $-S(O)_2-R_{20}$ or $-S(O)_2-NR_5R_{21}$ radical; or
(4) $-NR_5R_{21}$, $-NR_{22}-C(O)-R_{21}$ or $-NR_{22}-S(O)_2-R_{20}$ radical;

5

R_5 is a hydrogen radical;

each R_{20} is independently

- (1) C_1-C_6 alkyl radicals optionally substituted by 1-3
10 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-(methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C_5-C_6 cycloalkyl, heterocyclyl,
15 phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2
20 radicals of hydroxy or C_1-C_4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

25

each R_{21} is independently hydrogen radical or R_{20} ;

each R_{22} is independently hydrogen or methyl radical;

- 30 R_{11} is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals; and

35

221

R₁₂ is a 4-pyridyl, 4-quinoliny, 4-imidazolyl or 4-pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

5

10. The compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein

10 Y is a

(1) -C(O)-R₂₀ radical;(2) -OR₂₁, -SR₂₁, -S(O)-R₂₀, -S(O)₂-R₂₀ or -S(O)₂-NR₅R₂₁ radical; or(3) -NR₅R₂₁, -NR₂₂-C(O)-R₂₁ or -NR₂₂-S(O)₂-R₂₀ radical;

15

each R₂₀ is independently(1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, t-butoxycarbonylamino, N-((t-butoxy)carbonyl)-N-20 (methyl)amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl, methylsulfonyl, halo or C₅-C₆ cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, 25 hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;

(2) heterocyclyl radical; or

(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy,

30 methoxy, methylthio, halo, methyl or trifluoromethyl radicals; and

each R₂₁ is independently hydrogen radical or R₂₀.

35

11. The compound of Claim 10 or a pharmaceutically acceptable salt thereof, wherein

Y is a -OR₂₁, -SR₂₁ or -NR₅R₂₁ radical;

each R₂₀ is independently

- 5 (1) C₁-C₆ alkyl radicals optionally substituted by 1-3 radicals of amino, methylamino, dimethylamino, hydroxy or phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl
10 radicals;
(2) heterocyclyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl
15 radicals;

each R₂₁ is independently hydrogen radical or R₂₀;

- R₁₁ is an unsubstituted phenyl radical or a phenyl
20 radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl, methyl or trifluoromethyl radicals; and
R₁₂ is a 4-pyridyl radical optionally substituted by a
25 radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals.

30

12. The compound of Claim 1 which is:

- 5-(4-Fluorophenyl)-2-(4-pyridyl)-4-(4-pyridyl)-pyrimidine,
35 5-(4-Fluorophenyl)-2-(2-methylthiazol-4-yl)-4-(4-pyridyl)-pyrimidine,

- 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-thienyl)-
pyrimidine,
2-(2-Diethylaminoethylamino)-5-(4-fluorophenyl)-4-(4-
pyridyl)-pyrimidine,
5 2-(4-Aminobutylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine,
2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-
pyrimidine,
2-(2,6-Dichlorophenylamino)-5-(4-fluorophenyl)-4-(4-
10 pyridyl)-pyrimidine,
2-(2,6-Dimethylphenylamino)-5-(4-fluorophenyl)-4-(4-
pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-methoxyphenylamino)-4-(4-
pyridyl)-pyrimidine,
15 5-(4-Fluorophenyl)-2-(4-fluorophenylamino)-4-(4-
pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-phenylthiomethyl-4-(4-pyridinyl)-
pyrimidine,
2-(2-(4-Aminophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
20 (4-pyridyl)-pyrimidine,
2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine,
2-(2-(4-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine,
25 2-(2-(3-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
(4-pyridyl)-pyrimidine,
2-(2-(2,4-Dichlorophenyl)ethyl-amino)-5-(4-
fluorophenyl)-4-(4-pyridyl)-pyrimidine,
2-(2-(4-Bromophenyl)ethyl-amino)-5-(4-fluorophenyl)-4-
30 (4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-(2-methoxyphenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-(3-methoxyphenyl)ethyl-amino)-4-
(4-pyridyl)-pyrimidine,
35 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-
4-(4-pyridyl)-pyrimidine,

- 5-(4-Fluorophenyl)-2-((4-phenyl-butyl)-amino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-morpholino-4-(4-pyridyl)-pyrimidine,
5 5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(2-pyrrolidinoethylamino)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-morpholinoethylamino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-piperidinoethylamino)-4-(4-pyridyl)-pyrimidine,
10 5-(4-Fluorophenyl)-2-(3-(2-pyrrolidinon-1-yl)propyl-amino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-phenoxyethyl)thio-6-(4-pyridyl)-4-hydroxy-pyrimidine,
15 5-(4-Fluorophenyl)-2-(2-phenylaminoethyl)thio-6-(4-pyridyl)-4-hydroxy-pyrimidine,
2-(2-Aminoethylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
2-(3-Aminopropylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
20 2-(Benzylamino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-phenylethylamino)-4-(4-pyridyl)-pyrimidine,
25 5-(4-Fluorophenyl)-2-(N-methyl-N-(2-phenylethyl)-amino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-hydroxy-2-phenyl-ethyl)amino-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-(4-hydroxyphenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine,
30 5-(4-Fluorophenyl)-2-(2-(4-fluorophenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-(2-fluorophenyl)ethyl-amino)-4-(4-pyridyl)-pyrimidine,
35 5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine,

- 2-((2(S)-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-(2-phenylaminoethylamino)-4-(4-pyridyl)-pyrimidine,
5 5-(4-Fluorophenyl)-2-((3-imidazolylpropyl)-amino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-4-(4-pyridyl)-2-pyrrolidino-pyrimidine,
5-(4-Fluorophenyl)-2-(1-piperazinyl)-4-(4-pyridyl)-
10 pyrimidine,
2-(2,6-Dichlorobenzyl)-5-(4-fluorophenyl)-6-(4-pyridyl)-4-hydroxy-pyrimidine,
5-(4-Fluorophenyl)-2-(2-phenylethyl)thio-6-(4-pyridyl)-4-hydroxy-pyrimidine,
15 5-(4-Fluorophenyl)-2-(3-phenylpropyl)thio-6-(4-pyridyl)-4-hydroxy-pyrimidine,
2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4-hydroxy-pyrimidine,
5-(4-Fluorophenyl)-2-((3-phenylpropyl)-amino)-6-(4-pyridyl)-4-hydroxy-pyrimidine,
20 5-(4-Fluorophenyl)-2-((1-methyl-3-phenylpropyl)-amino)-6-(4-pyridyl)-4-hydroxy-pyrimidine,
2-(2-(2-Chlorophenyl)ethyl-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4-hydroxy-pyrimidine,
25 2-((S)-2-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
2-((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
30 2-((S)-2-N,N-Dimethylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
2-((3-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
35 2-((3-Amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,

- 2-((3-Amino-3-(2-fluorophenyl)propyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-((3-Amino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
- 5 2-((2-Amino-2-methyl-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
2-((3-Hydroxy-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
2-(((2S,3S)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-
- 10 (4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-(((2R,3R)-3-Amino-2-methyl-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-((S)-3-Benzylpiperazinyl)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
- 15 4-(4-Pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethylen)amino)-5-(3-trifluoromethylphenyl)-pyrimidine,
5-(3-Methylphenyl)-4-(4-pyridyl)-2-(((S)-tetrahydroisoquinol-3-ylmethylen)amino)-pyrimidine,
- 20 2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-(((S)-2-N-Isopropylamino-3-phenylpropyl)-amino)-5-(3-
- 25 methylphenyl)-4-(4-pyridyl)-pyrimidine,
2-(((S)-2-N-Butylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
2-(((S)-2-N-Cyclohexylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,
- 30 5-(4-Fluorophenyl)-2-(((S)-2-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine,
5-(4-Fluorophenyl)-2-((3-N-isopropylamino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine,
2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-4-(4-
- 35 pyridyl)-5-(3-trifluoromethylphenyl)-pyrimidine,
2-(((S)-2-N-Glycylamino-3-phenylpropyl)-amino)-5-(3-methylphenyl)-4-(4-pyridyl)-pyrimidine,

- 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-chloro-4-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-fluorophenyl)-4-(4-pyridyl)-pyrimidine,
5 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(3-isopropylphenyl)-4-(4-pyridyl)-pyrimidine,
5-(3-Acetamidophenyl)-2-(((S)-2-amino-3-phenylpropyl)-amino)-4-(4-pyridyl)-pyrimidine,
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-chlorophenyl)-4-(4-pyridyl)-pyrimidine,
10 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(benzothienyl)-4-(4-pyridyl)-pyrimidine,
2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(2-naphthyl)-4-(4-pyridyl)-pyrimidine, or
15 2-(((S)-2-Amino-3-phenylpropyl)-amino)-5-(4-fluorophenyl)-6-(4-pyridyl)-4(3H)pyrimidinone
or a pharmaceutically acceptable salt thereof.
- 20 13. A pharmaceutical composition comprising a compound of Claims 1 to 12 and a pharmaceutically acceptable carrier.
- 25 14. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a compound of Claims 1 to 12.
- 30 15. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a composition of Claim 13.
- 35 16. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress

syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a compound of Claims 1-12.

17. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount of a composition of Claim 13.

18. A method of lowering plasma concentrations of either or both TNF- α and IL-1 comprising administering an effective amount of a compound of Claims 1-12.

19. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a composition of Claim 13.

5

20. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a compound of Claims 1-12.

10

21. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a composition of Claim 13.

22. A method of prophylaxis or treatment of
15 diabetes disease in a mammal comprising administering an effective amount of a compound according to claims 1 to 12 to produce a glucagon antagonist effect.

23. A method of prophylaxis or treatment of
20 diabetes disease in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13 to produce a glucagon antagonist effect.

24. A method of prophylaxis or treatment of a pain
25 disorder in a mammal comprising administering an effective amount of a compound according to claims 1 to 12.

25. A method of prophylaxis or treatment of a pain
30 disorder in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.

26. A method of decreasing prostaglandins
35 production in a mammal comprising administering an

230

effective amount of a compound according to claims 1 to 12.

27. A method of decreasing prostaglandins
5 production in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 13.

28. A method of decreasing cyclooxygenase enzyme
10 activity in a mammal comprising administering an effective amount of a compound according to claims 1 to 12.

29. The method of claim 28 wherein the
15 cyclooxygenase enzyme is COX-2.

30. A method of decreasing cyclooxygenase enzyme
activity in a mammal comprising administering an effective amount of a pharmaceutical composition
20 according to claim 13.

31. The method of claim 30 wherein the
cyclooxygenase enzyme is COX-2.

25

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 401/04, 403/04, 405/04, 401/14, 409/14, 403/14, 417/14, 239/42, A61K 31/44, 31/505</p>	<p>A3</p>	<p>(11) International Publication Number: WO 98/24782</p> <p>(43) International Publication Date: 11 June 1998 (11.06.98)</p>									
<p>(21) International Application Number: PCT/US97/22390</p> <p>(22) International Filing Date: 4 December 1997 (04.12.97)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>60/032,128</td> <td>5 December 1996 (05.12.96)</td> <td>US</td> </tr> <tr> <td>60/050,950</td> <td>13 June 1997 (13.06.97)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>21 November 1997 (21.11.97)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): AMGEN INC. [US/US]; Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SPOHR, Ulrike, D. [CA/US]; 2925 Glenwood Drive #305, Boulder, CO 80301 (US). MALONE, Michael, J. [US/US]; 6054H Gunbarrel Avenue, Boulder, CO 80301 (US). MANTLO, Nathan, B. [US/US]; 2538 Ginny Way, Lafayette, CO 80026 (US).</p> <p>(74) Agents: ODRE, Steven, M. et al.; Amgen, Inc., Amgen Center, 1840 De Havilland Drive, Thousand Oaks, CA 91320-1789 (US).</p>		60/032,128	5 December 1996 (05.12.96)	US	60/050,950	13 June 1997 (13.06.97)	US	Not furnished	21 November 1997 (21.11.97)	US	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 27 August 1998 (27.08.98)</p>
60/032,128	5 December 1996 (05.12.96)	US									
60/050,950	13 June 1997 (13.06.97)	US									
Not furnished	21 November 1997 (21.11.97)	US									
<p>(54) Title: SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE</p> <p>(57) Abstract</p> <p>Selected novel substituted pyrimidine compounds are effective for prophylaxis and treatment of diseases, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.</p>											

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/22390

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D401/04 C07D403/04 C07D405/04 C07D401/14 C07D409/14
C07D403/14 C07D417/14 C07D239/42 A61K31/44 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 97 33883 A (SMITHKLINE BEECHAM CORP.) 18 September 1997 cited in the application see page 20, compound 5; see page 23, compound 5 see claims 10, 16, 19, 26 ---	1-6, 13
X	US 4 438 117 A (S. C. CHERKOFISKY) 20 March 1984 see claims 1, 7; table 1 ---	1-6, 13
X	EP 0 130 046 A (ELI LILLY AND CO.) 2 January 1985 see claims 1, 5, 6 --- -/-	1-6, 13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "8" document member of the same patent family

Date of the actual completion of the international search

26 May 1998

Date of mailing of the international search report

03.07.98

Name and mailing address of the ISA
European Patent Office, P.B. 5816 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	M. TAKAHASHI ET AL.: HETEROCYCLES, vol. 22, no. 3, 1984, pages 581-4, XP002064343 see page 582, compound 8g ---	1-6
X	DE 33 19 843 A (A.-A. POURZAL) 6 December 1984 see page 4, compound 1; page 10, example 4 ---	1-6
X	US 5 077 142 A (Y. SAKON ET AL.) 31 December 1991 see columns 67, 68, compound no. 146 ---	1-6
X	DE 20 56 407 A (SANDOZ AG) 27 May 1971 see page 29, example 5c, starting compound 5,6-diphenylpyrimidin-2-ol ---	1-6
A	DE 12 71 116 B (FARBENFABRIKEN BAYER) 27 June 1968 cited in the application see columns 3-8, table ---	1
A	G. B. BENNETT ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 21, no. 7, 1978, pages 623-8, XP000612140 cited in the application see page 625, table III, compounds 3a-c, 4a-p; page 626, table IV, compounds 7a, 7b ---	1
A	H.-J. KABBE: LIEBIGS ANNALEN DER CHEMIE, vol. 704, 1967, pages 144-9, XP002065898 cited in the application see tables 1,2 ---	1
A	L. GIAMMANCO: ATTI DELLA ACCADEMIA DI SCIENZE LETTERE E ARTI DI PALERMO, vol. 27, 1968, pages 469-83, XP002064350 see page 474, compound (XVII) ---	1
A	L. GIAMMANCO ET AL.: ANNALI DI CHIMICA, vol. 60, no. 3, March 1970, pages 188-97, XP002064349 see page 189, compound VI ---	1
A	WO 96 03387 A (G. D. SEARLE & CO.) 8 February 1996 cited in the application see abstract; claims 1,10; examples --- -/--	1,13

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/22390

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	WO 97 16442 A (MERCK & CO., INC.) 9 May 1997 cited in the application see abstract; claims 1,17-20,22,39 ---	1,13
A,P	WO 97 12876 A (MERCK & CO., INC.) 10 April 1997 cited in the application see claims 1,21,22,24,26 ---	1,13
A	R. J. IFE ET AL.: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 5, no. 6, 1995, pages 543-6, XP002065899 cited in the application see page 544, scheme 1; page 545, table 1 -----	1,13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/22390

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-31
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 1-11, 13
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 14-31 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 14-31

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Claims Nos.: 1-11,13

In view of the large number of compounds, which are defined by the general definition in the independent claims, the search had to be restricted for economic reasons. The search was based upon though not limited to the examples and tables given in the description, and to the general idea underlying the application. (see Arts. 6, 15 and Rule 33 PCT).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22390

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9733883	A	18-09-1997	NONE	
US 4438117	A	20-03-1984	NONE	
EP 130046	A	02-01-1985	US 4500533 A DK 300884 A GB 2142025 A,B JP 60013767 A	19-02-1985 23-12-1984 09-01-1985 24-01-1985
DE 3319843	A	06-12-1984	NONE	
US 5077142	A	31-12-1991	NONE	
DE 2056407	A	27-05-1971	BE 759123 A BE 759176 A CA 962272 A CH 539047 A DE 2056406 A FR 2077528 A FR 2073390 A GB 1328857 A NL 7016942 A NL 7016977 A US 3772288 A DK 126042 B OA 3525 A	18-05-1971 19-05-1971 04-02-1975 31-08-1973 27-05-1971 29-10-1971 01-10-1971 05-09-1973 24-05-1971 24-05-1971 13-11-1973 04-06-1973 30-03-1971
DE 1271116	B		NONE	
WO 9603387	A	08-02-1996	US 5620999 A AU 3271695 A CA 2195846 A EP 0772601 A	15-04-1997 22-02-1996 08-02-1996 14-05-1997
WO 9716442	A	09-05-1997	AU 1120897 A	22-05-1997
WO 9712876	A	10-04-1997	AU 7514396 A	28-04-1997